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Abstract 
There is strong evidence for a protective association of vitamin D on head and neck cancer (HNC) 
incidence and prognosis from mechanistic and observational epidemiological studies, with the most 
recent estimate suggesting a 30% reduction in odds of HNC (95% confidence interval (CI): 44%, 12%) 
even after correcting for smoking and alcohol use. This thesis aims to identify the causal effect of 
vitamin D on HNC risk and prognosis by triangulating estimates from the most robust observational 
sources and Mendelian randomization (MR). 
I have undertaken the most recent observational study of vitamin D on HNC risk and prognosis in a 
case-cohort study in UK Biobank. Incident oral, oropharyngeal and laryngeal cancer cases were 
identified from cancer registry data and participants with no cancer diagnosis were used as controls. 
In survival analyses, death was identified from linked death registry data. The association between 
pre-diagnosis serum 25 hydroxyvitamin D (25(OH)D), the commonly measured blood metabolite, 
and HNC risk and prognosis was assessed using logistic and Cox proportional hazards regression 
respectively. A doubling in vitamin D was related to a reduction in oral (OR = 0.61 (95% CI: 0.50, 
0.76)) and oropharyngeal (OR = 0.75 (95% CI: 0.61, 0.91)) cancer risk as well as a reduction in 
hazards of death for all HNC sites combined (HR = 0.64 (85% CI: 0.53, 0.77)). 
As part of a small team, I also performed genome-wide association study of 25(OH)D in 17 cohort 
studies, including two with whole genome sequencing data, and meta-analysed. This study identified 
three novel associations including an association with a low-frequency genetic variant (rs117913124) 
with large effects on 25(OH)D (-0.43 standard deviation change per A allele). Genetic variants 
identified as being robustly related to 25(OH)D were combined into a genetic proxy for serum 
25(OH)D. This genetic proxy was compared to the serum 25(OH)D measure in a phenome-wide 
association study of 25(OH)D to assess the confounding structure of the two measures. 
Further, I used MR to assess the causal association of 25(OH)D on HNC risk in the GAME-ON study 
and HNC prognosis in Head and Neck 5000 using the genetic proxy identified above. For risk the MR 
estimate for a doubling of 25(OH)D was OR = 0.74 (95% CI: 0.50, 1.10) and 1.12 (95% CI: 0.52,2.39) 
for oral and oropharyngeal cancer respectively. For HNC prognosis, a doubling of 25(OH)D 
corresponded to a HR of 0.90 (95% CI: 0.51, 1.57) for all HNC sites combined. 
In summary, this thesis cannot rule out small effects of 25(OH)D on cancer risk but suggests that the 
effects as large as those reported in observational studies are unlikely. The genetic proxy for 
25(OH)D has been improved by the work of this thesis but questions remain about how appropriate 
a genetic proxy for 25(OH)D may be in studies of cancer.  
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Chapter 1 :  Overview 
1.1 Chapter objectives 
The aims of this chapter are to provide an overview of the thesis including a brief background, 
rationale and aims of the project.  
1.2 Thesis overview 
In this thesis I have conducted a series of studies to investigate the causal association between 
vitamin D and head and neck cancer risk and where possible applied the same methods to 
investigate the causal association between vitamin D and head and neck cancer prognosis. 
Descriptive 
Chapter 2 provides an introduction to head and neck cancer, the biology of vitamin D and a review 
of the scientific literature that underpins the association between vitamin D and head and neck 
cancers. Chapter 3 introduces the concept of causality and the framework by which causality will be 
assessed in this thesis. An outline of the main methods and datasets used within this thesis are then 
given, chapter specific methods are detailed at the beginning of each chapter. Observational 
epidemiology, genome-wide association study (GWAS), Mendelian randomization  and meta-analysis 
methods are discussed as well as the Avon Longitudinal Study of Parents and Children, UK Biobank, 
GAME-ON and Head and Neck 5000 studies. 
Application 
In chapter 4, an observational nested case control study is described which investigates the 
association of vitamin D with head and neck cancer. The results of this are then meta-analysed and 
compared with previous studies to provide the most precise estimate of the vitamin D effect 
available. 
Chapter 5 describes a genome wide association study of vitamin D which attempts to identify new 
associations between genetic variants and vitamin D that can act as reliable proxies for vitamin D in 
MR studies. In Chapter 6, the quality of this genetic proxy and its suitability for Mendelian 
randomization is discussed with reference to the assumptions of Mendelian randomization. A 
hypothesis free approach is applied to the 30,000 plus measured variables in UK Biobank to identify 
how the confounding structure of the vitamin D proxy and serum vitamin D measures differ. 
In Chapter 7, Mendelian randomization is applied, using the improved genetic proxy identified in 
chapter 5, to assess the vitamin D head and neck cancer association. 
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Chapter 8 introduces the additional complexities that arise when Mendelian randomization is used 
to investigate vitamin D associations with head and neck cancer prognosis. Work is presented for a 
Mendelian randomization study in a case-only setting to estimate the causal association of vitamin D 
on cancer prognosis. 
Synthesis 
Chapter 9 aims to synthesise the findings of this thesis and those in the literature to report on the 
vitamin D-HNC association using the framework set out in Chapter 3. A critique of the methods used 
in this thesis is given alongside a discussion of how future studies may be able to navigate these 
issues. 
1.3 Brief background and rationale 
Head and neck cancer (HNC) is the world’s sixth most common cancer and incidence is increasing. 
Annually, more than 600,000 new patients are diagnosed with HNC and approximately 350,000 die.1 
Furthermore, only 40–50% of patients with HNC will survive beyond five years and those that do 
often have facial disfigurement, loss of function and pain as result of surgery or radiotherapy. 
The majority of HNC are squamous cell carcinomas (SCC) and the oral cavity and oropharynx are the 
most commonly affected sites.1 Despite the majority being SCCs, HNCs are heterogeneous with 
separate sites having slightly different aetiology.2 The well-established risk factors for developing 
HNC are tobacco use, alcohol consumption and oral human papilloma virus infection,3,4 yet factors 
that affect prognosis are less well understood. Despite the main risk factors being well understood, 
approximately 30% of population attributable risk cannot be explained by these factors.5 In addition, 
there has been a recent shift in characteristics and a worrying increase in the incidence of oral cavity 
cancer and non-HPV related oropharyngeal cancer.6 This change is difficult to explain with the 
parallel reduction in smoking levels and stable levels of alcohol use and there is therefore a 
requirement to identify novel causal risk factors which may explain these trends. 
Vitamin D is predominantly synthesised in the skin on exposure to ultra-violet B radiation and plays a 
role in calcium and phosphate balance and bone structure.7 Despite vitamin D being linked to many 
disease states over recent decades, evidence of strong causal associations is difficult to establish. 
Vitamin D is easily modifiable and supplementation is becoming more common, despite this there 
are concerns that changes in working and lifestyle patterns mean populations have chronically low 
vitamin D levels. 
There is strong evidence for a protective association of vitamin D on cancer incidence and prognosis 
from mechanistic and observational epidemiological studies. Laboratory studies have shown vitamin 
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D and its related metabolites have anticarcinogenic effects with relevance to cancers including HNC8 
and randomised controlled trials (RCTs) of vitamin D supplementation corroborate a potential 
protective effect (relative risk cancer death = 0.89 (95% CI 0.78, 1.02).9 Vitamin D has also been 
associated with improved outcome and reduced tumour aggressiveness in breast, colorectal and 
prostate cancer.10  
For HNC, the observational estimates suggest large reductions in risk, particularly for oral cavity 
cancer. Vitamin D levels, measured before or at diagnosis, have also been strongly associated with 
improved cancer prognosis. Smoking is likely to be a strong confounder of the relationship with HNC 
incidence but well-designed prospective studies have shown clinically relevant effects even after 
robust correction for smoking. Despite this strong observational evidence, causality has not been 
established in either cancer incidence or prognosis. RCTs are not a practical method to investigate 
HNC incidence due to the relatively rare disease in question and trials of vitamin D as an adjuvant in 
HNC patients would require stronger evidence before clinical trials would be indicated. 
Alternative methods are required to assess the causal effect of vitamin D on HNC incidence and 
prognosis to inform whether resources should be used in this area. It is into this unoccupied niche 
which this thesis fits. 
1.4 Thesis aims and objectives 
This thesis aims to identify the true causal effect of vitamin D on head and neck cancer risk by 
triangulating evidence from the most robust observational sources and Mendelian randomization. 
This information can be used to inform whether future research and health resources should be 
used in this area. Secondly, the thesis aims to conduct preliminary studies to apply these methods in 
the study of the true causal association between vitamin D and HNC prognosis.  
1.4.1 Objectives 
1. Provide the most precise estimate of the effect of vitamin D on HNC risk and prognosis using 
observational epidemiology 
2. Identify a robust genetic proxy for vitamin D and demonstrate that it is minimally affected by 
confounding and reverse causality 
3. Use this genetic proxy in Mendelian randomization studies to estimate the causal effect of 
vitamin D on HNC risk and prognosis 
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1.5 Peer-review and publication of work presented in this thesis 
Published 
• Manousaki, D., Dudding, T. et al. Low-Frequency Synonymous Coding Variation in CYP2R1 
Has Large Effects on Vitamin D Levels and Risk of Multiple Sclerosis. Am. J. Hum. Genet. 101, 
(2017). (Joint first author) – Appendix Paper 1. 
This paper is based on the GWAS work presented in Chapter 5. I conducted this study as part 
of a collaboration. Within the collaboration, I was a member of a small team who led the 
study and writing of the manuscript. I ran the GWAS analyses in the whole genome 
sequenced and imputed ALSPAC data and helped write and edit the manuscript. The meta-
analysis of studies was conducted by colleagues at The University of McGill, however I have 
conducted similar meta-analyses of GWAS dataset for the HNC prognosis pilot work 
presented in the Appendix. In the paper, the haplotype analyses are presented for the 
TwinsUK cohort, for this thesis I present equivalent analyses conducted by myself in the 
ALSPAC cohort. 
• Dudding, T. et al. Assessing the causal association between 25-hydroxyvitamin D and the risk 
of oral and oropharyngeal cancer using Mendelian randomization. Int. J. Cancer 143, 1029–
1036 (2018). (First author) – Appendix Paper 2 
This paper is based on the work presented in Chapter 7. For this work I designed the study, 
conducted all analyses and wrote the manuscript. 
Other relevant published research: 
GWAS methodology 
• Haworth, S. et al. Consortium genome-wide meta-analysis for childhood dental caries traits. 
Hum. Mol. Genet. (2018). doi:10.1093/hmg/ddy237 (Contributing author) 
• Dudding, T. et al. Genome wide analysis for mouth ulcers identifies associations at immune 
regulatory loci. Nat. Commun. 10, 1052 (2019). (First author) 
• Haworth, S. et al. Apparent latent structure within the UK Biobank sample has implications 
for epidemiological analysis. Nat. Commun. (2019). doi:10.1038/s41467-018-08219-1 
(Contributing author) 
MR methodology  
• Dudding, T., Thomas, S. J., Duncan, K., Lawlor, D. A. & Timpson, N. J. Re-Examining the 
Association between Vitamin D and Childhood Caries. PLoS One 10, e0143769 (2015). (First 
author) 
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• Tan, V. Y. et al. Reassessing the association between circulating Vitamin D and IGFBP-3: 
Observational and Mendelian randomization estimates from independent sources. Cancer 
Epidemiol. Biomarkers Prev. 27, 1462–1471 (2018). (Contributing author) 
• Dudding T. et al. Examining the causal relationship between vitamin D and serum metabolic 
measures: A Mendelian randomization study. American Society of Human Genetics, Orlando 
2017 
Observational Epidemiology 
• Gormley M., Richmond R., Dudding T., & Thomas S. Poster: The changing aetiology of Head 
and Neck Cancer. International Association of Dental Research 2018. 
Planned publications 
• Observational association of vitamin D and HNC incidence and prognosis in UK Biobank 
• Vitamin D phenome wide association scan in UK Biobank 
• Genome-wide association of HNC prognosis 
• Mendelian randomization study assessing causal effect of vitamin D on HNC prognosis. 
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Chapter 2 :  Introduction 
2.1 Chapter objectives 
The aims of this chapter are to provide a detailed outline of head and neck cancer, vitamin D and the 
association between the two. The concepts and rationale briefly discussed in Chapter 1 will be 
elaborated and include a summary of the current literature assessing the association between 
vitamin D and head and neck cancer. 
2.2 Head and neck cancer 
2.2.1 Background 
Head and neck cancer (HNC) is the world’s sixth most common cancer and incidence is increasing. 
Annually, more than 600,000 people are diagnosed with HNC and approximately 350,000 people die 
from this cancer.1  
HNCs often present at an advanced stage, particularly in the more occult sites such as the 
oropharynx. They tend to have a poor prognosis with only 40–50% of patients surviving beyond five 
years, although this varies across subtypes. Treatment of HNC is dependent on anatomical site and 
cancer stage and aetiology. The most common treatment modalities are surgery, where anatomical 
site allows, and radiotherapy often combined with chemotherapy.11 Despite advances in surgical and 
radiotherapy techniques, people with HNC often suffer life-long facial disfigurement, loss of function 
and pain as a result of their treatment.  
HNC consists of cancers of the oral, oropharyngeal and nasal cavities, the paranasal sinuses, the 
major and minor salivary glands, the larynx, the lymphatic tissues of the neck and the thyroid. The 
vast majority of these cancers (approximately 90%) are squamous cell carcinomas (SCC), other 
histological types include lymphomas, blastomas, sarcomas and neuroendocrine tumours which are 
much rarer. Originally, these SCCs were thought to differ only in their anatomical location however 
more recently they have been shown to be heterogeneous, with different sub-sites having different 
risk-factors, pathogenesis and clinical behaviours.2 This thesis will focus on SSC of the oropharynx 
and oral cavity, with some chapters including data on larynx and hypopharynx cancers where 
available. Other anatomical sites and histological types will not be studied as they are highly 
heterogeneous and very rare meaning collections of particular types of these cancer will be very 
small. The main HNC sites and their corresponding ICD10 codes used throughout this thesis are 
given in the table below (Table 2-1). 
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Table 2-1: ICD10 codes of head and neck cancer sites used throughout this thesis. 
Cancer site ICD codes 
Oral cavity 
cancer 
ICD10 C003, C004, C005, C006, C009, C020, C021, C022, ,C028, C029, C030, 
C031, C039, C040, C041, C048, C049, C050, C058, C059, C060, C061, 
C062, C068, C069 
Oropharynx 
cancer 
ICD10 C01, C024, C090, C091, C098, C099, C100, C101, C102,C103, C104, C108, 
C109, C140, C142, C051, C052 
Larynx 
cancer 
ICD10 C320, C321, C322, C323, C328, C329 
Other HNC 
cancer 
ICD10 C148, CD000, C110, C111, C118, C119 
 
2.2.1.1 Oral cavity 
Anatomically the oral cavity starts anteriorly from the vermillion borders of the lip and extends 
posteriorly to the border of the hard and soft palate (superiorly), the circumvallate papilla 
(inferiorly) and the anterior pillar of fauces laterally. As with other HNC sites, 90% of oral cavity 
cancers (OC) are SCCs and an array of premalignant legions have been reported to be related to the 
development of these cancers. These include white (leukoplakia) and red (erythroplakia) patches 
which cannot be attributed clinically to any other cause. 
Despite the accessible nature of these cancers allowing easy self-examination, patients often 
present late and there is a high incidence of spread to the lymph nodes of the neck. Surgical excision 
is the first line treatment as anatomical access is favourable. Excision is often accompanied by neck 
dissection to remove the regional lymph nodes. The method of reconstruction depends on the 
extent of the excision and can vary from primary closure to the use of microvascular free flaps, with 
or without bone to reconstruct the bony defect. Adjunctive radiotherapy (and to a lesser extent 
chemotherapy) is considered, for example in cases with large primary tumours or metastases to 
lower levels of the neck. 
OC incidence has increased slightly in the last 10 years and is predicted to continue to do so (Figure 
2-1).6 Prognosis differs according to the stage at diagnosis (Figure 2-2)12 and in the UK age 
standardised one- and five-year probability of cancer death is 22.6% and 42.8% respectively.13  
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Figure 2-1: Change and projected incidence of head and neck cancers in the UK (from 6 with 
permission from Elsevier) 
 
 
Figure 2-2: Oral cavity cancer survival by stage at diagnosis (from 12 with permission from 
Elsevier) 
 
2.2.1.2 Oropharynx cancer 
The oropharynx constitutes the mid portion of the pharynx and contains the tongue base (posterior 
to the circumvallate papillae, tonsils (palatine), soft palate and pharyngeal walls. Again 90% of 
oropharyngeal cancers (OPC) are SCCs. The separation of the oropharynx from the oral cavity is not 
purely an anatomical one, the tongue base and tonsils contain large amounts of lymphoid tissue 
whereas the mucosa of the oral cavity does not. This lymphoid tissue forms part of the body’s 
Chapter 2: Introduction 
 9 
immuno-surveillance and because of that this tissue encounters many foreign antigens that enter 
the body via the mouth or nose. 
OPCs can be split into Human Papilloma Virus (HPV) positive and HPV negative cancers, with each 
now considered a separate disease entity.3 HPV positive OPC patients tend to be younger, more 
sexually active, generally healthier and of higher socio-economic group whereas HPV-negative OPC 
patients tend to be heavier smokers and consumers of alcohol and be older.14 
The treatment of OPC is determined by the p16 status which indicates the aetiological role of HPV. 
Factors including patient comorbidities, the anatomical position and cancer stage are also important. 
Treatment consists of either radiotherapy often combined with chemotherapy or surgery. Surgery 
involves resection of the primary site usually combined with a neck dissection (removal of the 
draining lymphatics). 15 
OPC incidence is increasing dramatically in the UK (Figure 2-1) and this is largely attributed to rising 
HPV infection16 however, non-HPV related OPC is also increasing at a similar rate17 (see section 2.2.5 
Changing aetiology). Oropharyngeal cancer prognosis is better than that of oral cavity cancer with 
probability of one- and five- year cancer specific deaths being 22.4% and 41.0% respectively in the 
UK, this is particularly the case for HPV driven cancers.13 
2.2.1.3 Larynx cancer 
The larynx is positioned in the anterior of the neck between the C3 and C7 vertebrae and connects 
the hypopharynx to the trachea. It extends from the tip of the epiglottis to the inferior border of the 
cricoid cartilage. The larynx is split into three regions: the supraglottic region which lies above the 
vocal cords, the glottic region which includes the vocal cords and the area immediately surrounding 
and inferior to this is the sub-glottic region. Similarly, to both oral and oropharyngeal cancers, 
laryngeal lancers (LC) are at least 90% SCCs. 
LC tend to present earlier than OC and OPC due to voice changes associated with these tumours.18 
They are much more common in men (80%) and this is likely to be due to the higher prevalence of 
the major risk factors of tobacco and alcohol in males. Together these risk factors are considered to 
be multiplicative (see 2.2.4 Major risk factors). There is weak evidence linking LC with some dietary 
and environmental exposures but causal associations have not been established.19 
Treatment of LC depends predominantly on the stage of the cancer at diagnosis but also on location 
(supra-glottic, glottic or sub-glottic) with more inferior sites having more difficult access for 
minimally invasive surgery. Early stage LCs are often treated with minimally invasive trans-oral 
surgical approaches or radiotherapy. In patients with mid to advanced stage cancers, attempts are 
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made to preserve the larynx where possible using chemo-radiotherapy, avoiding surgical resection. 
Where tumours have invaded the cartilage, total laryngectomy is often the treatment of choice. 
Neck dissection depends on the presence of nodal involvement and the response to the primary 
treatment.20 
The incidence of LCs is steadily reducing in the UK (Figure 2-1) and this likely reflects a decline in 
smoking. Cancer specific death is lower than in OC and OPC with 13% dying within 1 year and 33% 
dying within 5 years.13 
2.2.2 HNC genetic epidemiology 
There have been several studies which utilise genetic epidemiology to investigate HNC susceptibility 
over the past few decades. These include various candidate gene studies which have been combined 
into meta-analyses. These studies tend to focus on genes involved in the metabolism of carcinogens 
such as ADH (the genes for alcohol dehydrogenase isoenzymes) and are reviewed by Cadoni et al.21 
In summary, they report some evidence that glutathione S-transferases (GSTM1), glutathione S-
transferases (GSTT1) and human microsomal epoxide hydrolase (EPHX1) genes are associated with 
HNC risk but individual studies are heterogeneous and evidence is statistically weak. The INHANCE 
consortium of head and neck cancer studies also investigated a list of candidate studies and found 
some evidence for association with MGMT (OR = 0.79, 95% CI = 0.68–0.93), XRCC1 (OR = 2.3, 95% 
CI = 1.1–4.7), ADH1B (OR = 2.7, 95% CI = 1.9–4.0), ADH1C (OR = 1.2, 95% CI = 1.1–1.4), and GSTM1 
(OR = 1.1, 95% CI = 1.0–1.2) although false positives cannot be ruled out, 
Two genome wide association studies (GWAS) have been performed to identify genetic variants 
associated with HNC risk. This method uses a hypothesis free approach across the genome and is 
discussed further in Chapter 3. These studies have identified several genetic variants with strong 
evidence for association with HNC including variants in alcohol dehydrogenase genes and in the 
human leukocyte antigen region of chromosome six which is thought to be related to susceptibility 
to HPV infection.22,23 
This thesis will utilise Mendelian randomization, a method which utilises genetic data to help infer 
causality from observational data. At the start of this theses there had been one study using this 
method to investigate HNC. This study examined the causal effect of alcohol on HNC using genetic 
variants in the ALDH2 gene and found evidence that increased alcohol use increased the risk of 
HNC.24 
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2.2.3 Cancer heterogeneity 
In cancer the term heterogeneity can take many forms beyond that of tumour heterogeneity which, 
is of current interest to the research community.25 Despite the fact that the majority of HNC are 
SCCs, there is heterogeneity across and within anatomical sites as well as more broadly 
geographically. 
It is clear from the descriptions of the three cancer sites above that there is heterogeneity in terms 
of incidence and aetiology. There is also important within site heterogeneity. As mentioned, OPC 
cancers can be further stratified into HPV positive and HPV negative cancers with each considered 
distinct disease entities.3 A different type of heterogeneity exists in OC. Each location within the oral 
cavity has distinct tissue compositions, for example the tissue composition of the gingiva and hard 
palate consists of dense collagenous stroma attached to the periosteum of the bone, the buccal 
mucosa consists of dense stroma with the presence of minor salivary glands and the tongue is 
primarily muscular. Furthermore, each of these areas will have different exposure to carcinogens, 
for example users of betel quid (a combination of areca nut, catechu, slaked lime, and often tobacco 
wrapped in a betel leaf) will have very high exposure of carcinogens to the buccal mucosa as this is 
where the folded leaf is placed in the oral cavity. These differences may lead to subtly different 
cancer pathogenesis across the locations of the oral cavity and also within each tumour, referred to 
as inter-tumoral heterogeneity.26 
Geographic heterogeneity is present, for example, the difference in HPV positive OPC in South 
America compared to North America and Europe. In South America only 4.1% (95% CI: 1.1, 7.1) of 
OPC tumours are HPV positive compared to 59.3(95% CI: 53.1, 65.5) and 31.1 (95% CI: 22.7, 39.5) in 
North America and Europe respectively.27 
These various heterogeneities make investigating HNC complex and highlight the need to stratify by 
various factors. Without this, associations that are not shared across strata may be missed when 
analysing all sites or regions together. Even with awareness, this process is difficult in HNC research 
due to relatively small numbers with each stratum. 
2.2.4 Major risk factors 
Alcohol and tobacco use are the major risk factors for OC and OPC,4,28 together explaining 
approximately 63.7% (95% CI: 44.7, 74.7) and 71.5% (95% CI: 57.6, 80.2) of the population 
attributable risk (PAR) respectively.5 Infection with HPV has emerged more recently as an important 
risk factor, particularly in OPC.29 
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2.2.4.1 Tobacco and Alcohol 
Tobacco use is known to be a causal risk factor for HNCs30 with the most precise estimate being ever 
smokers having three and a half times greater odds of developing HNC than never smokers (Odds 
ratio (OR) = 3.46 (95% CI: 3.24, 3.70)). There is a dose response relationship with both intensity 
(number of cigarettes smoked per day) and duration (number of years smoked) of smoking, with 
smoking duration being more important than intensity.31 There was also strong associations exist for 
cigarette, pipe and cigar smoking.32 The PAR for tobacco alone (not including the effect of alcohol) in 
OC and for OPC is approximately 24% for both cancers with the PAR for tobacco alone in LC being 
more than double this (52.2% (95% CI:77.8, 36.0)).5 
Alcohol has been considered by the International Agency for Research on Cancer (IARC) as a 
convincing risk factor for HNCs since the late 1980s33 and was considered a causal risk factor in their 
2010 Monograph.34 A pooled analysis in the International Head And Neck Cancer Epidemiology 
(INHANCE) Consortium showed increased odds of OC and OPC with increased intensity and duration 
of alcohol consumption, but little effect of these factors on LC35 and this finding is mirrored by 
several other epidemiological studies. There is currently little evidence to support that different 
types of alcoholic beverage contribute differing levels of HNC risk, although there is potentially a 
lower risk attributable to wine compared to beer or liquor at low to moderate alcohol 
consumption.36 The PAR for alcohol alone (not including the effect of smoking) in OC is near zero, 
suggesting most of the effect of alcohol acts through the effect of tobacco. For OPC and LC the PAR 
for alcohol alone is 5.6 (95% CI: 1.9, 7.3) and 2.9 (95% CI: -0.3, 4.4) respectively.5 
As alluded to for OC above, tobacco and alcohol use is highly correlated, and it can be difficult to 
identify independent effects of these risk factors. In a study from the INHANCE consortium, in non-
drinkers the OR for HNC for ever versus never smoking was 2.13 (95% CI = 1.52 to 2.98), slightly 
lower than seen when drinkers and non-drinkers are studied together. Interestingly, in never 
smokers, the odds of developing HNC was only greater when the frequency of alcohol consumed 
was high (OR for three or more drinks per day versus never drinking = 2.04, 95% CI = 1.29 to 3.21) 
with no evidence of increased odds at lower alcohol intake frequencies. 
The effect of tobacco and alcohol has been shown to interact in the association with HNCs. This is 
demonstrated nicely in work by Hashibe and colleagues5 where they partition the PAR into that 
which is for alcohol alone, tobacco alone and the portion which is attributed to both risk factors 
together. For all HNCs, the total PAR is reported as 72.0% (95% CI: 61.2, 79.1) with almost half of this 
attributable to the synergistic effect of alcohol and tobacco, and less than 40% attributable to 
Chapter 2: Introduction 
 13 
tobacco use alone (PAR=33.0% (95% CI: 42.6, 25.9)) plus alcohol use alone (PAR=4.0% (95% CI: 1.5, 
5.3)). 
2.2.4.2 Human papilloma virus infection 
HPV, the causative infective agent for many cervical and anal cancers, has been strongly linked with 
oropharyngeal cancers for more than two decades. Research in the early 2000s confirmed it as a 
causative agent in many OPC cases.37 HPV16 is the predominant form and is found in the tumour 
tissue of approximately 36% of oropharyngeal cases,38 with estimates ranging from 0 to 86%.39 
HPV16 positivity is lower in OC (23.5% (95 CI: 21.9, 25.1)) and LC 24.0% (95% CI: 21.8, 26.3)) tumour 
tissue where the role of HPV is less clear. There has been a global increase in the incidence of OPC 
which is predominantly driven by the emergence of HPV.3 
2.2.4.3 Socio-economic status 
Socioeconomic status (SES) is a strong risk factor for head and neck cancer with lower SES being 
associated with a higher risk. As might be expected, this association was partly but driven by other 
risk factors40 but a larger study estimated that approximately one third of the effect of SES was not 
driven by smoking and alcohol use.41 More recently, a study found evidence to suggest an 
interaction between SES and the other major risk factors of smoking and alcohol use, with the 
effects of these stronger in lower SES groups than in higher SES groups.42 
2.2.4.4 Age and Sex 
HNCs are more common in males than females with the age-standardised incidence rates in males 
being more than double that in females in the UK (CRUK). This pattern may reflect higher levels of 
smoking and alcohol use in males than females. The age distribution of HNC does not differ by sex 
with the peak age of diagnosis being 65 to 69 years in both sexes. 
2.2.4.5 Other risk factors 
Several other factors have been linked with an increase in the risk of HNC without strong causal links 
being established. These included a diet low in fresh fruit and vegetables, low BMI, poor oral health, 
Marijuana use and sexual health.43 
2.2.5 Changing aetiology 
The use of tobacco is generally on the decline across the world. World Health Organisation (WHO) 
predictions suggest that tobacco use in females is declining for all regions and in males for all regions 
except Africa and Eastern Mediterranean.44 This decline is mirrored in the UK with smoking 
prevalence approximately 15% in 2017, down from 45% in the mid 1970s (Figure 2-3). Alcohol 
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consumption worldwide has been relatively stable45 (Figure 2-4) and again this is mirrored in the UK 
(Figure 2-5). 
Figure 2-3: UK smoking prevalence, 1970-2017. 
 
Data from UK Office for national statistics. Adult smoking habits in the UK: 2017 46 
Figure 2-4: Recorded adult per capita consumption, in litres of pure alcohol, by WHO region 
and the world, 1990-2005 (Reprinted from45 with permission of WHO). 
 
AFR= African region, AMR=Region of the Americas, EMR= Eastern Mediterranean region, EUR=European 
region, SEAR=South-East Asia region, Western Pacific region, WHO=World Heath Organisation 
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Figure 2-5: Volume of pure alcohol (litres) sold per adult (16+) 
Scotland and England & Wales, 1994-2016 
 
Data from: Monitoring and Evaluating Scotland’s Alcohol Strategy: Monitoring Report 2017. 
http://www.healthscotland.scot/publications/mesas-monitoring-report-2017 
Given the burden of HNC is largely related to these two risk factors, particularly tobacco use, the 
incidence of HNCs would be expected to decline over time, alongside the reduction in tobacco use. 
This reduction has been demonstrated in Europe for other smoking related cancers such as lung and 
LC6 but the incidence of OC and OPC has increased during the same period across Europe6 and in the 
UK.47 
A review by D’Souza and Dempsey48 demonstrated that tumour HPV positivity is increasing over 
time (Figure 2-6). This pattern could explain the worrying increase in OPC incidence in developed 
countries over the past few decades,29,49,50 despite the decrease in tobacco use. However, within the 
UK the proportion of HPV related OPC is unchanged and there is also an increase in non-HPV OPC.17 
This suggests that the increase in OPC cases cannot be explained solely by an increase in HPV 
infection.17,47 Furthermore, there has been an increase in OC incidence in the UK. Comparing 
demographic and lifestyle factors in HN5000, a contemporary clinical cohort with previous HNC 
collections shows a higher proportion of these OCs being in female, non-smoking individuals who do 
not report engaging in oral sex. This trend which is unlikely to be specific to the UK is concerning and 
suggests there may be an unknown aetiology causing a proportion of these OC. 
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Figure 2-6: Percentage of oropharyngeal tumours that were HPV positive in studies from 
1975 – 2010 (from48 with permission from Elsevier)  
 
In light of there being a portion of HNC risk not attributable to tobacco, alcohol or HPV and the 
recent changes in the profile of the three main HNCs it is important that research is focused on 
identifying potential novel risk factors. 
2.3 Vitamin D 
2.3.1 Background and history 
Vitamin D is a steroid related compound that has important roles in calcium homeostasis and is 
therefore important for skeletal health.51 More recently however it has also been linked to non-
skeletal diseases such as cardiovascular disease,52 autoimmune diseases53 and cancer.54 
Vitamin D was identified in the early 20th century principally due to its ability to cure rickets. Sir 
Edward Mellanby had identified that rickets in dogs could be cured by feeding them cod-liver oil, 55 
known to contain vitamin A. Elmer McCollum meanwhile destroyed the vitamin A in cod-liver oil by 
oxygenation and found that the oil could no longer cure vitamin A deficiency but could still cure 
rickets.56 He correctly identified a new vitamin was present in cod-liver oil, which was subsequently 
named vitamin D. Vitamin D2, or ergocalciferol, was isolated and its structure identified in 193057 
with vitamin D3, or cholecalciferol, identified in 1937 (reviewed in58). It was hypothesised that 
vitamin D3 was formed by exposure to sunlight but this was not confirmed until 1972.59 This raised 
the question of whether vitamin D3 was a true vitamin in the classical sense as it can be produced by 
the body in sufficient quantities and therefore behaves more like a hormone than an essential 
nutrient. 
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2.3.2 Vitamin D synthesis and metabolism 
Vitamin D3 is predominantly synthesised in the skin on direct exposure to ultra-violet B (UVB) 
radiation. 7-dehydrocholesterol (7-DHC) is photoisomerised to pre-vitamin D on absorption of UVB 
radiation of wavelengths between 280 and 315 nm.60 This pre-vitamin is then converted into vitamin 
D3 via a heat isomerisation reaction or further photoisomerised back to 7-DHC or to inactive 
metabolites (lumisterol and tachysterol).60 Availability of 7-DHC in the skin is determined by the 
activity of 7-dehydrocholesterol reductase (DHCR7) that converts 7-DHC into cholesterol. Increased 
activity of the DHCR7 enzyme reduces the availability of the 7-DHC substrate for the initial 
photoisomerization reaction to form pre-vitamin D. 
Vitamin D can be absorbed from the diet. Vitamin D2 is absorbed from plants or artificially fortified 
foods and vitamin D3 from oily fish. Supplementation with vitamin D is common and can be in either 
of the two forms, concentrations vary dramatically across different formulations and there is no 
consensus on the ideal form or concentration. 
Vitamin D2 and D3 are lipid soluble and stored in adipose tissue61 whereas the circulating form is 25-
hydroxyvitamin D (25(OH)D). This metabolite is formed in the liver by hydroxylation of either vitamin 
D2 or D3 by the cytochrome P450 family 2 subfamily R member 1 (CYP2R1) enzyme, also known as 
vitamin D 25-hydroxylase. 25(OH)D is transported in the blood predominantly bound to the vitamin 
D binding protein (DBP) (80-90%) or albumin (10-20%) with a tiny fraction unbound, which is 
referred to as free 25(OH)D.62 
The active form of vitamin D, 1,25-di-hydroxyvitamin D (1,25(OH)2D), also known as calcitriol, is 
formed by a second hydroxylation step. 25(OH)D is hydroxylated by the cytochrome P450 family 27 
subfamily B member 1 (CYP27B1) enzyme, also known as 25-hydroxyvitamin D 1-alpha hydroxylase, 
to 1,25(OH)2D predominantly in the kidneys. 25(OH)D is transported into the renal cells attached to 
DBP via a megalin-mediated exocytosis. Extrarenal conversion has also been reported in skin, 
placenta, and lymph nodes with some activity also likely in adrenal medulla, brain, pancreas, and 
colon.63 Like the inactive form, 1,25(OH)2D is predominantly transported to where it is required in 
the circulation, bound to DBP. At these tissues 1,25(OH)2D exerts its effects by binding the vitamin D 
receptor (VDR) intracellularly. 
Breakdown of 1,25(OH)2D occurs in the kidney and target tissues where cytochrome P450 family 24 
subfamily A member 1 (CYP24A1) is expressed.64 This enzyme catalyses the hydroxylation of both 
1,25(OH)2D and 25(OH)D at an additional carbon, a step which marks the metabolites for further 
breakdown and excretion predominantly through bile in the faeces.65 
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Figure 2-7: Diagrammatic representation of the synthesis and degradation of vitamin D 
detailing the important enzymes involved in the process. 
 
2.3.3 Measurement of vitamin D 
Vitamin D is measured using an assay of 25(OH)D rather than a measure of the active metabolite, 
1,25(OH)2D. Although it may seem that 1,25(OH)2D concentration would provide a better measure of 
vitamin D status this is not the case. 1,25(OH)2D is buffered by an increase in parathyroid hormone 
in vitamin D deficient patients. This would lead to near-normal 1,25(OH)2D assay results even in 
deficient patients. Furthermore, the half-life of 1,25(OH)2D is four to six hours and is therefore highly 
susceptible to short term fluctuations whereas the half-life of 25(OH)D is several weeks. Finally, the 
concentration of the active vitamin D form is 1000-fold lower than its inactive precursor, making the 
practicality of its measurement more prone to error.66 
The 25(OH)D assay measures the total 25(OH)D in circulation, this includes the bound component 
(to either DBP or albumin) and the free component. There is controversy within the literature as to 
whether the total or free component of 25(OH)D better reflects vitamin D status.67,68 There is strong 
evidence that the levels are highly correlated, suggesting 25(OH)D is an adequate measure. 
However, the same study also shows that in vitamin D deficient individuals, the proportion of total 
25(OH)D which is made up of free 25(OH)D, increases at low 25(OH)D levels.69 This may have 
implications for studies investigating vitamin D deficient populations. 
As discussed in detail below, UVB exposure and hence season is a major factor in vitamin D levels. It 
is important that the season of blood draw is taken into account when measuring vitamin D across 
populations over a period of time. Several adjustment methods have been utilised in 
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epidemiological studies, including making a correction of the 25(OH)D measure by season (summer, 
autumn, winter, spring) or modelling the seasonal variation in a sinusoid pattern. 
2.3.4 Optimal vitamin D levels 
Clinically, and in epidemiological studies, vitamin D is measured using an assay for 25(OH)D. This 
inactive metabolite has a half-life of approximately three weeks and is therefore relatively stable to 
daily diet and sunlight exposure variation. The active vitamin D metabolite 1,25(OH)D2 has a half-life 
of approximately four hours and is therefore a poor long-term indicator of vitamin D levels. 
It has been proposed that 25(OH)D levels in excess of 50 nmol/L are adequate for bone health65 with 
this level being a minimum at the end of winter rather than a year-round average.70 One group has 
suggested higher thresholds (>80 nmol/L)  based on the levels of specific biomarkers that vitamin D 
effects, such as intact parathyroid hormone, calcium absorption and bone mineral density. These 
guidelines mainly relate to bone health however and there is little robust evidence to suggest levels 
which may be sufficient for the non-skeletal effects of vitamin D. 
2.3.5 Factors that affect vitamin D levels 
Many factors affect vitamin D levels. The main contributor to serum vitamin D levels is exposure to 
UVB radiation, although UVB radiation is not a risk factor for HNC (other than the external lip which 
in not included in this thesis) understanding the production of vitamin D in the body is important to 
several aspects of this thesis. One chapter of this thesis involves identifying genetic variants as proxy 
measures of vitamin D and applying them in causal analyses therefore the genetic factors that 
influence vitamin D are discussed. Additionally, the factors that are important to both vitamin D 
levels and HNC are summarised as these will be the main factors that may impact analyses 
investigating the association between vitamin D and HNC risk and prognosis. The impact could either 
be as a confounder, where the factor is a common cause of both decreased vitamin D and increase 
HNC incidence or an effect modifier, where vitamin D has an effect on HNC but it is dependent on 
the factor. 
2.3.5.1 Exposure to ultraviolet B radiation 
Given the initiation of vitamin D synthesis requires UVB photons to collide with 7-DHC, it is 
unsurprising that vitamin D levels are strongly influenced by UVB exposure. Factors that can affect 
this exposure can be external or internal to the individual. 
External factors 
The main external factors that control the ambient UVB are highly predictable as they affect the 
angle at which sunlight reaches the Earth’s surface, or solar zenith angle (SZA). These include 
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latitude, season and time-of-day. Ambient UVB decreases as the SZA increases as this corresponds to 
an increased path distance through the atmosphere and an increased surface area of absorption. 
Small SZA, and therefore high UVB radiation, corresponds to low latitudes (closer to the equator), 
summer and when the sun is highest in the sky (noon). This factor creates a link between geographic 
location and vitamin D which can be important when considering studies of vitamin D conducted 
around the world. 
Some external factors which are less predictable involve influences which absorb UVB radiation 
before they can reach the Earth’s surface. More cloud cover, thicker ozone and higher pollution 
levels all absorb more UVB radiation and ultimately decrease conversion of 7-DHC to vitamin D.60 
Internal factors 
Internal factors relate to those pertinent to the individual with the major factor being skin type. This 
genetically determined influence affects the amount of vitamin D that can be synthesised for a given 
amount of UVB radiation. Melanin in the skin absorbs UVB radiation as a protective mechanism 
against UVB damage but also prevents the conversion of 7-DHC to pre-vitamin D3. Evolutionarily, 
dark-skinned races have greater melanin due to originating at lower latitudes where UVB radiation is 
high. Pale skin, that maximises the use of available UVB radiation, was an evolutionary advantage at 
latitudes where risk of damage from UVB radiation is low. Migration of dark-skinned individuals to 
higher latitudes puts these populations at risk of sub-optimal vitamin D levels without the use of 
supplementation or targeted diets.60 
Other internal factors that reduce the exposure of an individual to UVB radiation are skin coverage 
with clothing or sunscreen which absorb UVB radiation and reduce the amount available for vitamin 
D synthesis. 60 Cultural and behavioural patterns will also affect UVB exposure, in cultures where it is 
the norm to cover-up exposed skin there will be less surface area for UVB absorption. 60 Jobs and 
past times that involve being outside will increase the potential for UVB exposure whereas 
sedentary indoor jobs and reduced levels of physical activity will have the opposite effect. The 
recent increase in obesity has been partly blamed on an increase in sedentary occupations and more 
time spend indoors (watching television and being on the computer). There is the potential that 
these lifestyle changes are also having vitamin D lowering impacts. Good quality trend data for 
vitamin D in not available in the UK however there has been a dramatic increase in the number of 
tests for low vitamin D levels in the NHS.71 This may suggest a higher incidence of low vitamin D 
levels but may also reflect a greater awareness amongst clinicians to the potential health 
consequences of low vitamin D. 
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2.3.5.2 Genetic factors 
There have been many studies which have investigated and demonstrated a genetic component of 
vitamin D levels. These studies are of varied design and are summarised below: 
Family and twin studies 
Vitamin D levels have been shown to be heritable, but estimates vary dramatically. 25(OH)D 
heritability estimates in Caucasian populations have been reported between 0.22 and 0.86.72–78 The 
variation in these estimates may be down to the changeable environmental factors such as season, 
Karohl et al.78 estimated the heritability of 25(OH)D to be 0.7 (95% CI: 0.31, 0.80) in winter and 0.00 
(95% CI: 0.00, 0.35) in summer. There are very few studies estimating heritability in non-Caucasian 
populations but studies investigating Asian79 and Hispanic80 populations show similar estimates to 
Caucasian populations.  
Linkage studies 
Several studies have attempted to identify regions of the genome that are associated with 25(OH)D 
using linkage, none of these have identified regions with robust results that pass multiple testing 
thresholds.74,77 
Candidate gene studies 
Candidate gene studies look for associations between single nucleotide polymorphisms (SNP), single 
base-pair changes in DNA, with 25(OH)D levels. These studies do have limitations however: 
1. Phenotype characterisation is often heterogeneous across studies which limits the ability to 
replicate findings 
2. Sample sizes are often small 
3. Multiple testing is not always adequately dealt with which can lead to type II errors. 
The SNPs under investigation are selected using prior knowledge of the vitamin D related pathways 
(see 2.3.2 Vitamin D synthesis and metabolism). An overview of results is provided below. 
CYP27B1 
Cytochrome P450 family 27 subfamily B member 1 (CYP27B1) is found on chromosome 12 and 
encodes the 25(OH)D 1-alpha hydroxylase protein which catalyses the conversion of 25(OH)D to 
1,25(OH)2D. The C allele of rs10877012 has been associated with lower 25(OH)D in three studies81–83 
but it is unclear how this SNP exerts effects. Two other SNPs in this gene have also been associated 
with 25(OH)D in candidate gene studies.75 
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CYP2R1 
Cytochrome P450 family 2 subfamily R member 1 (CYP2R1) encodes vitamin D 25-hydroxylase which 
converts vitamin D into 25(OH)D. This gene, found on chromosome 11 was first considered 
important in vitamin D metabolism when a mutation on exon 2 was identified to lead to vitamin D 
deficiency.84 Later rs10741657,85–87 rs1279471486,87 and rs1076619774,86 have been shown to have 
associations with 25(OH)D. 
GC 
The DBP, a group specific component is encoded by the GC gene on chromosome four and has been 
shown to be associated with 25(OH)D levels in gene level association studies.88 Two SNPs have been 
consistently associated with 25(OH)D levels in numerous studies; rs7041 encodes a Glutamine to 
Aspartate change at codon 41680,87–91 and rs4588 encodes a Threonine to Lysine amino acid change 
at codon 426.80,87,89,90,92–94 A third SNP, rs2282679 in GC, is of interest as it shows consistent effects 
on 25(OH)D across American,91 African American,83 British87 and Han Chinese populations.90 
VDR 
Vitamin D receptor protein is encoded by the Vitamin D receptor gene (VDR) on chromosome 12. 
This protein is a nuclear receptor transcription factor that binds 1,25(OH)2D to exert its effects. 
rs2228570 (a mutation also referred to as FokI) increases the amino acid structure of this protein by 
three amino acids and influences its activity. This SNP has also been associated with increased 
25(OH)D levels.75,95 The C-G haplotype of rs7139166 and rs54516035 has been shown to increase the 
VDR protein activity in one study.96 
CYP24A1 
The cytochrome P450 family 24 subfamily A member 1 (CYP24A1) gene on chromosome 20, encodes 
an enzyme involved in the breakdown of the 25(OH)D and 1,25(OH)2D. rs17219315 in CYP24A1 has 
been associated with 25(OH)D levels in a single study.74 
Genome-wide association studies 
Genome-wide association studies (GWAS) look across the genome in an unbiased manner to identify 
SNPs which have associations with the trait of interest, in this case 25(OH)D. Due to the number of 
SNPs tested they require large sample sizes to overcome the multiple testing burden. A more 
detailed description of GWAS is given in Chapter 3 and more recent findings from GWAS, including 
results from this thesis are discussed in Chapter 5. 
The first 25(OH)D GWAS had limited coverage of the genome (<80,000 SNPs) and was conducted in a 
small sample, it is unsurprising then that no robust associations were identified.97 Two larger GWAS 
Chapter 2: Introduction 
 23 
with discovery and replication sets have been more informative. Ahn et al. investigated 4,501 as a 
discovery and 2,221 in a replication set98 whereas the largest GWAS (preceding this thesis) was a 
meta-GWAS of 15 cohorts totalling 33,996 across discovery and replications sets by the SUNLIGHT 
consortium (Study of Underlying Genetic Determinants of Vitamin D and Highly Related Traits). SNPs 
in GC and CYP2R1 were identified as having statistical evidence of association beyond the multiple 
testing threshold in both studies, corroborating the candidate gene findings. A SNP near the 7-
dehydrocholesterol reductase gene (DHCR7) was also identified in both studies. This gene is involved 
in the early stages of production of vitamin D in the skin from UV light. Additionally, the SUNLIGHT 
consortium confirmed the link with CYP24A1 from a single candidate study74 by identifying an 
association in the same locus. One limitation of this latter GWAS however was the authors did not 
adjust for ancestry informative principal components. This may have resulted in false positives as 
described in more detail in Chapter 3. 
2.3.5.3 Age 
Vitamin D levels have been shown to decrease with age.99 This is likely to be partly due to changes in 
behaviour but levels of 7-DHC, the substrate for vitamin D synthesis, are also depleted in the skin of 
the elderly.100 
2.3.5.4 Body mass index 
It has been observed for some time that there is an inverse correlation between vitamin D and body 
mass index and other similar anthropometric traits.101 More recently, this inverse association has 
been demonstrated for 25(OH)D with total body fat in women,102 for 25(OH)D and 1,25(OH)2D with 
BMI and total fat mass103 and for 25(OH)D and 1,25(OH)2D with BMI.104 
Despite the consistent correlation being reported, the direction of causality has been difficult to 
determine. A Mendelian randomization study that assessed the association in both directions 
reported a robust causal vitamin D lowering effect of BMI but, if the reverse causal association 
exists, it is likely to be of a very small magnitude.105 
2.3.5.5 Smoking 
The association between vitamin D and smoking has been the subject of several studies, most of 
which report lower 25(OH)D levels in smokers compared to non-smokers in a range of 
populations.106–109 In the most recent of these studies conducted in a Chinese cohort, there was a 
dose response relationship with increased number of cigarettes smoked per day being associated 
with progressively lower 25(OH)D.108 Contrary to these reported associations, one study has found 
no evidence of association between smoking and 25(OH)D levels,110 and in another study the 
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association was seen in males but not females.111 One study examined the effect of the assay used 
to measure 25(OH)D, and found that some commonly used assays over-report 25(OH)D in smokers 
compared to non-smokers.112 This may mean the magnitude of the association between smoking 
and 25(OH)D has been under-estimated. Despite the majority of studies demonstrating a vitamin D 
lowering effect of smoking even after correcting for likely confounders, the true causal link is not 
well understood. 
2.3.5.6 Alcohol use 
Given the correlation between alcohol and smoking, an association between vitamin D and alcohol 
would not be surprising. A systematic review reported that out of 49 papers with effect estimates of 
the association between alcohol use and vitamin D, 30.7% showed higher 25(OH)D levels with higher 
alcohol consumption, 36.7% showed the opposite direction of effect and 32.7% showed no evidence 
of an association.113 This review also commented that over 70% of the studies were of cross-
sectional design and therefore, even when associations were present, effect direction was difficult 
to determine. A further study which was not captured by the search terms of the above systematic 
review showed no evidence of an effect in a Greek population.109 
2.3.6 Vitamin D supplementation 
 Guidelines from several sources exist which recommend vitamin D supplementation of the general 
population.114 There is a range of suggested doses from 600 to 2000 International Units (IU) per day, 
with a maximum recommended dose of 4000 IU per day. The stated aims of the guidelines differ 
with some focussing on reducing skeletal problems, some on reducing vitamin D deficiency and 
others suggesting general health as the reason for supplementation. These recommendations are 
reflected in the global vitamin D market which is expected to be worth $2.5 billion by 2020 with an 
annual growth of approximately 11%.115 
In the US increased vitamin D supplementation has been linked to a modest increase in vitamin D 
levels, as measured by 25(OH)D.116 The increase was greatest in females, especially those known to 
use vitamin D supplements, and it is unlikely that this section of the population is of greatest risk of 
vitamin D deficiency. There is limited evidence of vitamin D levels increasing elsewhere across the 
globe. In contrast there are reports of higher incidences of vitamin D deficiency in the UK117 and 
rickets in Australia118 which may suggest the opposite trend. 
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2.4 The association between vitamin D and head and neck cancer 
2.4.1 Vitamin D and cancer 
The link between vitamin D and cancer dates back nearly 80 years. An IARC review provides a 
detailed breakdown of the evidence assessing the association of 25(OH)D with the most common 
cancers.9 The key findings are summarised below. 
The first evidence linking vitamin D to cancer arose from ecological evidence of UVB exposure and 
cancer incidence and mortality. The hypothesis that low vitamin D increases cancer risk assumes 
that the greater the distance from the equator the lower the UVB exposure, and therefore the lower 
the population’s vitamin D level. In 1941 Apperly looked at UVB exposure and cancer mortality 
across US states and Canada.119 This work reported a positive correlation between index of radiation 
(a measure of UVB exposure) and skin cancer mortality, but an inverse association with all cancer 
mortality. Forty years later Garland and Garland reported the same inverse association for colorectal 
cancer across US states (Figure 2-8).120 
Figure 2-8: The association of solar radiation with colon cancer mortality rate in US states 
from 1959 -1961. (from 120 by permission of Oxford University Press) 
 
Since the 1980s approximately 20 studies have investigated the ecological link between UVB 
exposure and cancer with strong inverse associations identified for colorectal, prostate and breast 
cancers (see IARC review9). There is evidence for an association in the same direction between UVB 
exposure and non-Hodgkin’s lymphoma, ovarian, cervical and uterine cancers but the evidence is 
weak. These studies are all however subject to the limitations of their study design including the 
ecological fallacy, confounding and misclassification which, unlike in individual level data, in 
ecological studies is more likely to bias estimates away from the null. 
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Participant level observational studies of sun exposure and cancer incidence also show evidence for 
a protective effect of increased UVB exposure on breast, colon and prostate cancers (see IARC 
review9). Studies of dietary vitamin D exposure of this type are less conclusive with weak evidence 
for a protective effect of dietary vitamin D on colorectal cancer but limited evidence for other 
cancers.9 
Many observational studies have investigated the association of serum vitamin D levels, usually 
25(OH)D, and cancer. The IARC review has meta-analysed these findings where possible and shows a 
strong protective effect of 25(OH)D on colorectal cancer incidence but less strong effects on breast 
and prostate cancers (Figure 2-9). 
 
Figure 2-9: Meta-analysis of studies assessing association of 25(OH)D on (A) colorectal (B) 
breast and (B) prostate cancer incidence (Reprinted from9 with permission of WHO). 
 
2.4.2 Vitamin D and head and neck cancer 
There are no published studies comparing the population trends of vitamin D levels to that of HNC 
incidence. However, as discussed in the previous sections on HNC and vitamin D, there is a steady 
increase in HNC incidence (despite decreasing smoking prevalence) and the potential for decreasing 
vitamin D levels, due to changes in lifestyle meaning individuals spend much less time outdoors. This 
provides a potential link between vitamin D and HNC which may be able to partly explain the recent 
changes in incidence. In the section below, the evidence linking these two factors is discussed. 
2.4.2.1 Observational epidemiology for HNC risk 
The association between vitamin D and cancers of the head and neck is less well studied than the 
association with colorectal, breast and prostate cancer. This is partly due to it being a relatively rare 
cancer, particularly when the sub-sites are considered independently, limiting power even in large 
cohort studies. Below, the epidemiological studies that have assessed the association of vitamin D 
and HNC are discussed. The study results are combined into a table but it should be made clear that 
the studies differ in terms of their design, vitamin D measure, vitamin D scale and summary effect 
A B C 
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measure. For this reason, the studies should not be directly compared, the aim of the table is to give 
an overall representation of the observational evidence to date (Table 2-2). 
The first interest in the association with HNC was an unexpected finding. Giovannucci et al. 
attempted to improve on the ecological studies that had preceded it, by using a prediction model of 
six 25(OH)D determinants, to estimate individual 25(OH)D levels in over 47,000 men in the Health 
Professionals Follow-Up Study, a prospective cohort study. The model, which explained 28% of the 
variability in 25(OH)D was trained in 1,095 men with the six determinants and serum 25(OH)D 
measured. The association between the predicted 25(OH)D measure and a variety of cancers was 
assessed, including 51 oral or pharyngeal cancer cases. Despite expecting to find associations for the 
digestive-system related cancers, the strongest effect was seen for the oral and pharyngeal cancers 
combined.  After correcting for the common HNC risk factors of smoking and alcohol use, they 
identified a 70% (95% CI: 19% to 89%) reduction in risk of oral or pharyngeal cancer per 25 nmol/L 
increase in estimated vitamin D.121 
A later case-control study of 804 oral and pharyngeal cancer cases assessed dietary intake, recruiting 
cancer cases at diagnosis and using hospital-based controls. Dietary questionnaire data was used to 
estimate vitamin D intake. This estimated vitamin D intake was then split into tertiles. For oral and 
pharyngeal cancer combined, there was a 24% decrease (95% CI: 6% to 40%) in the odds of 
developing cancer in the highest tertile of vitamin D intake compared to the lowest.122 After 
stratifying by smoking and drinking the effect of vitamin D intake was only seen in the highest 
smoking and drinking strata. Estimates were stratified by HNC site, but no obvious differences were 
seen between oral cavity and pharynx cancers. 
Subsequent studies have measured serum 25(OH)D concentration, a reliable biomarker of vitamin D 
from all sources rather than a predicted measure from diet, sunlight exposure or a combination of 
these and other determinants. A case control study investigating the effect of 25(OH)D 
concentration on the risk of oral cavity, pharynx and larynx cancers was nested in the Alpha-
Tocopherol Beta-Carotene Cancer (ATBC) Study, a randomised, double blind, placebo-controlled 
primary cancer prevention trial in Finland. Cases and controls, all males smoking more than five 
cigarettes per day, were selected from the trial participants matched for age at randomization and 
date of baseline serum 25(OH)D measure. 25(OH)D was measured at the pre-randomization phase. 
In this study there was little evidence to support an association between 25(OH)D and the three 
cancer sites combined or individually, although estimates were imprecise with confidence intervals 
including relatively large effects in both directions.123 
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Afzal et al.124 conducted a prospective study of 9,791 participants with baseline serum 25(OH)D 
measures, to investigate the association between serum 25(OH)D concentration and cancer. 
Although they do report results for all cancers combined, their particular focus was tobacco related 
cancers including head and neck cancer (n=122), lung cancer (n=507), bladder cancer (n=112), 
pancreatic cancer (n=109), stomach cancer (n=64), kidney cancer (n=55), liver cancer (n=55) and 
other tobacco-related cancers (n=96). The HR for all cancers, for a 50% reduction in 25(OH)D, was 
1.06 (95% CI: 1.02 to 1.11). This effect was driven by the tobacco-related cancers only (HR=1.20 (95% 
CI: 1.13 to 1.28)) with very little heterogeneity seen between these cancers (I2=0%, P for 
heterogeneity = 0.48). Additionally, a clear dose response relationship was seen across 25(OH)D 
strata for the tobacco-related cancers. Similar to the study by Giovannucci et al.,121 the strongest 
association in the tobacco-related cancers was seen for HNC (HR=1.44 (95% CI: 1.19 to 1.73)).  
In a Danish prospective cohort study of 12,204 participants with serum 25(OH)D measures at 
baseline the association between serum 25(OH)D and several cancers was assessed including 44 
HNC cases. There was some weak evidence to support an association between serum 25(OH)D and 
HNC (HR per 10nmol/L increase in serum 25(OH)D = 0.88 (95% CI: 0.77 to 1.02)). However, this effect 
was almost completely attenuated after correcting for several confounders including smoking (HR = 
0.97 (95% CI: 0.84 to 1.12)).125 
The largest and most recent study examining the association between vitamin D and HNC was 
conducted in the European Prospective Investigation into Cancer and Nutrition (EPIC).126 This nested 
case-control study included 250 HNCs and up to 940 controls, with baseline serum 25(OH)D 
measures. It found a strong protective effect of 25(OH)D, with a doubling of 25(OH)D associated 
with a 46% reduction in the odds of HNC (95% CI: 32% to 56%). This effect is very similar to the 
effect reported in the study by Afzal et al.124 (OR1/2=1.44) when the effect in the EPIC study is re-
scaled for a halving of 25(OH)D (OR1/2=1.45). Correction for alcohol consumption and tobacco use, 
including cotinine in current smokers, led to some attenuation of the effect but this was still of a 
clinically relevant magnitude (reduction of odds = 30% (95% CI: 44% to 12%)). When stratified by 
HNC site, the strongest fully adjusted estimate was seen for larynx and hypopharynx cancers (OR 
= 0.55 (95% CI: 0.39 to 0.78)), then oral cavity cancers (OR = 0.60 (95% CI: 0.42 to 0.87)) whereas 
there was little evidence for an effect in oropharynx cancers (OR = 0.92 (95% CI: 0.58 to 1.45)). Given 
the heterogeneity across HNC sites discussed above, it is not surprising that these different effect 
sizes exist, and they may reflect real differences in causal effects of vitamin D or different 
confounding structure across sites. 
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Table 2-2: Effect of vitamin D on HNC risk from observational studies. 
   
These studies vary in terms of design, vitamin D measure, vitamin D scale and summary effect measure. 
They should not be directly compared but the figure should give a feel for the overall observational evidence 
to date.  
Although these studies are difficult to compare directly, they all would be consistent with an 
increase in vitamin D reducing the risk of HNC (although some would also be consistent with a null or 
opposite association). Of these studies, three were of case-control design122,123,126 and so would 
usually be subject to recall bias. However, the Fanidi et al.126 and the Arem et al.123 studies were 
nested within an RCT and a prospective cohort respectively. As a result, the measurement of the 
exposures can be considered as robust as those from a cohort study design (discussed below). The 
Lipworth et al.122  study however, used a recall diet diary at the time of diagnosis to assess vitamin D 
levels for the previous two years. The recall of this information will certainly be subject to random 
error but may also be affected by recall bias as, the recent diagnosis of HNC may affect how a 
patient recalled their recent dietary intake, potentially over-estimating the effect of dietary vitamin 
D. 
Three of the studies reported above are prospective in design with 25(OH)D measures at baseline. In 
terms of the measurement of exposures, the nested case-control (often referred to as case-cohort) 
studies can be considered alongside these. In most settings, prospectively measured 25(OH)D should 
be unbiased with respect to the outcome however this may not be the case here. HNC cancer has a 
very long latency, meaning its developing may be subclinical for many years or even decades before 
diagnosis. Even with the assumption that 25(OH)D casually effects HNC, it is unclear at what 
timepoint 25(OH)D levels are important in the development of HNC but it is likely to be years to 
decades rather than months to years from diagnosis. This has two implications on the results of the 
prospective cohort studies and the nested case-control studies. Firstly, despite serum 25(OH)D being 
a good measure of recent vitamin D levels, it is unlikely that the 25(OH)D measurement in these 
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the individual. This would result in reduced power to detect 25(OH)D effects on HNC. Secondly, in 
studies where follow-up is relatively short such as in the Fanidi et al. (6.3 years) and Arem et al. (~8 
years) studies, there is a chance that the (as yet undetected) subclinical HNC is influencing the 
25(OH)D levels. This would result in reverse causality and overestimate the effect of vitamin D on 
HNC risk. As the results from the studies above are not directly comparable, it is difficult to interpret 
what the effect of longer follow up has on the study results but the longest follow-up is 27 years in 
the Afzal et al. study which does report strong evidence of a protective effect of 25(OH)D on HNC 
risk. 
A major limitation of both case-control and cohort studies is the inability to fully account for 
confounding. In both study designs, multivariable regression methods are used to correct for 
measured confounders but little can be done to account for unmeasured confounders or 
confounders which are measured with error or bias as is likely to be the case in retrospective 
studies. This concept is discussed further in the section below using tobacco use as an example. 
2.4.2.2 Tobacco use and the association between vitamin D and HNC risk 
Many of the observational studies reported above suggest that tobacco plays a role in the 
association between vitamin D and HNC risk. In all studies that report adjusted and unadjusted 
estimates, there is some attenuation of the effect after correcting for potential confounders, 
including smoking.121,122,125,126 Additionally, where studies identified an association between vitamin 
D and HNC, the effect of vitamin D was seen predominantly in the current or former smokers.122,124–
126 
The study by Afzal et al. focussed on tobacco-related cancers, but the study was conducted in both 
ever and never smokers. As mentioned above, the effect of 25(OH)D on tobacco-related cancers was 
attenuated in the never smokers, although the estimate was imprecise, given the relatively small 
proportion (20%) of never smokers developing a tobacco-related cancer. Interestingly, within the 
smokers, there was minimal variation in the effect size across strata of current tobacco consumption 
(reported as grams/day) or pack-years. The authors reported that they consider tobacco use to be a 
confounder of the 25(OH)D – cancer association rather than an effect modifier however, the power 
to provide clear evidence of this interaction would have been limited in this study. 
In the EPIC study,126 the authors point out that residual confounding by tobacco exposure was 
identified as a concern. In sensitivity analyses a correction was made for additional indicators of 
tobacco exposure in the current and former smoker strata. These adjustments had little effect on 
the associations leading the authors to conclude that they did not feel residual confounding was able 
to explain the protective association identified in this study. 
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Smoking has been shown to reduce 25(OH)D levels (see section 2.3.5.5) and is the largest known risk 
factor for HNC, particularly for oral, laryngeal and non-HPV oropharyngeal cancers. There are two 
ways in which smoking may influence the effect of vitamin D on HNCs. Firstly, smoking is a known 
confounder of the association as shown by the attenuation of effects when adjustments are made 
for it. Residual confounding may partly explain any remaining effect of vitamin D on HNC. Secondly, 
smoking may act as an effect modifier of the vitamin D effect. In this scenario, the protective effect 
of vitamin D is causal but is only seen in smokers – having no effect in non-smokers. This theory is 
partly supported by several of the studies above which identify an effect of vitamin D only in 
smokers and previous smokers. 
2.4.2.3 Randomised controlled trials 
Double blinded randomised controlled trials (RCT) are the gold standard study design when 
assessing for causality between an intervention and an outcome. To date there have been no HNC 
specific RCTs to assess the effect of vitamin D supplementation. Four large RCTs which have cancer 
incidence as a primary or secondary outcome have been conducted. The first of those, the UK Trial 
for Prevention of Osteoporotic Fracture, assessed cancer incidence as a secondary outcome but 
found little evidence of a protective effect of vitamin D supplementation (age adjusted RR = 1.11 
(95% CI: 0.86 to 1.42)). The Women’s Health Initiative Trial assessed colorectal cancer incidence as a 
primary endpoint, finding no evidence of an association. They also reported a near null association 
with all cancer incidence (RR = 0.98 (95% CI: 0.85 to 1.09). The Nebraska Trial, much like the UK 
study, assessed osteoporotic fracture as a primary endpoint but also reported a protective effect of 
vitamin D on all-cancer incidence. The results of this trial have been much criticised127–129 with claims 
of failed randomization, incorrect choice of statistical tests and not reporting key details that would 
be considered compulsory by the CONSORT guidelines. Re-analysis in the IARC report suggests the 
vitamin D effect would be near null using the correct methodology.9 More recently the very large 
VITAL study randomised over 25,000 participants over the age of 50 years of age in a two-by-two 
factorial randomised double blind placebo controlled trial assessing vitamin D and omega 3 fatty 
acids. The primary outcome was primary cancer prevention and the 2000 IU per day vitamin D 
supplement was associated with a near null effect after the five year follow up (RR=0.96 (95% CI: 
0.88 to 1.06)). 
The VITAL trial was the largest of its type but even at this size we would expect only about 35 cases 
of HNC over the course of the trial. Assuming the incidence of HNC is approximately 20 per 100,000 
people, even if the effect estimate is as large as that reported in the EPIC study above, a vitamin D 
trial would need approximately 300,000 participants in each arm to detect an effect. Given the VITAL 
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study cost approximately $22 million a trial assessing the effect of vitamin D and HNC using a RCT is 
not feasible. 
2.4.2.4 Vitamin D and head and neck cancer prognosis 
When considering epidemiological evidence there is a need to consider factors that affect the risk of 
cancer, often looked at in the general population, differently to those that affect the survival or 
prognosis of a cancer patient. This distinction is important and the factors that affect cancer risk are 
not necessarily the same as those that will influence the prognosis after diagnosis. One example is 
smoking and lung cancer; stopping smoking will have a large effect on an individual’s risk of 
developing lung cancer but once lung cancer has developed, stopping smoking may only have a 
trivial effect on a patient’s prognosis. In some study designs, such as the ecological studies 
mentioned above, that look at cancer mortality in the general population, the outcome is a 
combination of developing a cancer and then that cancer progressing, but this is not usually the 
case. 
This thesis will focus predominantly on the effect of vitamin D on HNC incidence (risk), but where 
data are available it will assess the effect with cancer prognosis. The epidemiological evidence 
assessing the effect of vitamin D on prognosis is limited and is summarised below. 
Meyer and colleagues first assessed the effect of 25(OH)D on HNC prognosis in 2011130 is a study 
nested within a randomised trial for b-carotene or vitamin E. Serum 25(OH)D and vitamin D intake 
(from diet and supplements) was recorded at diagnosis and split into quartiles in the 540 
participants. Associations between serum 25(OH)D or vitamin D intake quartile were assessed with 
HNC recurrence, second primary and overall mortality. There was no strong evidence for association 
of either exposure with the outcomes, although for overall mortality, the direction of effect was 
protective (lowest versus highest 25(OH)D quartile HR = 0.85 (95% CI: 0.57, 1.28)). 
A study later that year investigating 88 consecutive newly diagnosed HNC patients found evidence of 
a protective effect of 25(OH)D levels at diagnosis with disease free survival (RR per 1ng/ml increase 
in 25(OH)D = 0.85 (95% CI: 0.75, 0.90)) and overall survival (RR = 0.89 (95% CI: 0.83, 0.97)).131 
The most recent work assessing the association between 25(OH)D levels at diagnosis and HNC 
survival identified a similar protective effect.132 In this study HNC patients were split into low (below 
the mean) and high (equal or higher than the mean) 25(OH)D groups. In the low vitamin D group 
42.6% of patients died during follow up but in the high vitamin D group only 30.3% of patients died, 
equivalent to a risk ratio of 0.71. 
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These studies seem to suggest an observational protective effect of vitamin D on HNC prognosis 
however they may all be affected by measuring vitamin D at diagnosis. It is conceivable that patients 
who have more advanced disease are more likely to remain inside and have poorer diets than those 
with less advanced disease, reducing their vitamin D levels. If this is the case, 25(OH)D may be a 
marker of cancer stage rather than a causal factor in patient prognosis. One study nested within the 
EPIC cohort study126 recorded pre-diagnosis 25(OH)D so would not be affected by this issue. In this 
study of 250 HNC participants the hazard ratio (HR) for a doubling of 25(OH)D was 0.73 (95% CI: 
0.53, 0.97). This association was not attenuated by adjusting for confounding or when only including 
participants who had 25(OH)D measures greater than five years before diagnosis. This suggests that 
cancer-related lowering of 25(OH)D is unlikely to be responsible for the association seen in the 
previously discussed studies. It does however seem as though stage at diagnosis has a role in the 
25(OH)D – HNC prognosis association, in the 161 cases with stage data in this study, the association 
was attenuated after correction for stage. 
2.4.3 Vitamin D cancer protective mechanisms 
The clear distinction between the epidemiological study of risk and prognosis does not necessarily 
hold true for mechanistic studies of cancer. Cancer mechanisms are multi-stage processes which 
likely require errors to occur in multiple normal cellular processes. It can be difficult to distinguish if 
these process errors map to the concept of cancer risk, prognosis or both. They can however, be 
considered more closely related to cancer initiation (increased proliferation, errors in differentiation 
and reduced apoptosis) or more closely related to the prognosis of a cancer patient (factors that 
affect local spread and metastasis e.g. angiogenesis). 
There is a large body of work investigating the mechanism by which vitamin D may exert protective 
effects on cancer. Much of this work focusses on the cancer sites that have also received the most 
focus in epidemiological studies, colorectal, breast and prostate cancers. This work has been 
reviewed by Deeb and collegues133 and is summarised in Figure 2-10. Those processes that are of 
particular importance in HNC are described below. 
Chapter 2: Introduction 
 34 
Figure 2-10: Key cancer-related signalling pathways targeted by 1,25(OH)2D (from 133 
Reprinted by permission from Springer Nature) 
 
2.4.3.1 Epidermal growth factor (Figure 2-10a) 
Epidermal growth factor (EGFR) is a cell surface receptor which when activated by its ligand, 
transforming growth factor alpha (TGFa), inhibits cell differentiation, apoptosis and growth. The 
active form of vitamin D, 1,25(OH)2D, has been shown to inhibit this pathway to exert its anti-cancer 
effects. It has been shown that EGFR mRNA is on average 29-fold higher in normal oral tissue of 91% 
of HNC patients compared to controls and TGFa mRNA is on average five-fold higher in 95% of 
normal tissue of HNC patients compared to controls, with differences even more pronounced in 
tumour tissue.134 
2.4.3.2 Cyclin-dependent kinase inhibitor 1B and cyclin D (Figure 2-10e) 
Cyclin-dependent kinase inhibitor 1B (p27) is an enzyme inhibitor which downregulates cell cycle 
progression at G1 by inhibiting cyclin D dependent phosphorylation of retinoblastoma in the nucleus. 
1,25(OH)2D has been shown to activate p27 and therefore maintain control of cell cycle progression 
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but p27 is downregulated in oral SSCs suggesting it may have a role in these cancers.135 This is 
further supported by studies showing cyclin D is amplified in 20-50% of oral SCC.136 
2.4.3.3 Transforming growth factor beta (Figure 2-10f) 
Transforming growth factor beta (TGFb) acts via SMAD proteins to inhibit cell cycle progression via a 
different mechanism to cyclin D, a process which is activated by 1,25(OH)2D. TGFb is thought to have 
several roles in HNC including a role in cancer initiation, as a potent tumour suppressor and later in 
the cancer mechanism by being involved in epithelial-mesenchymal transition and facilitating 
metastasis.137 
2.5 Summary 
HNC has an extremely high level of morbidity and mortality. Despite the main risk factors being well 
understood, approximately 30% of PAR cannot be explained by these factors. In addition, there has 
been a recent shift in characteristics and worrying increase in incidence of OC and non-HPV related 
OPC. This change is difficult to explain with the parallel reduction in smoking levels and stable levels 
of alcohol use and there is therefore a requirement to identify novel causal risk factors which may 
explain these trends. 
Vitamin D has been linked to many disease states over recent decades but evidence of strong causal 
associations is difficult to establish. Vitamin D deficiency is easily modifiable and supplementation is 
becoming more common, despite this there are concerns that changes in working and lifestyle 
patterns mean populations have chronically low vitamin D levels. 
There is strong evidence for a protective association of vitamin D on cancer incidence and prognosis 
from mechanistic and observational epidemiological studies. For HNC, the observational estimates 
suggest large reductions in risk, particularly for OC. Vitamin D levels, measured before or at 
diagnosis, have also been strongly associated with improved cancer prognosis. Despite this 
observational evidence, causality has not been established in either cancer incidence or prognosis. 
Smoking is likely to be a strong confounder of the relationship with HNC incidence but well-designed 
prospective studies have shown clinically relevant effects even after robust correction for smoking. 
There is inconsistency across studies however and where strong evidence exists it tends to attenuate 
in non-smokers. Additionally, there is likely to be residual confounding of other imprecisely 
measured or unmeasured confounders, biasing the observational estimates away from the null. 
RCTs are not a practical method to investigate HNC incidence due to the relatively rare disease in 
question and trials of vitamin D as an adjuvant in HNC patients would require stronger evidence 
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before clinical trials would be indicated. Alternative methods are required to assess the causal effect 
of vitamin D on HNC incidence and prognosis to inform whether future research and health 
resources should be used in this area. It is into this unoccupied niche which this thesis sits. 
This thesis aims to identify the true causal effect of vitamin D on oral and oropharyngeal SCC risk by 
triangulating evidence from the most robust observational sources and Mendelian randomization. 
Secondly, the thesis aims to conduct preliminary studies to apply these methods to study the true 
causal association between vitamin D and oral and oropharyngeal SCC prognosis. 
The next chapter 
In the next chapter I introduce the concept of causality and present a series of models by which to 
appraise evidence for causal inference. The general methods and resources used in the rest of this 
thesis are also described.  
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Chapter 3 :  Methodological Overview 
3.1 Chapter objectives 
In this chapter I introduce the concept of causality and issues which can prevent causal inference. I 
go on to describe the approaches that will be used in this thesis and how they can contribute to 
estimating a causal effect estimate. Finally, I describe the main resources used within the following 
results chapters. 
3.2 Causality 
3.2.1 What is causality 
Causality in epidemiology is not a straightforward concept and there are various definitions that 
exist within the field that stem from many centuries of philosophical discussion. They span a range 
of concepts of causality138 but typically relate to a “difference making” approach.139 One such view of 
causality is the counterfactual view that, had the cause been “different”, or more specifically absent, 
then the effect would also be absent, in at least some of those being studied. A second view is that 
of contrastive causation, in which the exposure is only a cause given a particular contrast e.g. 
moderate smoking is only a cause of lung cancer with reference to smoking abstinence but not with 
reference to heavy smoking. Within this view, the contrasts can be identified for both exposure and 
outcome. The third view, interventionist causation, relies on a cause being something we can 
imagine intervening on. This can be further split into thinking about causes which are possible to 
intervene on, e.g. a drug, or those that we can in principal intervene on but are not necessarily 
possible or feasible at the current time. An example of the latter is the BRCA1 mutation which 
cannot currently be altered but is a very well-established cause of breast cancer. In the possible 
interventionist view of causality, the BRCA1 mutation would not be considered causally related to 
breast cancer. This view of causality limits the type of causal questions which can be posed and 
limits the epidemiological tools available to investigate causality to only those that implement a 
possible intervention.139 In this thesis, the less restrictive view of causality will be used in which 
anything we can imagine intervening on can be considered causal. 
3.2.2 How do we investigate causality? 
As discussed in Chapter 2, conducting a large RCT for 25(OH)D supplementation to assess the causal 
effect on HNC risk is possible but not necessarily feasible. In order to investigate causality in this 
question other strategies, other than an RCT are required. Sir Austin Bradford Hill proposed nine 
concepts that should be studied when deciding if any factor should be considered causal or merely 
the result of association. Hill suggested that these concepts should be applied to the research 
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question under study before deciding if the most likely interpretation is causality. The nine concepts 
are described below in the context of this thesis: 
3.2.2.1 Strength of association 
In this concept Hill argues that the larger the strength of the association the more likely it is to be 
true. In the context of HNC, the odds of developing laryngeal cancer in non-drinking heavy smokers 
(31-40 cigarettes per day) versus never smokers is very high (OR~18). In comparison the odds of 
developing oral cavity cancer in non-drinking heavy smokers is much more moderate (OR~3). It is 
inconceivable that a third factor could be so strongly interlinked with smoking that it was the real 
underlying cause in larynx cancer, without that third factor being easily detected. On the other hand, 
it is much more conceivable that a third factor could be related to smoking, for example poor oral 
hygiene, that might explain the smaller association with oral cavity cancer, without it being easily 
detected. It should be noted however that this concept does not work in reverse, as there are many 
instances in medicine in which factors that have small effects on an outcome are genuinely causally 
related. 
3.2.2.2 Consistency 
This concept relates to multiple sources of evidence all pointing to the same finding. The greater the 
variety of evidence, be that relating to situation or technique of the study, the lower the likelihood 
of there being a constant error that would explain a non-causal association in all situations. It is 
important to note that there may be circumstances where a constant error is in fact present in 
nearly all situations and if this is the case, there will likely be an alternative hypothesis to causality. 
In the context of this thesis, there is observational evidence for an effect of 25(OH)D on HNC risk 
from several prospective and retrospective sources and this begins to provide stronger evidence of a 
causal relationship. However, when smoking is considered across these differing studies the effect is 
often only seen in non-smokers. This may point to a consistent failure to appropriately account for 
smoking in each of the studies and therefore, the alternative hypothesis, that residual confounding 
explains the association across the differing study designs, is more likely. This concept is similar to 
that of Triangulation, which is discussed below. 
3.2.2.3 Specificity 
A specific effect of an exposure on a particular outcome may provide stronger evidence of a causal 
effect compared to that same exposure having an effect on many outcomes. The example Hill 
quotes relates to the causal association of a workplace exposure leading to death by a specific 
disease but, not being associated with other causes of death.140 This would suggest that the 
exposure is causally related to the disease leading to death. Vitamin D has been linked to many 
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diseases over recent decades and so does not necessarily fulfil this criteria but this is also true for 
smoking. In these cases, where an exposure is related to many health outcomes, Hill suggests 
referring back to his first concept and assessing for specific (and large) effect sizes for a particular 
disease. 
3.2.2.4 Temporality 
The concept of temporality relates to identifying the order of exposure and outcome. Although this 
is often easily identified, it can be problematic in diseases which develop relatively slowly such as 
HNC. For vitamin D to be causally related to HNC, low levels must precede development of the 
cancer. The alternative hypothesis is that an early cancer may, unbeknown to the patient or 
researcher, influence diet and lifestyle and result in lower vitamin D levels, essentially the cancer 
becomes the cause for the low vitamin D (often referred to as reverse causality). 
3.2.2.5 Biological gradient 
This concept relates to an increase in the exposure corresponding to an increase in the outcome, 
often referred to as a dose-response relationship. An example is again provided by the effect of 
smoking on laryngeal cancer which, shows a clear dose-response relationship with both number of 
cigarettes smoked per day and the number of years smoked.32 This gradient of effect is much more 
convincing of causality than an association which is stronger in light smokers than in heavy smokers. 
3.2.2.6 Plausibility 
This concept relates to there being an understanding of the biological mechanism underpinning the 
association. Hill suggested we should not hold this concept too highly, as it relies on biological 
knowledge at the time of study. There have been many, now established, causes of disease which 
did not seem plausible at the time of discovery. 
3.2.2.7 Coherence 
The concept of coherence is opposite to that of plausibility. Any causal association should not 
conflict with the known natural history and biology of the disease. For example, the incidence of 
laryngeal cancer does not conflict with the sex and geographical distribution of smoking, nor does it 
conflict with the understanding that tobacco smoke, a known carcinogen, contacts the laryngeal 
tissue during inhalation. 
3.2.2.8 Experiment 
In certain situations, the relationship under examination can be assessed using experimental 
evidence. In the case of this thesis, 25(OH)D supplementation is possible and an experimental study 
could form very strong evidence of causality if the study design is appropriate. Experiment does not 
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solely relate to RCTs as many other experimental methods exist and can contribute to assigning 
causality without being convincing on their own. 
3.2.2.9 Analogy 
This concept relies on there being similar causal associations which we can use to judge another. 
Analogy may be particularly useful when new evidence is found of a potential causative agent 
and/or when the consequences of ignoring a potentially causal relationship are very high. For 
example, if a drug similar to thalidomide was available it would be sensible for it not to be given to 
pregnant people. A HNC related example of this could be used when investigating explanations for 
the recent rise in non-HPV related oropharyngeal cancer in non-smokers. In the past, a similar 
increase in the incidence of oropharyngeal cancer occurred and it is now known to be an increase in 
HPV infection that was the cause. It would be unwise to ignore evidence of a new infective risk 
factor for oropharyngeal cancer, given what is known about the causal effect of HPV on this cancer. 
Hill stated in his President’s address to the Royal Society of Medicine, that these concepts do not 
form “hard-and-fast rules of evidence that must be obeyed before we accept cause and effect” 140 
but instead provide a framework on which to base the study of causality. 
3.2.2.10 Triangulation 
One aspects of Hill’s approach, the concept of consistency, is very similar to the practice of 
triangulation which is another useful framework when investigating causality. Triangulation is 
defined as: 
“The practice of strengthening causal inferences by integrating results from several 
different approaches, where each approach has different (and assumed to be largely 
unrelated) key sources of potential bias.” 141 
Lawlor et al. set out a series of criteria that should be met for triangulation to be valid in 
observational epidemiology. These are: 141 
• Results from at least two, but ideally more, different approaches, with differing and 
unrelated key sources of potential biases, are compared. 
• The different approaches address the same underlying causal question. 
• Related to the above criterion, for each approach the duration and timing of exposure that it 
assesses is taken into account when comparing results. 
• For each approach the key sources of bias are explicitly acknowledged when comparing 
results. 
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• For each approach the expected direction of all key sources of potential bias are made 
explicit where this is feasible, and ideally within the set of approaches being compared there 
are approaches with potential biases that are in opposite directions. 
3.2.2.11 Causality in the context of this thesis 
Triangulation and Hill criteria overlap but provide a sensible approach to assess the question of 
causality in the association between vitamin D and HNC risk (and prognosis). Potential explanations 
for the association between vitamin D and HNC risk are depicted in the directed acyclic graphs 
(DAGs) below. These DAGs represent the extreme situations to demonstrate the different potential 
relationships between vitamin D and HNC clearly and in reality more than one may be true at the 
same time. In terms of causal diagrams, the aim of this thesis is to identify which of these DAGs most 
likely represents the association between vitamin D (exposure - E) and HNC incidence (outcome - O). 
In these diagrams, measured covariables (C) and unmeasured covariables (U) are also included to 
demonstrate the possible situations. 
Causal association 
Figure 3-1: Directed acyclic graph representing a causal association between vitamin D and 
HNC incidence. 
 
In the causal model vitamin D (E) is causally related to HNC incidence (O). Measured and unmeasured 
variables (C/U) also cause O. For the estimate of E-O to be unbiased there must be no effect of C/U on E. 
There is a special case of this model in which E is causally related to O, but only when a third variable (such 
as smoking) is present. This special case represents an interaction between E and C (C is acting as an effect  
modifer) and can be investigated by calculating E-O across levels of C. 
Complete confounded association 
Figure 3-2: Directed acyclic graph representing a complete confounded association between 
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In the complete confounded association vitamin D (E) does not cause HNC (O). The apparent association 
seen can be explained by a measured or unmeasured variable (O/U) being related to both E and O. If this 
variable is measured without error, conditioning the outcome by C should give a effect magnitude of zero. In 
cases when C is measured with error, or is unmeasured (U) the effect of E-O will be non-zero due to residual 
confounding. There may also be situations when there is partial confounding when a true causal 
relationship is biased by confounding, unless the study design or statistical approach is appropriate, this can 
be difficult to distinguah from residual confounding. 
Reverse causal association 
Figure 3-3: Directed acyclic graph representing a reverse causal association between vitamin 
D and HNC incidence. 
 
 
In the reverse causal association, E does not cause O but O does cause E. This may be because the onset of 
the disease alters behaviour in some way. Assessing the association with proper understanding of 
temporality will usually allow the reverse causal to be distinguished from the causal. 
In this thesis I will attempt to apply as many of the concepts of Hill and triangulation as possible to 
investigate the association between vitamin D and HNC. To accomplish and distinguish between the 
DAGs presented above, I will use a series of statistical approaches across a variety of study designs. 
These approaches and others used within the thesis are summarised below, I then provide 
summaries of the resources in which these approaches are applied. 
3.3 Statistical approaches used in this thesis 
3.3.1 Multivariable regression 
Regression modelling is the process of fitting a line to best describe a relationship between two 
variables to give you the intercept and the slope of that line. In this thesis linear, logistic, conditional 
logistic and Cox-proportional hazards regression will be used to investigate continuous, binary, 
paired binary and time to event data respectfully (these are discussed in more detail below). 
Using linear regression, the simplest form of regression, as an example, the intercept will be the 
value of the outcome when the exposure is zero and the slope (beta or regression coefficient) will 
equal the effect size for a one unit increase the exposure. In the case of a normally distributed 
continuous outcome and a binary exposure, this beta will be the difference between the means of 
the two levels of the exposure and the test for evidence against the null is equivalent to a t-test. 
E O 
C/U 
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Multivariable regression allows us to include more than one exposure into the model and has two 
main advantages over calculating effect sizes numerically. Firstly, it allows the effect size of an 
exposure on an outcome to be estimated while taking into account other measured exposures which 
influence the outcome. This approach can be used to account for confounding in situations such as 
that detailed in Figure 3-2 above. In this thesis I will use this approach to adjust estimates of effect 
between vitamin D and HNC for bias by confounding. The second advantage, which does not apply 
for logistic and Cox regression, is that when other variables that explain variance in the outcome are 
included in the model, the standard error of the regression coefficient (effect size) will be lower and 
therefore improve the statistical power of the analysis. 
3.3.1.1 Linear regression 
As explained in the example above, linear regression is used to investigate the association between 
at least one exposure and a continuous outcome. In this thesis this approach will be used to assess 
the association of a range of variables with both serum and proxy measures of vitamin D. There are 
two main assumptions which should be met for the approach to be valid. Firstly, for any value of the 
exposure the outcome must be normally distributed. This is not always the case and an example of 
this is 25(OH)D which is right skewed. In these instances, transformation of the outcome is required 
so that it approximates normality. Secondly, the spread of the points around the regression line is 
assumed to be equal across the full length of the line. Linear regression is limited to estimating linear 
associations and if the exposure and outcome are not related in a linear fashion the effect estimate 
from this approach will be invalid. 
3.3.1.2 Logistic regression 
Logistic regression is an approach to investigate the effect of at least one exposure on a binary 
outcome. This approach is particularly important in this thesis to investigate factors which are 
related to getting HNC or not (a binary phenotype). Logistic regression allows a (generalised) linear 
model to be applied to a binary outcome by modelling the binary outcome on a log odds scale. 
When considering a binary exposure, the coefficient of a logistic regression is the log odds ratio for 
having HNC in the exposed group compared to the unexposed group and the intercept is the log 
odds of having HNC in the unexposed group (baseline odds). Commonly, the log odds ratio of being 
exposed is exponentiated to an odds ratio (OR) which would be comparable to calculate this value 
from a two-by-two table. This approach can be extended to a continuous exposure where the 
interpretation of the OR is the ratio of odds between an exposure of x+1 relative to an exposure of x. 
Much like linear regression the main advantage of logistic regression is to allow for the correction of 
confounding by measured covariables. This is achieved by including more than one exposure in the 
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model. Logistic regression requires observations to be independent of each other, there must be 
little or no co-linearity between the independent variables and the independent variables should be 
linearly related to the log odds. 
3.3.1.3 Conditional logistic regression 
Conditional logistic regression is a special case of logistic regression where there is the assumption 
that there is pairing of cases and controls. The pairing is achieved by matching values of specific 
confounders so that each individual with a matched set has the same (or very similar) value. In 
conditional logistic regression, confounding by the specific confounders is accounted for as the 
association between the exposure of interest and the outcome is only made within the matched 
sets. Adjustment for additional confounders, which have not been matched, can be achieved by 
including them in the regression model. 
3.3.1.4 Cox proportional hazards regression 
This is the most common approach when conducting regression analyses in time to event data or 
survival data. In this method the values of the exposures for an individual who has just had an event 
is compared to the exposures of all the other subjects who have not yet had an event. For this 
approach to be valid, the ratio of the hazards comparing different exposure groups must remain 
constant over time. The output (or coefficient) of the regression is the log hazard ratio but the 
baseline hazard is not estimated as it can change over time. Similarly, to the other regression 
approaches discussed above, the main advantage of Cox regression is that multiple exposure 
variables can be included in the model to account for confounding. 
3.3.2 Stratification 
Stratification is an alternative approach to correct for confounding. In this approach the association 
of interest, e.g. between vitamin D and HNC, is assessed within strata of the confounder of interest. 
Much like conditional logistic regression, the effect of the confounder is removed as there is no 
variation in the confounder within the strata. In order to achieve an overall effect estimate which 
accounts for the confounder, similar to that from a multivariable regression model, the strata 
specific effect estimates can be combined using a weighted average. A second advantage of 
stratified analyses is to identify if that variable is acting as an effect modifier. In this scenario, the 
effect of the exposure on the outcome will vary according to the level of the confounder. Effect 
modification is one of the explanations for the association between vitamin D and HNC risk only 
being identified in current or former smokers and stratification will be used to investigate this in this 
thesis. 
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3.3.3 Genome-wide association studies 
Genome-wide association studies (GWAS) scan across the genome to identify genetic variation 
which is associated with a disease or trait of interest in a largely unbiased approach.142 In this thesis I 
will use this method to identify genetic variation that robustly influences serum 25(OH)D levels 
which can then be used as genetic proxies for vitamin D. In a GWAS, a trait and genetic information 
from across the genome is measured in all individuals in the sample. As an example, consider a 
single nucleotide polymorphism (SNP) in which an adenine (A) or a cytosine (C) nucleotide base 
(referred to as alleles) exists at that genomic position in the population. In each individual, the SNP 
can either be homozygous for the reference base (AA, zero effect alleles), heterozygous (AC, one 
effect allele) or homozygous for the effect allele (CC, two effect alleles). This three-level variable 
becomes an ordered categorical exposure and is regressed against the trait of interest. This is 
repeated across all genetic sites. The output of a GWAS is an effect size and standard error for a one 
unit increase in the effect allele and a P-value against the null hypothesis of no effect. For GWAS 
estimates to be correct they assume that genotypes are randomly distributed across the sample 
population and that if the design in case-control in nature that the cases were drawn from the 
control population (in terms of genetics). Violation of these assumptions can invalidate findings and 
some examples are discussed below. 
3.3.3.1 Measuring genetic information 
Measuring genetic information is usually achieved using a genotyping array which uses a high 
throughput approach to genotype a set number of positions on the genome, approximately 500,000. 
These positions are strategically selected as they provide enough information to infer the remaining 
genetic information using imputation. Genetic imputation relies on linkage disequilibrium, where 
runs of genetic sites between breakpoints are inherited together. These breakpoints are identified 
from reference panels of whole genome sequenced individuals and then applied in a probabilistic 
approach to identify the most likely allele at sites not genotyped on the array. The genotyping stage 
is usually performed in batches as not all samples can be genotyped at the same time. 
Alternatives to array-based genotyping exist including whole genome or exome sequencing. In these 
processes, there is much greater coverage of the genome compared to array-based genotyping and 
the process of imputation is not required. In these genotyping methods we can be surer of a 
particular allele at certain sites, particularly those that have low frequency in the reference 
population. 
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3.3.3.2 Complications in GWAS studies 
Multiple testing burden 
As GWAS studies use an unbiased, hypothesis free approach to discover genetic variation, they 
conduct a very high number of statistical tests creating a large multiple testing burden. To reduce 
false positives, a Bonferroni corrected P-value threshold is used by dividing the arbitrary 5% alpha by 
the effective number of independent tests. This effective number of tests is lower than the actual 
number of tests performed as it takes into account the correlation between genetic sites. It is 
typically set a 5x10-8 and is often referred to as the genome wide significance threshold. 
Sample size 
Common genetic variation predominantly results is small effects on the trait of interest. Variation 
with large effects are either selected against, if detrimental, or predominate if beneficial and 
therefore are uncommon. Given these small effect sizes and the high multiple testing burden, 
identifying genetic variation requires very large sample sizes. Very large population-based studies 
are starting to be developed, for example UK Biobank which has over 500,000 participants 
(described below), but these are relatively recent projects. The main stay of GWAS are large 
collaborations of many smaller studies which are combined by meta-analysis to provide adequate 
power for discovery, often termed meta-GWAS. 
Sources of bias in GWAS studies 
Information bias is not often a problem in GWAS studies as genotyping completeness and quality is 
very high. Furthermore, any small error is not often related to the trait in question. An exception to 
this is when the genotyping batch correlates in some way with the trait of interest. This could 
happen if samples are genotyped as they are collected and therefore any trait with seasonal 
variation, such as vitamin D, may be associated with any small genotyping errors between batches. 
The avoidance of this type of error is relatively straight forward with careful study design. 
Selection bias can theoretically occur in case-control GWAS if the control population does not 
represent the population from which the cases are sampled or there is poor participation rates in 
the control sample. Despite this, very few instances of false positives have been reported due to this 
error and this is likely to be because the source of potential bias is not strongly associated with 
genotype.143 Furthermore, with the move towards large meta-GWAS, selection bias within any single 
study bias becomes even smaller with respect to the overall pooled estimate. 
Confounding bias in GWAS is most likely to come from population stratification. Genotypes are 
randomly allocated at gamete formation and segregation meaning that, in a population with 
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homogenous ancestry and the assumption of random mating, the association between genetic 
variant and trait of interest is unconfounded. However, in a non-homogenous population, 
differences in allele frequency which relate to ancestry may correlate with environmental or 
behavioural differences introducing bias. Vitamin D may be particularly affected by population 
stratification as 25(OH)D levels are strongly influenced by skin colour and latitude, both of which will 
be related to ancestry. For example, any genetic variants which are correlated with ancestry in a 
similar way to those that influence skin colour, but do not causally influence vitamin D may be 
identified in GWAS by error if ancestry is not dealt with. This type of bias can be addressed by 
including genetic principal components in the statistical model to account for the differences in 
allele frequency across sub-populations, or alternatively using a linear mixed model for the analysis. 
Further details of how other forms of latent structure in genetic studies can influence results of 
applied genetic analyses is discussed in work to which I contributed.144 
3.3.4 Mendelian randomization 
MR is an analytical approach to estimate causal effects between an exposure and an outcome.145,146 
It is a type of instrumental variable analysis as it uses a proxy measure of the exposure which, is 
unrelated to confounders and only influences the outcome through the exposure. In MR one or 
more genetic variants, robustly associated with the exposure of interest, are used as the 
instrumental variable. Genetic variants are randomly allocated at gamete formation and segregation 
and as a consequence are not associated with typical confounding factors at the population level. 
Furthermore, genetic variants are unaffected by behaviour, environment or disease. Given these 
two properties, the estimates of effect from MR are largely free from bias by confounding and 
reverse causality and therefore approximate the true causal effect estimate, as long as three crucial 
assumptions hold. 
3.3.4.1 Assumptions 
MR relies on certain assumptions for the effect estimate to be a valid estimate of the true causal 
estimate. These are: 
A. The relevance assumption: The genetic variants used within the MR analysis are robustly 
associated with the exposure of interest. 
B. The independence assumption: The genetic variants share no common cause with the 
outcome of interest, i.e. are not confounded. 
C. The exclusion restriction assumption: The genetic variants only affect the outcome of 
interest through the exposure of interest, i.e. are not pleiotropic (see below for more detail 
on pleiotropy). 
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There are further assumptions of MR including monotonicity of genetic instruments, which assumes 
the genetic proxy influences every individual in the same direction, and no assortative mating, which 
assumes that individuals mate randomly with respect to the phenotype under study. 
3.3.4.2 One sample MR 
The first MR analyses required the exposure, genotype(s) related to that exposure and outcome to 
all be measured in the same study, now referred to as single-sample MR. These studies were limited 
in sample size due to the practicalities of having all these variables measured in large enough 
samples. 
3.3.4.3 Two sample MR 
Two sample MR has greatly improved the power of MR analyses. In this approach, the effect of the 
genetic variant on the exposure (G-E) is taken from one study and the effect of the genetic variant 
on the outcome (G-O) is taken from a separate study. These studies, usually meta-GWAS, are 
typically much larger than those used in the one sample MR analyses as they focus on either the 
exposure or the outcome and so only need genetic information and one other variable to be 
measured. 
The analyses methods of one and two sample MR are different but the estimates are roughly 
equivalent. In the most common type of two sample MR analyses, only summary statistics of the 
genetic variant effects are required from the exposure and outcome study. There is a strong move 
towards these summary data being made freely available for the scientific community and so 
summary level two sample MR is an attractive analysis option. In situations where there is only one 
genetic variant being used as a genetic proxy, the causal estimate is calculated via the Wald ratio 
which is the ratio of G-O to G-E. Where more than one genetic proxy is available, these are 
combined into a single estimate. One approach to combine the effects of different genetic variants 
into an overall causal estimate is the inverse variance weighted method. This method, similar to the 
combining of studies in meta-analysis, takes into account the variance of each of the summary effect 
estimates. For two-sample MR to be valid, the studies from which the two sample are drawn must 
be homogenous (in terms of ancestry) and be non-overlapping. Violation of these assumptions can 
lead to false positives. 
An alternative to only using summary level data, is to use the genetic variant effect on the exposure 
from a GWAS study but calculate the genetic variant effect on the outcome using individual level 
data. This approach has two main advantages, the first is that the effect of an exposure which is not 
measured in the study of interest can be estimated. For example, in Chapter 8, the effect of vitamin 
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D on HNC prognosis is estimated in the Head and Neck 5000 study which does not have serum 
25(OH)D measured in the participants. The second advantage is the analyses can be stratified by 
certain covariables to assess their impact on the causal effect, something which cannot be achieved 
in summary level outcome data. The most common strategy for this type of MR is to generate a 
genetic risk score (GRS) which is a combination of all the genetic variants associated with the 
exposure of interest. This GRS can be unweighted or weighted by the effect size of the genetic 
variant on the exposure (from the GWAS study) and scaled to match that of the exposure of interest. 
This scaled and weighted GRS then acts as a genetically predicted exposure level which is unrelated 
to the typical confounding factors and can be used as the explanatory variable in traditional 
regression analyses. 
One drawback of this approach compared to using summary level data only, is the imprecision of the 
genetic variant’s effect on the exposure is ignored, potentially creating over-precise causal estimates 
and increasing the chances of false positive findings. To correct for this, a boot strap method can be 
utilised to adjust the standard error of the causal effect estimate. 
3.3.4.4 Methodological issues in MR analyses 
There are several issues which must be considered when designing MR analyses as they can cause 
violation of the MR assumptions. Each of the genetic variants used in the MR analysis should meet 
the three assumptions detailed above. If this is not the case then the causal estimate may be biased. 
Several issues which can lead to the MR assumptions being violated are discussed below before a 
section which discusses how the assumptions can be tested. 
Weak instrument bias 
Weak instruments are those genetic variants that are valid, in that they would pass all the MR 
assumptions in an infinite sample but have very small effects on the exposure of interest. This 
becomes a problem in finite samples where they can bias causal estimates. This bias occurs because 
of chance correlation between the genetic variants and confounders of the exposure outcome 
relationship. Where genetic variant-exposure associations are strong, any effect of the genetic 
variant on the outcome will be via the exposure. However, in the weak instrument situation, the 
effect of the variant on the outcome via the confounder starts to predominate and will therefore 
bias the association. In a one sample setting this bias is towards the observational (confounded) 
estimate whereas in the two-sample setting the bias is towards the null.147 
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Pleiotropy 
Pleiotropy is where a genetic variant is associated with multiple risk factors. There are two types of 
pleiotropy, vertical and horizontal. Vertical pleiotropy is where a genetic variant is associated with 
two variables but they lie on the same biological pathway and therefore the effect of one is 
mediated by the other. This type of pleiotropy is not a concern in MR analyses. Horizontal pleiotropy 
is when a genetic variant is associated with more than one exposure but via different pathways. An 
example which could be if a genetic variant for smoking was actually related to risk taking behaviour. 
This variant, which increased the chances of smoking via increasing risky behaviour, would also likely 
increase alcohol use and unsafe sexual practices (both strong risk factors for HNC), but not through 
smoking. If this genetic variant was used in an MR analysis of smoking on HNC, the causal effect for 
that variant would be biased as it would account for smoking, alcohol use and unsafe sexual 
practices and likely overestimate the effect of smoking on HNC. In the context of this example, 
horizonal pleiotropy invalidates the exclusion restriction assumption but it can also invalidate the 
independence assumption if the genetic variant is pleiotropic with a confounder of the exposure 
outcome association. 
Canalisation 
This is the process of biological compensation for the role of a genetic variant so that the effect of 
that variant being absent or reduced is not seen in the phenotype.148 Canalisation does not 
necessarily violate the MR assumptions but can influence the interpretation of a MR causal estimate. 
The aim of an MR study is to estimate the causal effect of an exposure, not the genetic variant, so if 
canalisation is occurring the genetic variant does not act as a very good proxy as it does not mirror 
what would happen if the level of the exposure was altered. 
Linkage disequilibrium 
Linkage disequilibrium is the situation where genetic variants are correlated  because they are 
inherited together due to their proximity on the genome. Iit can be both useful and problematic in 
MR analyses. Although it is ideal to identify genetic variants that are causally related to the exposure 
of interest for use as instruments for an exposure, the inference is the same if a genetic variant 
which is highly correlated with the causal variant is used. Linkage disequilibrium can be problematic 
however when the variant used as an exposure proxy is correlated with another genetic variant 
which does not pass the MR assumptions. 
Population stratification 
Population stratification in MR analyses is similar to that described above for GWAS. This can 
introduce confounding to an MR analysis and therefore bias the causal estimate. 
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Ascertainment effects (collider bias) 
Ascertainment or collider bias is when artificial associations between two or more variables are 
induced because of the act of conditioning or selecting on a third variable. For collider bias to be an 
issue, the variable being conditioned on must be caused by at least two variables, i.e. the two causes 
‘collide’ onto the third variable (Figure 3-4).  
Figure 3-4: Ascertainment bias by selecting or conditioning on case status. 
 
In A. the figure depicts a situation where we are investigating the association between an exposure (E) and a 
disease (ID) where there are other causal risk factors for the disease (RF) but these are unrelated to E. In B. 
when we look only in the disease cases (indicated by the square around ID), there is an association induced 
between E and RF (red dashed arrow). 
MR relies on randomly assigned alleles to not be correlated with potential confounders of the 
exposure-outcome association under investigation. If the genetic variants associated with the 
exposure are associated with the chances of an individual being in the study then the distribution of 
the alleles for that genetic variant will not be the same as in the unselected population. This will 
induce spurious associations between the genetic variant and any other factors which are associated 
with being recruited into the study. 
These induced associations create an alternative route from the genetic variant to the outcome and 
will therefore bias the causal estimate. This bias is often termed collider bias as it results from 
conditioning or selecting a variable on which two causal associations “collide” (Figure 3-5). 
Figure 3-5: Collider bias in the context of studies assessing the causal association between 
an exposure and disease prognosis. 
 
The genetic variant for the exposure (GE) is causally related to the incidence of the disease (ID) through the 
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(PD). To investigate the effect of E on the prognosis of the disease (PD), an MR analysis in conducted in cases 
only (indicated by the square around ID). In the cases only GE is non-randomly assigned and a spurious 
association is induced between GE and RF (red dotted arrow). In the case only MR analysis, the causal effect 
of E – PD is biased via the aternative route from GE through other factors which affect disease risk and 
prognosis (RF).  
3.3.4.5 Testing the MR assumptions 
The relevance assumption 
As described above the genetic variants used in MR analyses as proxy measures are often identified 
from GWAS using largely hypothesis-free and unbiased approaches. Furthermore, due to the GWAS 
design, a variant must have very strong statistical evidence for an association for it to pass the 
multiple testing threshold. The most common approach is to only accept genetic variants which pass 
the genome-wide statistical threshold which means that those variants which are selected as proxies 
are highly likely to be robustly associated with the exposure of interest. Some MR studies relax the 
threshold at which genetic variants are identified149 which, will increasing the numbers of genetic 
variants used as a proxy. Some of these additional variants are likely to be false negatives (at the 
genome-wide threshold level) but there will also be an increased chance of identifying false positive 
associations which do not pass the relevance assumption. Regardless of whether the variant passes 
the relevance assumption, these variants are more likely to be weak instruments as there weaker 
statistical association most likely represents a smaller effect size on the exposure of interest. 
Statistical information should only be considered the first aspect of selecting genetic variants as 
proxy measures for MR analyses. Once genetic variants have been identified by statistical 
thresholds, it is important to assess the biological plausibility for a robust association with the 
exposure. This can be done using the set of Bradford-Hill criteria set out above, for example if a 
genetic variant has a strong, consistent and plausible association with the exposure it is more likely 
to be a valid genetic proxy than a genetic variant that does not show all these qualities. 
The independence assumption 
The assumption that the genetic variants used as a proxy share no common cause with the outcome 
can be tested in some MR studies. This process is similar to demonstrating the randomization in a 
RCT has been successful and so relies on having individual level data and measured confounders. If 
confounders are available in the study then associations between the genetic variant(s) and the 
potential confounders can be tested. In summary level, two-sample MR or when covariables are not 
available in the study of interest, testing of the genetic variant confounder association can be tested 
in a separate study or using summary level data. Neither of these strategies can test associations 
with unmeasured confounders. A further issue is that this method cannot distinguish between a 
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confounder and a variable which is on the causal pathway between exposure and outcome, a 
mediator. In the mediator scenario, you would expect an association of the genetic variant with the 
variable but this does not violate the assumption. It is best to assess these associations thinking 
about the biological processes in play to assess whether the genetic variant is violating this 
assumption. 
The exclusion restriction assumption 
This assumption cannot be easily tested and applying prior biological knowledge when choosing 
genetic variants is an important step as any other. One way to try to identify pleiotropic effects is to 
identify genetic variants which are outliers when comparing their effect on the exposure and 
outcome. Methods such as MR-Egger and Weighted Median use these methods to estimate 
pleiotropy robust MR estimates.150,151 
Figure 3-6: Fictional example of how outlier genetic variants can influence the causal 
estimate. 
 
In this fictional example the effect of the genetic variant on the exposure (BGX) is plotted on the x-axis and 
the effect of the genetic variant on the outcome (BGY) is plotted on the y-axis, the slope of the lines 
represents the causal estimate from MR. The dots represent the genetic variants with the two red dots 
representing pleiotropic varians which are therefore outliers. The outliers can influence the slope of the line 
as demonstrated by the difference between the green and red dashed lines. In this scenario removing the 
variants represented by the red dots would provide the true causal estimate (green dashed line). 
If the MR assumptions are valid for the genetic proxy, the effect on the outcome will be proportional 
to the effect on the exposure. Plotting one against the other can help to visualise genetic variants 
which are not related in a way consistent with other genetic variants but, this is not very helpful with 
few variants. Pleiotropy can be an issue in all MR methods including one-sample and two-sample 
approaches combining all genetic variants into a single instrument. The difficulty with having a single 
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instrument as in these MR methods is there are no outliers to identify. Another way to visualise a 
single genetic variant which is overtly influencing a causal estimate is to repeat analyses sequentially 
removing a single genetic variant, referred to as a leave-one-out analysis. If a single variant is 
influencing the causal estimate substantially, this may be evidence that it is pleiotropic and this can 
be conducted regardless of the MR methods used. 
There are several formal sensitivity analyses which can be conducted to assess the level of 
pleiotropy and estimate causal effect sizes which is not biased by the pleiotropy. One such method is 
the median estimator, which can provide reliable causal estimates when up to half of the genetic 
variants have pleiotropic effects.150 A second is the MR-Egger method which is an adaptation of the 
Egger test for small sample bias in meta-analysis.151 In this method, all instruments can be 
pleiotropic as long as the strength of the genetic variant exposure association is not correlated with 
the strength of the genetic variant pleiotropic association . Another benefit of the MR-Egger method 
is that is can provide a formal statistical test for the presence of unbalanced pleiotropy. 
Unfortunately, these sensitivity analyses, particularly MR-Egger lack power and utility when only a 
few genetic variants are available for the exposure of interest. 
3.3.5 Meta-analysis 
Meta-analysis is the combining of results from a number of studies. The idea of this approach is to 
combine effect estimates and precision of that estimate from multiple studies into a single pooled 
estimate of the effect. The method is designed to combine effects from RCTs with the assumption 
that each estimate is an unbiased estimate of the true population effect size and any difference 
between the estimates is due to sampling error, with that error being inversely proportional to the 
size of the study. The pooled estimated, a weighted average of the effect sizes from the individual 
studies, therefore represents the most precise estimate of the true causal effect in the population. 
There are two caveats to this interpretation. Firstly, it assumes that each of the RCTs included in the 
study was of good quality and therefore had no bias. If bias exists in some of the studies then this 
will bias the pooled estimate. Worse still, if the majority of the studies were conducted in a way that 
introduces the same bias then the pooled estimate will become a precise estimate of the biased 
effect. Secondly, meta-analysis assumes the studies being combined are representative of all the 
evidence available which have been identified using systematic searching approaches. Failure to 
identify studies or when studies reporting null or negative effects of a treatment are less likely to be 
reported, the results of the meta-analysis can be biased. 
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3.3.5.1 Meta-analysis of observational studies 
Meta-analysis of observational studies is similar in principal to that of meta-analysis of RCTs but 
there are more opportunities for bias to be problematic. Observational estimates, as discussed 
already in this thesis, are likely to be biased by residual confounding, selection bias or other sources 
of systematic error. As discussed above, Hill’s concept of consistency and the theory of triangulation 
rely on studies with different biases all pointing to the same result. When combining observational 
studies by meta-analysis however, it is highly likely that many of the studies will include similar 
biases resulting in a precise yet spurious pooled result. Meta-analysis of observational studies is still 
useful however as long as the analyst is aware that the process of meta-analysis will not mitigate the 
biases introduced within the individual studies. A more informative approach is to look at the 
heterogeneity between the individual estimates with an understanding of the magnitude of the 
biases that are potentially affecting them. This latter approach will be used in this thesis to combine 
observational estimates generated as part of this work with those from previous studies. 
In this thesis, meta-analysis will also be used to combine estimates from multiple GWAS into a meta-
GWAS study and estimates of causal effects from MR studies into a pooled MR-estimate. As 
explained above, both these study designs estimate an unbiased effect when their assumptions hold 
therefore, meta-analysis of effects from these studies is similar to that  of RCTs. 
3.3.5.2 Fixed versus random effects meta-analysis 
There are two approaches to combining the individual study estimates into a pooled estimate. The 
first, fixed-effects meta-analysis assumes that the underlying effect being estimated by each study is 
the same and that any variation is due to sampling error. To assess this assumption, a test for 
heterogeneity can be conducted and broadly speaking if there is strong evidence for heterogeneity 
between the individual estimates the assumption is violated and the pooled estimate is likely to be 
over precise. The second approach, random effects meta-analysis, allows for possible heterogeneity 
between the individual studies by including the additional between-study variance in the weighting 
of the individual effects. A random effects meta-analysis estimate gives more weight to smaller 
studies than in fixed-effect meta-analysis leading to wider confidence intervals for the pooled 
estimate and larger P-values.152 
3.4 Studies and participants 
There are several study designs that are mentioned within this thesis, the main ones and their 
assumptions will be briefly discussed before the individual studies are described. 
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3.4.1 Cohort study 
In this type of study the individuals are defined based on the basis of exposure to a suspected risk 
factor e.g. vitamin D. This can be either presence or absence or as in the case of vitamin D a 
continuous value. At the time of exposure status determination, all participants must be free from 
the disease in question. The “cohort” of individuals are then followed up over time to assess the 
development of the disease of interest in relation to the exposure level. 
As participants are disease free when the exposure status is measured these studies are often 
considered robust to reverse causality however long lag times can violate this assumption. Cohort 
studies can be expensive as they require large numbers and long follow-up periods, but a major 
advantage is that many exposures and outcomes can be investigated in the same study. Examples 
where this is the case are UK Biobank and ALSPAC (described below). Cohort studies can be 
prospective or retrospective. In retrospective studies, both exposures and the outcomes have 
occurred when the study is initiated. In prospective cohort studies at least the outcomes are yet to 
happen. 
Selection bias is often not considered to be a major problem in prospective cohort studies as the 
exposure is assessed before the occurrence of disease and the outcome can influence the 
classification or measurement of the exposure. Misclassification of exposure and outcome can be an 
issue in cohort studies. Non-differential misclassification, when there is some level of inaccuracy in 
the exposure or outcome status but this is similar across study groups, will tend to underestimate 
the effect towards the null but will not cause false positives. When classification error is related to 
exposure or disease status then directional bias in either direction can be expected. Similarly, loss to 
follow-up which is related to exposure or outcome status will introduce bias in either direction. 
3.4.2 Case-control studies 
Case control studies are designed by identifying individuals who are cases and controls of a 
particular disease. These individuals are then compared with respect to an exposure or multiple 
exposures of interest. This study design is good for studying rare diseases and with long latency 
periods. 
The major issue with case-control studies is that both the exposure and the disease have already 
happened so selection bias can be an issue. It is important to select cases of a single disease entity 
so that when examining exposures the associations identified are specific to that disease. For case 
control studies it is also important that the controls represent the population from which the cases 
are drawn, if not then selection bias will occur. Information bias can also be an issue in case control 
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studies as information pertaining to exposures is often collected from participants after the onset of 
the disease and this may affect how they report their exposure status. 
There are two variations of case control study which use an established cohort study. The advantage 
of these designs is that highly detailed information, which would be very expensive to collect for the 
whole cohort, can be collected for only those cases and controls included in the case-control like 
study. The first of these is the nested case-control study, in this study design, cases are identified 
from those followed up in a cohort study and then controls are selected from those still under 
observation in the cohort study. An alternative is the case-cohort study, in this design a sub-
population is randomly selected from the cohort. This sub-population, plus any other cases from the 
whole cohort are then investigated in more detail. This latter design is slightly more powerful and 
has the advantage that more than one disease can be investigated in the same sub-population. 
The following studies are used as the main sources of data in the thesis. An overview of each is given 
below in the order that they appear in the thesis, where chapter specific information is relevant this 
is in a specific methods section within each chapter. 
3.4.3 UK Biobank 
3.4.3.1 Study description 
UK Biobank is a population-based health research resource consisting of approximately 500,000 
people, aged between 38 and 73 years, who were recruited between the years 2006 and 2010 from 
across the UK.153 Participants provided a range of information pertinent to adult and later life health 
outcomes via questionnaires, interviews, physical measurement and donating biological samples 
(data showcase available at www.ukbiobank.ac.uk).154 UK Biobank received ethical approval from 
the North West Multi- centre Research Ethics Committee (REC reference for UK Biobank is 
11/NW/0382). 
3.4.3.2 Genetic data 
The UK Biobank genotype data (July 2017 release) contains 488,377 successfully genotyped samples. 
49,979 individuals were genotyped using the UKBiLEVE array and 438,398 using the UK Biobank 
axiom array. Pre-imputation quality control (QC), phasing and imputation were completed.155 In 
brief, prior to phasing, multiallelic variants or those with minor allele frequency ≤1% were removed. 
Phasing of genotype data was performed using a modified version of the SHAPEIT2 algorithm.156 
Genotype imputation was performed to a combined UK10K haplotype157 and Haplotype reference 
consortium (HRC) reference panels using IMPUTE2 algorithms.158 A further QC protocol was then 
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applied at the Wellcome Trust Centre for Human Genetics prior to release 
(http://biobank.ctsu.ox.ac.uk/crystal/docs/genotyping_qc.pdf). 
Individuals with sex-mismatch (derived by comparing genetic sex and reported sex) or individuals 
with sex-chromosome aneuploidy were excluded from the analysis (n=814). Estimated kinship 
coefficients using the KING toolset159 identified 107,162 pairs of related individuals.160 An in-house 
algorithm was then applied to this list and preferentially removed the individuals related to the 
greatest number of other individuals until no related pairs remain. These individuals were excluded 
(n=79,448). Additionally two individuals were removed due to them being relating to a very large 
number (>200) of individuals.161 Principal components were generated by UK BIOBANK using 
flashPCA. 
3.4.3.3 25 hydroxyvitamin D 
Blood was drawn from consenting participants at the baseline clinic and transported to the UK 
Biobank central laboratory in Stockport, UK. The whole blood was aliquoted and frozen within an 
average time of 24 hours (+/- 2.4 hours). 25(OH)D was measured by immunoassay on a DiaSorin LIA 
LIASON XL with a detection range of 10 nmol/L < 25(OH)D < 375 nmol/L. Where samples were above 
375 nmol/L and sufficient sample remained, a dilution was performed and the sample reanalysed. 
During the automated aliquoting process, an unintended dilution of the aliquots occurred however, 
approximately 92% of sample assay concentrations are affected by less than 1%, approximately 8% 
of assay concentrations are affected by less than 10% and very few are affected by more than this. 
Correction for this unintentional dilution has been made centrally by UK Biobank and more details 
can be found here: http://biobank.ndph.ox.ac.uk/showcase/docs/biomarker_issues.pdf. 
3.4.4 Avon Longitudinal Study of Parents and Children 
3.4.4.1 Study description 
The ALSPAC longitudinal birth cohort recruited pregnant women living near Bristol, UK with an 
estimated delivery date between 1991 and 1992. The initial number of pregnancies enrolled was 
14,541. Of these initial pregnancies, there was a total of 14,676 foetuses, resulting in 14,062 live 
births and 13,988 children who were alive at 1 year of age. When the oldest children were 
approximately 7 years of age, an attempt was made to bolster the initial sample with eligible cases 
who had failed to join the study originally. As a result, when considering variables collected from the 
age of seven onwards there are data available for more than the 14,541 pregnancies mentioned 
above. The number of new pregnancies not in the initial sample is 913. The phases of enrolment are 
described in more detail in the cohort profile paper and its update.162–164 The total sample size for 
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analyses using any data collected after the age of seven is therefore 15,454 pregnancies, resulting in 
15,589 foetuses. Of these 14,901 were alive at 1 year of age. Follow up has included clinical 
assessment and questionnaires and is ongoing. Ethical approval for the study was obtained from the 
ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Informed consent for 
the use of data collected via questionnaires and clinics was obtained from participants following the 
recommendations of the ALSPAC Ethics and Law Committee at the time. 
3.4.4.2 Genetic data 
ALSPAC children were genotyped using the Illumina HumanHap550 quad chip genotyping platforms 
by 23andme subcontracting the Wellcome Trust Sanger Institute, Cambridge, UK and the Laboratory 
Corporation of America, Burlington, NC, US. The resulting raw genome-wide data were subjected to 
standard quality control methods. Individuals were excluded on the basis of gender mismatches; 
minimal or excessive heterozygosity; disproportionate levels of individual missingness (>3%) and 
insufficient sample replication (IBD < 0.8). Population stratification was assessed by 
multidimensional scaling analysis and compared with Hapmap II (release 22) European descent 
(CEU), Han Chinese, Japanese and Yoruba reference populations; all individuals with non-European 
ancestry were removed. SNPs with a minor allele frequency of < 1%, a call rate of < 95% or evidence 
for violations of Hardy-Weinberg equilibrium (P < 5E-7) were removed. Cryptic relatedness was 
measured as proportion of identity by descent (IBD > 0.1). Related subjects that passed all other 
quality control thresholds were retained during subsequent phasing and imputation. 9,115 subjects 
and 500,527 SNPs passed these quality control filters. 
ALSPAC mothers were genotyped using the Illumina human660W-quad array at Centre National de 
Génotypage (CNG) and genotypes were called with Illumina GenomeStudio. PLINK (v1.07) was used 
to carry out quality control measures on an initial set of 10,015 subjects and 557,124 directly 
genotyped SNPs. SNPs were removed if they displayed more than 5% missingness or a Hardy-
Weinberg equilibrium P value of less than 1.0e-06. Additionally, SNPs with a minor allele frequency 
of less than 1% were removed. Samples were excluded if they displayed more than 5% missingness, 
had indeterminate X chromosome heterozygosity or extreme autosomal heterozygosity. Samples 
showing evidence of population stratification were identified by multidimensional scaling of 
genome-wide identity by state pairwise distances using the four HapMap populations as a reference, 
and then excluded. Cryptic relatedness was assessed using a IBD estimate of more than 0.125 which 
is expected to correspond to roughly 12.5% alleles shared IBD or a relatedness at the first cousin 
level. Related subjects that passed all other quality control thresholds were retained during 
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subsequent phasing and imputation. 9,048 subjects and 526,688 SNPs passed these quality control 
filters. 
SNP genotypes in common between the sample of mothers and sample of children were combined 
(477,482). SNPs with genotype missingness above 1% were removed due to poor quality (11,396 
SNPs removed), a further 321 subjects were removed due to potential ID mismatches. This resulted 
in a dataset of 17,842 subjects containing 6,305 duos and 465,740 SNPs (112 were removed during 
liftover and 234 were out of HWE after combination). Haplotypes were estimated using ShapeIT 
(v2.r644) which utilises relatedness during phasing. The phased haplotypes were then imputed to 
the Haplotype Reference Consortium (HRC) panel of approximately 31,000 phased whole genomes. 
The HRC panel was phased using ShapeIt v2, and the imputation was performed using Impute V3. 
Whole genome sequence (WGS) data are described within Appendix as it was sequenced alongside 
the Twins UK study. 
3.4.4.3 25 Hydroxyvitamin D 
After collection, blood samples were immediately spun, frozen, and stored at −80°C. Assays were 
performed after a maximum of 12 years in storage with no previous freeze-thaw cycles. The 
25(OH)D3 and 25(OH)D2 concentrations were measured with HPLC tandem mass spectrometry using 
internal standard in a laboratory meeting the performance target set by the Vitamin D External 
Quality Assessment Scheme Advisory Panel for 25(OH)D assays. Interassay coefficients of variation 
for the assay were less than 10% across a working range of 2.5–624 nmol/L for both 25(OH)D3 and 
25(OH)D2.165 Total serum 25(OH)D concentrations were calculated as the sum of 25(OH)D3 and 
25(OH)D2. 
3.4.5 GAME ON 
3.4.5.1 Study description 
The study comprised 6,034 head and neck cancer cases and 6,585 controls from studies which were 
part of the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network. Cases and 
controls from 10 different case-control studies were included, as well as from the European cohort 
study (EPIC) and cases from a UK case series (Head and Neck 5000). Details of the studies included 
have been described previously.22 Informed consent was obtained for all participants and studies 
were approved by respective institutional review boards. 
Chapter 3: Methodological Overview 
 61 
3.4.5.2 Genetic data 
DNA was isolated from buccal cells or blood and was genotyped on the Illumina OncoArray by the 
Centre for Inherited disease Research (CIDR). The genotyping array was custom designed to be 
specific for the study of cancer by the OncoArray Consortium which was part of the Genetic 
Associations and Mechanisms in Oncology Network (GAME-ON). All cases and the majority of 
controls were genotyped together as part of the oral and pharynx OncoArray project. An additional 
2,476 shared controls were genotyped as part of the Lung OncoArray project, also by CIDR. 
Genotype calls were made using the GenomeStudio software (Illumina). After single nucleotide 
polymorphism (SNP) filtering by call rate, 513,311 probes remained for analysis. Within each 
geographical area, principal components were generated using EIGENSTRAT166. Imputation of 
unknown genetic variation was performed on the Michigan Imputation Server167 using the first 
release of the Haplotype Reference consortium panel. 
3.4.6 Head and Neck 5000 
3.4.6.1 Study description 
Head and Neck 5000 (HN5000) is a large HNC clinical cohort, full details of the study methods and 
population are described elsewhere.168 Briefly, 5,511 people with a new HNC diagnosis were 
recruited from 76 centres across the UK between April 2011 and December 2014. Recruitment rates 
to the study varied by centre, from around 20% to around 90% of eligible HNC cases. Individuals 
were recruited before they started treatment, unless their treatment was their diagnostic 
procedure. At baseline, 5,474 (99%) data capture forms and 4,099 (74%) health and lifestyle 
questionnaires were completed.169 Baseline blood samples were obtained from 4,676 (85%) 
individuals. Full ethical approval was granted by The South West – Frenchay Regional Ethics 
Committee (ref: 10/H0107/57). 
Baseline information was collected via data capture from clinical notes and questionnaires. Formal 
study-based follow-up was conducted with further data capture and questionnaires at 4 months, 12 
months and 3 years. Data linkage with death registry sources provided details of survival with the 
last recorded data freeze being ???. 
3.4.6.2 Genetic data 
Blood samples were taken at recruitment and stored in EDTA tubes. Blood samples were spun at 
3,500 rpm for 10 minutes and the buffy coat layer stored for future DNA extraction. DNA extraction 
was performed by LGC genomics (http://www.lgcgenomics.com/) using the Kleargene spin column 
extraction method (http://www.lgcgroup.com/products/dna-extraction-kits). 
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DNA samples from 1,079 participants were included in the genotyping of the GAME-ON study 
described above using the Illumina OncoArray. Imputation was completed using the HRC reference 
panel alongside all other GAME-ON samples. 
The next chapter 
In the next chapter I will assess the observational association between serum 25(OH)D and HNC 
incidence and prognosis in the UK Biobank study, using some of the methods described above. As far 
as is possible, I will attempt to mitigate the bias of confounding using multivariable regression and 
stratification. The results from this study will then be compared and combined with the estimates 
from previous observational evidence of these associations.
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Chapter 4 :  Revisiting the observational 
vitamin D HNC association 
4.1 Chapter objectives 
In the introduction, the body of observational evidence linking vitamin D to HNC risk and prognosis 
was presented. In Chapter 4 observational methods will be used to conduct a prospective study 
investigating this association. The results are then pooled with those from Fanidi et al. (2016)126, the 
most recent observational study investigating this association. The aim of this chapter is to use 
newly available data in UK Biobank to re-examine the association between serum 25(OH)D and head 
and neck cancer risk and prognosis and to produce the most precise observational estimates of the 
association to date. 
4.2 Introduction 
In Chapter 2 epidemiological studies assessing the association between 25(OH)D and HNC were 
described. There is however heterogeneity in the design of these studies. Some of the early studies 
used predicted or dietary vitamin D levels whereas the more recent studies used serum 25(OH)D and 
there is inconsistency in how different sites within the head and neck region are combined. Given 
these differences, it is not surprising that there is also inconsistency in the results, with several 
studies reporting strong protective effects on HNC risk and prognosis and others providing no robust 
evidence for an effect of vitamin D on either. 
The most recent study by Fanidi et al. (2016), is the largest and most robustly designed of the 
observational studies investigating the effect of vitamin D on head and neck cancer. As discussed, 
the prospective design and correction by known confounders likely provides the most valid estimate 
of the effect of 25(OH)D on HNC risk and prognosis to date. The results however, have not yet been 
replicated in a similarly designed and well powered study. 
UK Biobank, a large prospective cohort study, provides an opportunity to replicate the findings of 
Fanidi et al. in an independent cohort. The breadth of data available in UK Biobank allows the 
analysis plan of Fanidi et al. to be closely replicated with consistency in vitamin D measurement and 
how HNC sites are defined. This will allow comparison between the studies and meta-analysis of the 
results. As set out in Hill’s criteria for causation,140 consistency between the study results and large 
effect magnitudes can add to the view that the association may be causal. Through meta-analysis of 
the results of the work in this chapter with the Fanidi et al. study, a more precise estimate of the 
association magnitude can be identified. It must be noted however, that any association identified in 
Chapter 4: Revisiting the observational vitamin D HNC association 
 64 
this work could still be biased by unmeasured confounding and it is therefore important that the 
results are assessed for the impact of the major confounders such as smoking. 
4.3 Methods 
4.3.1 Overview 
In this chapter UK Biobank data was analysed to mirror the analyses of the Fanidi et al.126 study to 
assess the association of vitamin D with HNC risk and prognosis. In the analyses for HNC risk, to 
make the best use of the large numbers of participants in UK Biobank and to ensure analyses were 
consistent with those in the Fanidi et al. study,126 two parallel study designs were used. Firstly, a 
matched case-control analysis was conducted where each case was matched to three controls.  
Secondly, a case-cohort design was used to ensure maximum power. 
In the analyses assessing the effect of vitamin D with HNC prognosis, survival analyses were used in 
the cases only, using all-cause and HNC-specific mortality as end points. The results were meta-
analysed to further refine the association estimates and the results are assessed for the effect of 
major confounders. 
4.3.2 Studies 
The study was conducted in UK Biobank, a population-based study of approximately 500,000 
participants. A detailed description of this study and the 25(OH)D measures are given in Chapter 3. 
4.3.3 Identification of incident cancer cases 
Incident cancer cases were identified from UK cancer registry data which is linked to the UK Biobank 
resource (version: March 2019). The cancer cases were defined based on the ICD10 codes from the 
Fanidi et al. study.126 As UK Biobank includes some cancer cases identified before the adoption of 
the ICD10 codes, equivalent ICD9 codes were also identified. These ICD9 and ICD10 codes were then 
allocated to the oral, oropharynx, larynx, hypopharynx and other HNC subsites as specified in Table 
4-1. 
The ICD codes were used to identify participants who had been diagnosed with a HNC in UK Biobank. 
For each diagnosis, the date of diagnosis, histology, behaviour (benign, carcinoma-in-situ, malignant, 
metastatic cancer) and age at diagnosis was extracted from the UK Biobank dataset. This process 
was repeated to identify participants diagnosed with any other cancer (except non-melanoma skin 
cancer). 
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Table 4-1: ICD codes for major head and neck cancer sites 
Cancer site ICD codes 
Oral cavity 
cancer 
ICD10 C003, C004, C005, C006, C009, C020, C021, C022, ,C028, C029, C030, C031, 
C039, C040, C041, C048, C049, C050, C058, C059, C060, C061, C062, C068, 
C069 
ICD9 1403, 1404, 1405, 1406, 1409, 1411, 1412, 1413, 1422, 1428, 1419, 1430, 




ICD10 C01, C024, C090, C091, C098, C099, C100, C101, C102,C103, C104, C108, 
C109, C140, C142, C051, C052 
ICD9 1410, 1416, 1461, 1462, 1468, 1460, 1463, 1464, 1466, 1467, 1468, 1469, 
1490, 1491, 1453, 1454 
Larynx 
cancer 
ICD10 C320, C321, C322, C323, C328, C329 
ICD9 1610, 1611, 1612, 1813, 1618, 1619 
Other HNC 
cancer 
ICD10 C148, CD000, C110, C111, C118, C119 
ICD9 1498, 2300, 1470, 1471, 1478, 1479 
 
Cases who had a history of another cancer (except non-melanoma skin cancer) were excluded. Due 
to the different aetiology of squamous cell carcinoma (SCC) compared with other non-SCC cancers, 
non-SCC cancers were also excluded. 
4.3.4 Identification of cancer control participants 
For each case, three controls were randomly selected from a risk set consisting of all cohort 
members alive and free of cancer (except non-melanoma skin cancer) at the time of diagnosis of the 
incident case. Matching criteria were sex, date of blood collection (± 1 month) and date of birth (± 1 
year). Three matched controls were chosen as this allowed matching of all criteria. To select more 
matched controls per case would have meant relaxing the matching criteria and therefore providing 
less robust control for these potential confounders. 
Additional unmatched controls were selected from the remaining UK Biobank participants who did 
not have a history of cancer (except non-melanoma skin cancer) and had serum 25(OH)D measured. 
Participants with non-melanoma skin cancer were included as cases and controls for two reasons. 
Firstly, these cancers are common and removing them would reduce the power of the study 
(particularly by the removal of cases). Secondly, as these cancers are caused by sun exposure and 
the hypothesis in question in this study relates to vitamin D which is largely determined by sun 
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exposure. There is the potential for bias to occur if sun exposure if differential between the cases 
and controls. For example, if sun exposure is correlated with other HNC risk factors, removing 
participants with non-melanoma skin cancers may reduce the average serum vitamin D levels of the 
case more than the controls, biasing the results away from the null. 
4.3.5 Follow-up of cancer cases 
Cancer cases identified above were followed up in cancer and death registry data to identify the 
date of cancer recurrence or death. 
Participants were considered to have had a cancer recurrence if they had a further diagnosis of any 
HNC site greater than three months after their initial HNC diagnosis. Although it is possible for a 
cancer to recur before this three-month period, it is very rare and more likely would relate to 
residual disease. Additionally, there are multiple occasions in the cancer registry data in UK Biobank 
where, the same participant has multiple records for the same cancer diagnosis – sometimes several 
weeks apart. Applying this three-month cut-off strategy reduces the chances of misclassifying a 
repeated cancer registry record as a cancer recurrence. 
All-cause mortality was identified from death registry data, linked to UK Biobank, as death of a HNC 
case from any cause. HNC-specific cause of death was identified if an ICD10 code, relating to any of 
the HNC sites above, was mentioned in either the underlying (primary) or contributory (secondary) 
causes of death on the death certificate. 
Survival time was calculated from time of diagnosis to the earlier of cancer recurrence or death from 
any cause. The survival analysis was censored at 14th February 2018 – the last recorded death in the 
UK Biobank data freeze used for this study. 
4.3.6 25 hydroxyvitamin D 
25(OH)D was measure from blood serum as described in Chapter 3. 
4.3.7 Covariables 
Covariables were chosen based on the prior knowledge of vitamin D related factors discussed in 
Chapter 2 and to match the analyses of the Fanidi et al. study.126 Day of birth is not available in UK 
Biobank to protect the anonymity of the participants. Therefore, for each participant the date of 
birth was generated assuming everyone was born on the first day of the month. Self-reported ethnic 
background was recorded at the study assessment centres and grouped into White, Mixed, Asian, 
Black and Other. Smoking was recorded at baseline and grouped into never, former or current. For 
former smokers, these were further categorised into those who had quit 10 or more years ago and 
those who had quit within the last 10 years. Alcohol drinking status (‘never’, ‘former’ or ‘current’) 
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and frequency of drinking alcohol was also recorded. For the latter, the following categories were 
specified: ‘daily or almost daily’, ‘three or four times a week’, ‘once or twice a week’, ‘one to three 
times a month’, ‘special occasions only’ or ‘never’. Highest education attainment was recorded and 
coded into the following categories: ‘college or University degree’, ‘other professional qualifications 
e.g.: nursing’, ‘A levels/AS levels or equivalent’, ‘NVQ or HND or HNC or equivalent’, ‘O levels/GCSEs 
or equivalent’ or ‘CSEs or equivalent’. For participants who did not answer this question, those that 
reported leaving school before age 16 years were placed in a category of ‘No formal qualifications’ 
and the remaining participants were coded as ‘missing’ but included in analyses. Body mass index 
(BMI) was calculated from height and weight measured at the initial assessment centre attendance 
and categorised into three categories (<25 kg/m2, 25-29.9 kg/m2, >30 kg/m2). For a subset of 
participants, a 24-hour food and beverage consumption questionnaire was used to estimate dietary 
vitamin D and calcium intake (excluding any supplements). Physical activity was recorded at initial 
study assessment centres as total Metabolic Equivalent Task (MET) minutes per week for all activity. 
UK Biobank is a UK-wide study with participants recruited from across the country. As discussed, 
vitamin D is related to geographic location with more northerly latitudes receiving less UV light. It is 
therefore expected that there is a gradient of 25(OH)D concentrations from north to south. 
Participants home location in the south-north direction measured in meters from the most southerly 
point of the UK was used as a measure of latitude. As this continuous variable has a non-normal 
distribution it was split into quartiles to form a categorical variable. The association of this 
categorical variable with 25(OH)D was assessed using linear regression and with HNC case status 
using the chi-squared test. 
4.3.8 Statistical analysis 
To remove the variation in serum 25(OH)D attributable to season, the 25(OH)D measures were 
adjusted using the ‘predict’ function of the ‘cosinor’ package in R170 to provide a predicted mean 
annual outcome value. Briefly, the package identifies an appropriate sinusoidal pattern to model the 
seasonal variation and then for each individual adds the residual from that model to the mean value 
of 25(OH)D. This method models the seasonal variation of the 25(OH)D concentration by providing 
smooth predictions without artificial discontinuities throughout the year (Figure 4-1) . Seasonally 
adjusted 25(OH)D values were log-2 transformed to normalise the distribution and allow easy 
interpretation of results – each unit increase in the exposure corresponds to a doubling of 25(OH)D. 
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Figure 4-1: Seasonal variation in unadjusted 25-hydroxyvitamin D levels. 
 
The plot demonstrates the seasonal variation in 25(OH)D across the recruitment period, gaps in sampling 
likely represent the Christmas to New Year period. Individual 25(OH)D levels are indicated with the black 
shading, darker shades represent a greater number of individuals with similar values. The red line 
represents the predicted geometric mean concentration modelled using the cosinor package in r. This 
predicted regression line was used to adjust the raw values removing seasonal variation in 25(OH)D. 
Within cases, matched and unmatched controls, categorical variables were described by frequency 
and percentage and continuous variables by median and interquartile range. Within the controls, 
associations between 25(OH)D and potential confounders was assessed using linear regression. 
For each HNC site and all HNC sites combined, conditional logistic regression, conditioning on 
matched case-control quads, was used to calculate OR and 95% confidence intervals for the base 2 
logarithm of seasonally adjusted 25(OH)D which, approximates the relative risk of doubling 
circulating 25(OH)D. To provide maximal power, matched and unmatched controls were combined 
in unconditional logistic regression models correcting for age at recruitment, sex and ethnicity. 
Combining the matched and un-matched controls could potentially reduce the representativeness of 
the control set however, in this study the matched controls were drawn randomly from those that 
were included in the unmatched analysis and should not be systematically different. This was 
assessed by comparing the baseline characteristics of the matched and unmatched controls. 
Additional adjustment was made for measured potential confounders, including smoking status, 
Chapter 4: Revisiting the observational vitamin D HNC association 
 69 
alcohol consumption frequency, highest educational attainment (including missing values), BMI and 
latitude. 
To assess whether a dose-response relationship exists between 25(OH)D and HNC risk, the effect 
was assessed across quintiles of 25(OH)D concentration, using the lowest 25(OH)D quintile as the 
reference. The assumption is that if the association is causal, the higher the quintile the stronger the 
effect on HNC should be. This was repeated for all and site specific HNCs. 
To investigate the effect of confounding and/or interactions, the logistic regression models were run 
within strata of covariables. Where heterogeneity existed between strata, the presence of an 
interaction between vitamin D and the covariable was investigated by conducting logistic regression 
including and excluding an interaction term. A log likelihood test was used to check for evidence that 
the model including the interaction term was of better fit than the model without an interaction 
term and if this was the case, this provides evidence that the covariable is modifying the effect of 
vitamin D. 
To provide the most precise estimate of the effect of 25(OH)D on HNC, the adjusted unconditional 
logistic regression estimate was meta-analysed with the estimates from Fanidi et al. (2016)126 using a 
fixed effect model. Heterogeneity between the two studies was assessed using the I2 statistic. 
The association between pre-diagnostic 25(OH)D and prognosis in incident HNC cases was assessed. 
Due to the low number of cases, all HNC sites were considered together in the primary analysis. 
Recurrence of HNC or death from any cause was considered an event and time since diagnosis was 
used as the time scale.  Participants were separated into low (<50 nmol/L) and high (>=50 nmol/L) 
25(OH)D categories and survival distributions compared using Kaplan Meier plots and the log-rank 
test.  
Using cox-proportional hazards regression, hazard ratios were estimated for a base 2 logarithm of 
seasonally adjusted 25(OH)D (i.e. a doubling of vitamin D) and adjustments for the same covariables 
as the unconditional logistic regression were made. 
Sensitivity analyses 
The OR and HR of a base 2 logarithm change in 25(OH)D was assessed stratified by the following 
variables: sex, ethnicity, smoking status, alcohol intake, educational level, age at diagnosis, time 
from blood draw to diagnosis and BMI. 
To account for the effect of UK Biobank geographic location clustering may have had on the 
precision of estimates, the unconditional logistic regression was repeated using a measure of 
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participant’s home location in the South to North direction as the cluster variable. Analyses were 
conducted using the “glm.cluster” function, in the ‘miceadds’ package in R,171 which computed 
cluster robust standard errors. 
In order to investigate if any effect of 25(OH)D on HNC prognosis was acting via effects on non-HNC 
causes of death, cox proportional hazards regression was repeated using HNC-specific death and 
compared with the estimates for all-cause mortality. 
Deaths that occur early after HNC diagnosis (< 6 months) are likely to have a different cause than 
those that occur later on (> 6 months). In order to assess this the survival analysis was repeated only 
for those participants who had an event later than 6 months after diagnosis. 
4.4 Results 
4.4.1 Baseline characteristics 
There were 502,543 participants enrolled into UK Biobank, 54,593 participants did not have valid 
seasonally adjusted vitamin D levels. After excluding participants with a previous diagnosis of any 
cancer except non-melanoma skin cancer (61,850) there were 386,100 participants included in the 
study. Overall there were 480 incident HNCs, of which 145 (30%) were oral cavity cancers, 220 (46%) 
were oropharyngeal cancers, 85 (18%) were laryngeal cancers and the remainder (6%) were other 
head and neck cancers including hypopharynx. 1,440 individually matched controls (three per case) 
and 384,180 additional unmatched controls were identified from UK Biobank (Figure 4-2). Greater 
than three quarters of the matched case-control sample were male compared to under half of the 
unmatched controls being male. Median age at recruitment was slightly lower in the unmatched 
control set (57 years, IQR: 49,63) compared to the matched cases and controls (59 years, IQR: 53, 
64). Cases were more likely to be current smokers or previous smokers who have quit within the last 
10 years, compared to matched and unmatched controls. There were a high proportion of cases 
from the two most northerly latitude quartiles whereas matched and un-matched controls were 
evenly spread across the quartiles (Table 4-2). In formal tests of association, there was no strong 
evidence for an association between latitude and the risk of HNC (c2 = 7.47, df = 3, P = 0.06) 
however this may reflect a lack for power. 
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N = 447,950 
Missing data
No serum 25(OH)D measures = 54,167
No date of blood draw = 411
Seasonally adjusted 25(OH)D <0 nmol/L = 15
N = 386,100
Exclusions
Other cancer prior to incident HNC = 61,273
Other HNC prior to incident HNC = 577
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Table 4-2: Baseline characteristics of cases and controls 
Summary Statistics Cases Matched Controls 
Unmatched 
Controls 
Ethnicity          
   Asian 11 (2) 31 (2) 8,728 (2) 
   Black 0 (0) 16 (1) 6,392 (2) 
   Mixed 3 (1) 7 (0) 2,341 (1) 
   Other 5 (1) 7 (0) 3,595 (1) 
   White 460 (96) 1,370 (96) 361,308 (94) 
   Missing 1 (0) 9 (1) 1,816 (0) 
Sex          
   Male 370 (77) 1,110 (77) 180,888 (47) 
   Female 110 (23) 330 (23) 203,292 (53) 
Education          
   College or University degree 121 (25) 477 (33) 126,734 (33) 
   Other professional qualifications 0 (0) 0 (0) 0 (0) 
   A levels/AS levels or equivalent 49 (10) 153 (11) 43,277 (11) 
   O levels/GCSEs or equivalent 109 (23) 285 (20) 81,108 (21) 
   NVQ or HND or HNC or equivalent 0 (0) 0 (0) 0 (0) 
   CSEs or equivalent 22 (5) 66 (5) 21,625 (6) 
   No formal qualifications 122 (25) 249 (17) 62,291 (16) 
   Missing 6 (1) 19 (1) 4,448 (1) 
Smoking Status          
   Never 136 (28) 739 (51) 212,981 (56) 
   Previous 188 (39) 543 (38) 129,916 (34) 
       Years since quitting < 10 56 (38) 94 (24) 23,567 (27) 
       Years since quitting ≥ 10 91 (62) 303 (76) 62,299 (73) 
   Current 154 (32) 158 (11) 39,401 (10) 
   Missing 2 (0) 0 (0) 1,882 (0) 
Alcohol Frequency          
   Never 49 (10) 101 (7) 30,131 (8) 
   Special occasions only 35 (7) 131 (9) 43,539 (11) 
   One to three times a month 27 (6) 141 (10) 43,017 (11) 
   Once or twice a week 140 (29) 387 (27) 99,832 (26) 
   Three or four times a week 89 (19) 331 (23) 89,699 (23) 
   Daily or almost daily 140 (29) 349 (24) 77,101 (20) 
   Missing 0 (0) 0 (0) 861 (0) 
BMI          
   <25 154 (32) 416 (29) 128,010 (33) 
   25-29.9 194 (41) 673 (47) 162,225 (42) 
   ≥30 130 (27) 351 (24) 92,446 (24) 
   Missing 2 (0) 0 (0) 1,499 (0) 
Latitude (quartiles)          
      1 (most southerly) 103 (22) 368 (26) 99,547 (26) 
      2 108 (23) 353 (25) 90,821 (24) 
      3 137 (29) 356 (25) 95,123 (25) 
      4 (most northerly) 128 (27) 355 (25) 94,737 (25) 
   Missing 4 (1) 8 (1) 3,952 (1) 
Continuous variables, Median (Interquartile 
range) 
         
   Age at recruitment 59 (53, 64) 59 (53, 64) 57 (49, 63) 
   Seasonally adj. 25-hydroxyvitamin (nmol/L) 43.10 (26.28, 60.85) 
47.80 (32.30, 
62.90) 46.70 (32.30, 62.30) 
   Physical activity METs (hours/week) 28.65 (9.95, 63.10) 28.75 (12.95, 56.87) 29.77 (13.55, 59.55) 
Dietary variables          
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   Vitamin D (ug/day) 1.58 (0.78, 2.96) 1.85 (0.93, 3.59) 1.73 (0.85, 3.31) 
   Calcium (mg/day) 872 (677, 1,153) 948 (730, 1,205) 920 (699, 1,188) 
Case only variables          
   Age at diagnosis 62.87 (57.79, 68.26) NA ( NA, NA) NA ( NA, NA) 
   Time from blood draw to diagnosis (years) 3.85 (2.10, 5.34) NA ( NA, NA) NA ( NA, NA) 
Tumour site, No. (%)          
   Oral 145 (30) 0 (0) 0 (NaN) 
   Oropharynx 220 (46) 0 (0) 0 (NaN) 
   Larynx 85 (18) 0 (0) 0 (NaN) 
   Hypopharynx 19 (4) 0 (0) 0 (NaN) 
   Other HNC 11 (2) 0 (0) 0 (NaN) 
Overall 480 1,440 384,180 
 
4.4.2 25(OH)D variation by baseline characteristics 
25(OH)D showed strong statistical associations with sex, age at recruitment, educational level, 
smoking status, alcohol frequency, BMI and latitude (Figure 4-3). However, the associations with sex, 
age at recruitment (per year increase), education and BMI (per unit increase) are of relatively small 
magnitude. Current smokers had on average approximately 4.6 nmol/L lower 25(OH)D compared to 
never smokers but Previous smokers had slightly higher 25(OH)D levels. Alcohol frequency showed a 
positive association with 25(OH)D levels, with those who drink daily or almost daily having 25(OH)D 
levels approximately 8 nmol/L higher than never drinkers. 
For the association with latitude, for each quartile further north the mean serum seasonally adjusted 
25(OH)D reduced by 0.54 nmol/L (95% CI: 0.48, 0.60, P=1.89x10-72). Although this is a small effect 
and the evidence for an association between HNC risk and latitude was weak, latitude was included 
as a covariate in the full adjusted regression models as it has the potential to confound the vitamin D 
HNC risk association. 
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Figure 4-3: Effects of potential confounders on circulating 25(OH)D. 
 
Change in serum 25(OH)D across levels of potential confounders given in nmols/L. For age at recruitment 
the beta is per year increase, for BMI the beta is per unit increase in BMI, for Latitude the beta is quartile of 
the variable which goes from the most southerly to the most northerly part of the UK. LCI = lower 
confidence interval, UCI = upper confidence interval, P = P value. BMI = body mass index. 
4.4.3 Association between 25(OH)D and HNC risk 
A unit increase in log2(25(OH)D), which corresponds to a doubling in 25(OH)D levels, was associated 
with a protective effect on all HNC sites combined. Unadjusted conditional logistic regression using 
three matched controls per case (OR = 0.69 (95% CI: 0.59 to 0.80)) and minimally adjusted 
unconditional logistic regression (OR = 0.63 (95% CI: 0.56 to 0.71)) showed relatively consistent 
magnitudes of effect, with the latter having slightly greater precision (Figure 4-4). As all results 
showed approximate consistency between conditional and unconditional analyses, only the 
unconditional estimates will be given in the text. 
When HNC were considered by site, the largest effect of 25(OH)D was seen for laryngeal cancer (OR 
= 0.51 (95% CI: 0.39 to 0.65)) with the smallest effect for oropharyngeal cancer (OR = 0.75 (95% CI: 
0.61 to 0.91)), the effect on oral cavity cancer was between these two effect sizes (OR = 0.61 (95% 
CI: 0.50 to 0.76)). 
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For HNC combined and when sites are considered separately, adjustment for education level, 
smoking status, alcohol frequency and BMI attenuated the magnitude of effect slightly in both 
conditional and unconditional logistic regression. In all sites combined and within each site, there 
was no obvious dose response relationship. The effect of 25(OH)D on HNC risk remained largely 
consistent across quintiles of 25(OH)D (Appendix 4.1). 
Figure 4-4: Odds ratio for developing HNC per log2 increase in 25(OH)D using conditional 
and unconditional logistic regression. 
 
*Unconditional unadjusted model includes age, sex and ethnicity to match the conditional analysis as 
closely as possible. 
4.4.4 Stratification of results by confounders 
When results are stratified by known confounders there was evidence of heterogeneity across strata 
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Figure 4-5: Odds ratio for developing HNC per log2 increase in 25(OH)D stratified by site and 
known confounders. 
 
4.4.4.1 Smoking status 
When stratified by smoking, there was strong evidence for heterogeneity between smoking status 
strata (I2 = 84.2% (95% CI: 52.9, 94.7), Phet = 0.002). A strong protective effect of 25(OH)D was seen in 
current smokers (OR = 0.58 (95% CI: 0.49 to 0.69) with a smaller effect magnitude in previous 
smokers (OR = 0.75 (95% CI: 0.59 to 0.94) and no evidence of an effect in never smokers (OR = 1.03 
(95% CI: 0.78 to 1.37). Logistic regression including and excluding an interaction term for 25(OH)D 
with smoking status was conducted and provided strong evidence that including an interaction term 
provides a better fit in the model (Log-likelihood ratio P = 0.002, c2 = 12.38, degrees of freedom = 2). 
When the interaction term is included, the model is in agreement with the stratified results 
suggesting no evidence for an effect of 25(OH)D on HNC risk in non-smokers but with a strong effect 
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Figure 4-6: The modelled probability of developing HNC within smoking status strata when 
an interaction between 25(OH)D and smoking status is included in the model. 
 
Each point represents the predicted probability (on the log scale) for each individual given their 25(OH)D 
level. Vertical error bars represent the 95% confidence interval for the prediction. The model includes an 
interaction between 25(OH)D and smoking status. A line with horizontal slope suggests no effect of 25(OH)D 
and a decreasing slope suggests that the probability of HNC decreases as 25(OH)D increases.   
4.4.4.2 Sex 
Table 4-3: Stratification by sex and smoking status.  
Cases Controls OR 95% CI 
Smoking Status: Female     
Never 43 122,653 1.35 0.82,2.22 
Previous 47 62,166 0.82 0.52,1.27 
Current 19 17,271 0.54 0.33,0.90 
Smoking Status: Male 
    
Never 93 90,378 0.90 0.64,1.26 
Previous 140 67,872 0.72 0.55,0.95 
Current 135 22,106 0.59 0.49,0.70 
 
When stratified by sex, there was some evidence that 25(OH)D had a smaller effect in females 
compared to males (OR = 0.84 (95% CI: 0.63 to 1.12) versus OR = 0.58 (95% CI: 0.51 to 0.67), I2 = 
80.6%, Phet = 0.023). The effect estimate in females was imprecise and there was some overlap of 
confidence intervals between the male and female estimates. When results are stratified by both 
smoking status and sex, effect estimates for current and previous smokers are similar in both sexes 
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but there is a large disparity in the imprecise estimates for non-smokers, between males and 
females (Table 4-3). 
4.4.4.3 Time from blood draw to diagnosis 
There was some very weak evidence of heterogeneity across strata of time from blood draw to 
diagnosis (Figure 4-5). There was not an obvious trend with increasing time from blood draw to 
diagnosis with the effect of 25(OH)D on HNC smaller at the extremes of time from blood draw. 
4.4.5 Sensitivity analyses 
When the unconditional analyses were repeated generating standard errors robust to geographic 
clustering of UK Biobank individuals, there was little decrease in the precision of the estimates. For 
example, the log OR and standard error for the unadjusted unconditional analysis was -0.34 and 
0.060 respectively and -0.34 and 0.061 respectively using the clustered analysis method. This small 
reduction in precision made no difference to the interpretation of the results. 
4.4.6 Comparison and meta-analysis of effect sizes with previously published 
estimates 
The estimates in this study are highly consistent with those from Fanidi et al. (2016),126 within cancer 
site and when all sites are combined. There was no strong evidence of heterogeneity identified 
however, power to detect heterogeneity was low. In fixed effect meta-analyses, the magnitudes of 
effect for each cancer site remain similar to those in this study with a modest improvement in 
precision (Figure 4-7). 
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Figure 4-7: Forest plots showing the meta-analysis of results with Fanidi et al. (2016). 
 
A = All HNC, B = Oral cavity cancer, C = Oropharyngeal cancer, D = Laryngeal cancer. 
4.4.7 The association between 25(OH)D and HNC prognosis 
The mean follow up time of the 480 incident HNCs identified in UK Biobank was 4.3 years (SD=2.3 
years). There were 114 (23.8 %) deaths from any cause of which 61.4 % (n=70) were HNC specific 
deaths, there were nine (1.9%) HNC recurrences resulting in 123 events (deaths or recurrences) in 
survival analyses. 
Of the 480 incident HNCs there were 297 participants in the low 25(OH)D group (mean 25(OH)D = 
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the disease-free survival distributions were compared, there was some evidence of poorer disease-
free survival in the low 25(OH)D group (Figure 4-8). 
Figure 4-8: Kaplan Meier plots of disease-free survival for low and high 25(OH)D. 
 
In minimally adjusted cox-proportional hazards regression a log2(25(OH)D) increase was associated 
with a HR of 0.64 (95% CI: 0.53 to 0.77) with minimal attenuation after correcting for smoking, 
alcohol consumption and BMI (HR = 0.67 (95% CI: 0.54 to 0.84)) (Figure 4-9). 
Figure 4-9: Hazard ratio for all-cause mortality or recurrence of HNC per log2 increase in 
25(OH)D using Cox proportional hazards regression. 
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4.4.8 Stratification of survival analyses 
Due to the relatively small number of cases in UK Biobank, there was limited power to identify 
effects within specific sites or strata of potential confounders. The effect of 25(OH)D on prognosis 
was similar across the major HNC sites, with the greatest protective effect seen in laryngeal (and 
hypopharyngeal) cancers. The protective effect in oral cavity cancers was weakest with confidence 
intervals consistent with a large protective effect or a small detrimental effect on HNC disease free 
survival. There was very little evidence of heterogeneous effects across strata of potential 
confounders (Figure 4-10). 
Figure 4-10: Hazard ratio for all-cause mortality or recurrence per log2 increase in 25(OH)D 
stratified by site and known confounders. 
 
4.4.8.1 Sensitivity analyses 
When HNC specific mortality only was considered, there was a small attenuation of effect size 
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(Figure 4-11). In analyses removing those who died within six months of diagnosis (55 participants), 
there was minimal difference when compared to analyses including all deaths (Figure 4-12). 
Figure 4-11: Hazard ratio for HNC specific mortality or recurrence of HNC per log2 increase in 
25(OH)D using Cox proportional hazards regression. 
 
Figure 4-12: Hazard ratio for all-cause mortality or recurrence of HNC per log2 increase in 
25(OH)D using Cox proportional hazards regression in participants who survived greater 
than six months post-diagnosis. 
 
4.5 Discussion 
In this chapter a protective effect of 25(OH)D on HNC risk is demonstrated in a prospective cohort 
study. The largest protective effect of 25(OH)D is seen for laryngeal and oral cavity cancers with 
weaker evidence for a small effect on oropharyngeal cancers. A protective effect is also seen on HNC 
prognosis, with higher 25(OH)D resulting in greater disease-free survival. The effects on both risk 
and prognosis are robust to correction by measured confounders and are similar to previous findings 
by Fanidi et al.126 
4.5.1 Head and neck cancer risk 
The effects of 25(OH)D on oral, laryngeal and oropharyngeal cancer risk identified here are 
consistent with several studies which have previously reported a protective effect of 25(OH)D on 
HNC cancers.124–126 The effect magnitudes for laryngeal and oral cavity cancers are relatively large 
and clinically relevant, for example nearing a 50% reduction in risk for laryngeal cancer when 
25(OH)D levels are doubled. The effect estimate for oropharyngeal cancer is smaller with confidence 
intervals crossing the null in adjusted conditional analyses. The effect estimates remain after 
correcting for known confounders. 
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As detailed in Chapter 2, there is a close relationship between tobacco use, vitamin D and HNC risk. 
Several previous studies that have identified protective effects of vitamin D on HNC risk, have 
commented that the effect was either stronger or only seen in smokers. This finding is replicated in 
this study, with the effect of 25(OH)D in only non-smokers having an OR of 1.0 but with very strong 
effects seen for smokers. 
There are several possible explanations for the heterogeneity in effect size across smoking strata, 
these have been discussed in general in Chapter 2. The differing effect sizes within the smoking 
status strata may reflect the largely unbiased situation with smoking acting as an effect modifier on 
the 25(OH)D – HNC association. This suggests that 25(OH)D may be causally associated with a 
reduction in risk of HNC, but only in smokers. In the second scenario, the effect could be due to a 
combination of residual confounding and misclassification of smoking status. In this scenario, 
correcting for smoking status using current, previous or never smoking may not fully capture the risk 
attributable to smoking. Furthermore, this misclassification of smoking, and therefore the degree of 
residual confounding, may increase as smoking increases, resulting in biased estimates in smokers 
and unbiased estimates in never smokers. The combined and within smoking strata estimates of 
effect would therefore be biased away from the null (towards a protective effect of 25(OH)D in this 
case) with the true effect size seen in the non-smokers.  
The results presented in this chapter could support smoking being either a confounder or an effect 
modifier, or even a combination of the two. Similar results were identified in the Fanidi et al. study 
where they had the advantage of cotinine measures as an unbiased measure of smoking status at 
blood draw. After correcting for cotinine levels, the researchers still saw heterogeneity across 
smoking strata and concluded that residual confounding was unlikely to fully explain this 
heterogeneity. Even with cotinine levels however, there is the potential for misclassification of the 
lifetime effect of smoking. Current smoking intensity (which is captured by cotinine) may not 
represent the overall risk of HNC attributable to smoking across the life-course and still leave the 
potential for residual confounding to bias estimates. 
In this study the aim is to estimate a causal association, as discussed in Chapter 3 causality is likely to 
lead to a dose-response relationship between the exposure and outcome. When 25(OH)D was 
stratified into quintiles, no such dose-response relationship was evident in any of the HNC sites. One 
explanation is that the association is not causal and the confounding structure is the same across the 
quintiles of vitamin D. Despite this, the consistency of the results of this study with the Fanidi et al. 
study lends some support to a causal association. It is unlikely that the confounding structure across 
the two studies is identical and it is also unlikely that the results would by so similar by chance. 
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However, smoking does have the potential to confound both studies in a similar way and therefore 
residual confounding could explain the results in both studies. Using meta-analysis to combine these 
studies does not generate a pooled estimate that is necessarily closer to the true causal estimate. As 
discussed in Chapter 3, the pooled estimate will include the error of the individual studies and if 
these are systematically biasing the individual studies in one direction then the pooled estimate will 
also be biased. 
4.5.2 Head and neck cancer prognosis 
In this chapter, strong protective effects of pre-diagnosis 25(OH)D on cancer prognosis have been 
identified. Due to the limited power in stratified analyses it is difficult to comment on how the effect 
of 25(OH)D may differ across HNC sites or within strata of potential confounders.  
This finding supports previous findings identifying a protective effect of pre-diagnosis 25(OH)D on 
HNC prognosis126 and two studies that found a protective effect of 25(OH)D levels at diagnosis on 
HNC prognosis.131,132 The latter two studies may have been biased by vitamin D levels dropping due 
to the ongoing but undiagnosed cancer process in the participants. However, in this work, pre-
diagnostic 25(OH)D levels were used to mitigate this issue. Furthermore, sensitivity analyses 
removing participants that were diagnosed within six months of blood draw did not alter the results 
or their interpretation. 
In this chapter we were able to identify participants that were thought to have died of HNC related 
deaths, as well as those that died from any cause. When analyses were restricted to those that died 
of HNC specific deaths, the effects of 25(OH)D were smaller and more imprecisely estimated. 
Conducting analyses in a case only study has the potential to induce ascertainment or collider bias. 
This bias will be an issue if 25(OH)D is a cause for HNC, because, in those with HNC, any HNC risk 
factors will become correlated, potentially inducing spurious relationships. This topic is discussed 
further in Chapter 8 in the context of observational and MR analyses. 
In this study routinely collected registry data was used to identify cancer cases and mortality data in 
the UK Biobank participants. As cancer and death registry data are collected as part of normal 
clinical care and not specifically for research purposes they have strengths and weaknesses. Registry 
data are largely complete and where data are missing it is most likely to be missing at random 
therefore, missing data will only lead to reduced precision rather than biased estimates. There are 
also likely to be errors in death registry data, particular relating to the cause of death.172,173 These 
errors will have implications on cause-specific survival analyses but should be less influential when 
investigating all-cause mortality. Finally, registry data are not collected for the purposes of this 
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specific study and therefore does not have the detail that may be desired if you were to design a 
bespoke data collection. One example in this study is the lack of cancer staging data from the UK 
cancer registry. The impact of not having data on stage is discussed below. 
Stage of cancer at diagnosis is one of the major determinants of prognosis and if vitamin D is a cause 
of cancer then it will likely be associated with stage. This relationship between vitamin D and stage 
can take one of two potential forms, each with its own impact on the survival analyses. Firstly, 
vitamin D may affect the biology of the cancer and therefore impact prognosis. In this scenario stage 
at diagnosis can be thought of as an intermediate on the causal pathway between vitamin D and 
prognosis. Therefore, correcting for stage will lead to estimating only the impact of vitamin D that 
does not act via its effect on cancer stage. Alternatively, vitamin D may be a good marker of cancer 
stage, rather than being a causal influence. In this scenario, cancer stage acts as a confounder and 
estimates that are not corrected for it, such as those in this study, will over-estimate the effect of 
vitamin D due to confounding by stage. It is unclear which of these scenarios or whether a 
combination of the two is the most likely. 
4.5.3 Conclusions 
Although it is not yet clear, there is growing evidence from this work and from Fanidi et al.126 that 
25(OH)D may be protective against HNC risk in smokers. If this is the case, there may be the 
potential for targeting high dose 25(OH)D interventions to smokers at high risk of developing HNC. 
However, given high profile failures of similar interventions in other cancers, for example vitamin E 
and selenium in prostate cancer,174 it would be sensible to seek further evidence of causality before 
proceeding to clinical trials. Additionally, the protective effect of 25(OH)D on HNC prognosis 
provides a potential avenue for an adjuvant treatment alongside the primary cancer treatment 
modality. Arguably, evidence from cell-based and mechanistic studies supports the effect on 
prognosis more than the effect on risk. Several pre-clinical studies have assessed the effectiveness of 
potent 25(OH)D analogues on HNC cell lines175–177 with some success but again further research to 
assess the true causal association of vitamin D on HNC prognosis is required. 
The next chapter 
The strong observational associations identified between vitamin D and HNC risk and prognosis, 
identified here and in previous similar studies, are likely to be affected by residual confounding. 
There is a need to assess the association using methods which are more robust to confounding such 
as MR. Effect estimates, from methods such as MR, that are consistent with the observational 
evidence will add credibility to a causal association existing between vitamin D and HNC risk and or 
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prognosis. In the next chapter, I conduct (as part of a small team) a study to identify new genetic 
variants which can proxy vitamin D in MR studies. After identifying these new variants, I combine 
them with previously identified variants and demonstrate that together these are a largely 
unconfounded measure of vitamin D and are therefore suitable to use in MR analyses. 
Chapter 5: Identifying vitamin D genetic variants 
 87 
Chapter 5 :  Identifying vitamin D genetic 
variants 
5.1 Chapter objectives 
In the previous chapter it was shown that there is a growing body of evidence from well-designed 
prospective observational studies that vitamin D may be protective in HNC risk and prognosis. 
However, despite these well-designed studies, causality has not been established and the 
associations may be due to residual confounding. MR is a method that can provide causal inference 
from observation data and requires a robust genetic proxy for vitamin D. In this chapter a genome-
wide association study (GWAS) of serum 25(OH)D is described with the aim to better understand the 
genetic underpinning of vitamin D biology and identify genetic variants which can be used as proxy 
measures for vitamin D in MR analyses. The findings from this study and similar published studies, 
are combined to select genetic variants which are robustly associated with 25(OH)D for use as proxy 
measures of vitamin D in MR analyses. In the following chapters, these proxies are assessed for 
suitability for use in MR analyses and then used in MR analyses to assess the causal association of 
vitamin D on HNC risk and prognosis. 
The work presented in this chapter was conducted as part of consortium of which I was a major 
contributor to the study design, analysis planning, analysis and final manuscript. In terms of analysis, 
I prepared the phenotype and conducted the GWAS analysis of the whole genome sequenced and 
imputed ALSPAC datasets. For this thesis, I additionally conducted all analyses presented here which 
were conducted on the ALSPAC cohort such as the haplotype analyses. Other aspects of the analysis, 
for which I was involved in the planning but not the actual conduct, such as the meta-analysis of 
individual studies, is presented here for completeness. 
5.2 Introduction 
Instrumental variable analyses such as MR rely on proxy variables for the exposure of interest. In this 
thesis, genetic variants associated with vitamin D are ideal as they are unrelated to factors that may 
confound the association between vitamin D and HNC risk or prognosis. The more variability in the 
exposure that is explained by the genetic proxy the greater power there will be in MR analyses. It is 
therefore of benefit to identify novel genetic variants for vitamin D which would increase the 
proportion of variance explained by the vitamin D proxy measure. 
As detailed in Chapter 2, approximately half of the variability in the concentration of the widely 
accepted vitamin D biomarker (25(OH)D), has been attributed to genetic factors in twin and family 
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studies.72,77 Four common genetic variants (minor allele frequency (MAF) >5%) in loci near four 
genes known to be involved in cholesterol synthesis (DHCR7), hydroxylation (CYP2R1), vitamin D 
transport (GC) and catabolism (CYP24A1) are strongly associated with 25(OH)D levels, yet explain 
little of its heritability.178 Low-frequency and rare genetic variants (defined as variants with a MAF of 
≤5% and ≤1% respectively) have recently been found to have large effects on clinically relevant 
traits179–181 providing an opportunity to better understand the biologic mechanisms influencing 
disease susceptibility in the general population. 
The objective of this study was to detect genetic variants with as yet undiscovered effects on 
25(OH)D levels through a large-scale meta-analysis. Unlike the previous GWAS of 25(OH)D,178 this 
study attempted to also identify low-frequency and rare variants with large effects on 25(OH)D. This 
has only recently been made possible through whole-genome sequencing and the use of improved 
genotype imputation for low frequency and rare variants, with the recent availability of large whole 
genome sequencing reference panels.157 
5.3 Methods 
5.3.1 Overview 
To achieve the objective of identifying novel genetic variants for vitamin D an association study of 
whole-genome sequence data and deeply imputed genome-wide genotypes was conducted to 
identify novel genetic determinants of serum 25(OH)D in 42,274 individuals. The study combined 
data from 17 studies by meta-analysis and also combined whole genome sequenced and imputed 
genetic data to identify variants which are rarer or have smaller effects than the previous studies. 
5.3.2 Studies 
All human studies were approved by each respective institutional or national ethics review 
committees, and all participants provided written informed consent. To investigate the role of rare 
and low-frequency genetic variation on 25(OH)D levels in individuals of European descent, whole 
genome sequencing (WGS) data at mean read depth of 6.7x in 2,619 subjects from two cohorts in 
the UK10K project182 with available 25(OH)D phenotypes were used (Table 5-1). Imputation 
reference panels were also used to impute variants that were missing, or poorly captured, from 
previous GWAS in 39,655 subjects (Table 5-1 and Figure 5-1). The participating individuals were 
drawn from independent cohorts of individuals of European descent. Detailed description of each of 
the participating studies is provided in the Appendix (Appendix 5.1). 
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Figure 5-1: Schematic of the discovery single variant meta-analysis 
 
Table 5-1: Participating cohorts and number of DNA samples per cohort 
Study Acronym* Imputed WGS 
ALSPAC 3,679 1,606 
TUK  1,919 1,013 
Generation R 1,442   
BPROOF 2,514   
FHS 5,402   
MrOS 3,265   
RSI 3,320   
RSII 2,022   
RSIII 2,913   
CHS 1,792   
BMDCS 863   
MrOS GBG 945   
GOOD 921   
MrOS Malmo 893   
PIVUS 943   
ULSAM 1,095   
NEO 5,727   
TOTAL = 42,274 39,655 2,619 
*For full names of the studies see Appendix (Appendix 5.1), WGS: Whole-Genome Sequenced 
5.3.3 Measurement of serum 25(OH)D 
The methods applied to measure 25(OH)D levels differed among the participating cohorts (Appendix 
5.1). The four methods used were tandem mass spectrometry (in BMDCS, MrOS and BPROOF), 
combined high-performance liquid chromatography with mass spectrometry (in ALSPAC, BPROOF, 
CHS, ULSAM, NEO, Generation R), chemiluminescence immunoassay (DiaSorin, Inc, Stillwater, MN) 
(in TUK, PIVUS, FHS, MrOS Malmo, MrOS GBG and GOOD) and an electrochemiluminescence 
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immunoassay (COBAS, Roche Diagnostics GmbH) (in RSI, RSII and RSIII). Detection limits for the 
different methods are provided in the Appendix (Appendix 5.1). 
5.3.4 Whole-genome sequencing, genotyping and imputation 
ALSPAC WGS and TUK WGS cohorts had been sequenced at an average read depth of 6.7x through 
the UK10K consortium (www.UK10K.org) using the Illumina HiSeq platform, and aligned to the 
GRCh37 human reference using Burrows-Wheeler Aligner (BWA)31.183 Single-nucleotide variant 
(SNV) calls were completed using samtools/bcftools,184  and VQSR185 and GATK were used to recall 
these variants. The whole genome sequencing for the ALSPAC and TwinsUK cohorts has been 
described in detail in a previous publication.180 Appendix 5.3 summarises the data generation 
method for sequencing-based cohorts. 
Participating studies separately genotyped samples and imputed them to WGS-based reference 
panels.  The most recent imputation panels, such as the UK10K and 1000Genomes Project (v3) 
combined panel, which in total contained 7,562 haplotypes from the  UK10K Project and 2,184 
haplotypes from the 1000 Genomes Project,157 and the Haplotype Reference Consortium (HRC) 
panel, with 64,976 haplotypes,186 enabled more accurate imputation of low frequency variants, 
when compared to the UK10K or the 1000Genomes reference panel alone.157 Specifically, 11 out of 
the 17 participating cohorts were imputed to the UK10K and 1000 Genomes reference panel (total 
number of imputed individuals included in the meta-analysis N=25,589). Three of the participating 
cohorts were imputed using the HRC panel (total number of imputed individuals N=5,717). Finally, 
two cohorts were imputed to the 1000Genomes panel (N=7,536), and one cohort was imputed to 
the UK10K panel (N=863). (Appendix 5.1). Details on genotyping methods and imputation for the 17 
participating cohorts are presented in Appendix 5.2. Info scores for the imputed SNVs per 
participating cohort are presented in Appendix 5.4. 
5.3.5 Statistical analysis 
A GWAS was conducted separately by each cohort using an additive genetic model for 25(OH)D 
levels. Because 25(OH)D concentrations were measured using different methods, log-transformed 
25(OH)D levels were standardized to z-scores, after being adjusted for age, sex, BMI, and season of 
measurement. Specifically, the phenotype for each GWAS study was prepared according to the 
following steps: 
1. 25(OH)D levels were log-transformed to ensure normality 
2. Linear regression models were used to generate cohort-specific residuals of log transformed 
25(OH)D levels adjusted for covariates (age, sex, BMI and season). Season was treated as a 
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non-ordinal categorical variable (summer: July to September, fall: October to December, 
winter: January to March, and spring: April to June) 
3. The mean of log transformed 25(OH)D levels was added to the residuals to create the 
adjusted 25(OH)D phenotype. 
4. The above phenotype was then normalized within each cohort (mean of zero with SD of 
one) to make the phenotype consistent across cohorts. 
5. Finally, outliers beyond 5 standard deviations were removed from step 4.  
For comparison purposes, 25(OH)D levels, adjusted for age, sex, BMI and season of measurement, 
were calculated in one cohort of the meta-analysis (ALSPAC WGS) in carriers and non-carriers of the 
lead SNV(s). 
The software used by each cohort to perform a GWAS is listed in Appendix 5.1. Single variant tests 
were undertaken for variants with MAF>0.1%, using an additive effect of the minor allele at each 
variant in each cohort. The type of software employed for single variant testing for each cohort is 
shown in Appendix 5.1. Studies with related individuals used software that accounted for 
relatedness. The mean lambda was 1.015, cohort-specific genomic inflation factors (lambdas) are 
shown in Appendix 5.1. 
The association results from all discovery cohorts were meta-analysed (N total = 42,274).  This stage 
included validation of results file format, filtering files by the above QC criteria, comparison of trait 
distributions among different studies, identification of potential biases (large betas and/or standard 
errors, inconsistent effect allele frequencies, extreme lambdas). Meta-analysis quality control of the 
GWAS data included the following SNV-level exclusion criteria: i) Info score <0.4, ii) HWE P-value 
<10-6 iii) Missingness >0.05, and iv) MAF <0.5%. Alignment of the SNVs across studies was done using 
the chromosome and position information for each variant according to genome build hg19. SNVs in 
the X chromosome were not included in the meta-analysis.  Fixed–effects meta-analysis was 
performed using the software package GWAMA187 adjusting for genomic control. Bi-allelic SNVs with 
MAF ≥ 0.5% were tested for association, declaring genome-wide statistical significance at P ≤ 1.2 × 
10−8 for variants present in more than one study. This stringent p-value threshold was set to adjust 
for all independent SNVs above the MAF threshold of 0.5%.188  
Conditional analysis was undertaken for the four previously described lead vitamin D SNVs from the 
SUNLIGHT consortium using the GCTA package.189 This method uses an approximate conditional 
analysis approach from summary-level statistics from the meta-analysis and linkage disequilibrium 
corrections between SNVs estimated from a reference sample. The UK10K individuals were used as 
the reference sample to calculate the linkage disequilibrium information of SNVs. The associated 
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regions flanking within 400kb of the top SNVs from SUNLIGHT were extracted and the conditional 
analyses were conducted within these regions. Conditional analyses of individual variants were 
conducted using GCTA v 0.93.9 using default parameters.  
Haplotype block analyses were used for the candidate variants of interest by deriving phased 
haplotypes from 1,060 individuals from the ALSPAC WGS cohort using adjusted but untransformed 
25(OH)D values. 
5.4 Results 
5.4.1 Low-frequency 25(OH)D-associated SNVs 
After strict quality control, the genomic inflation factor for the meta-analysis of 19 GWAS studies 
was 0.99, suggesting lack of bias due to population stratification (Figure 5-2). Through meta-analysis 
of 11,026,511 sequenced and imputed variants from our discovery cohorts (Table 5-1), we identified 
a signal at the chromosome 11p.15.2 locus, harbouring variants associated with 25(OH)D levels (lead 
low-frequency SNV p.Asp120Asp [rs117913124(A)], MAF = 2.5%, allelic effect size = -0.43 standard 
deviations of the standardized log-transformed 25(OH)D levels [SD], P = 1.5×10−88, Figure 5-3). The 
direction of effect was consistent across all discovery cohorts (Table 5-2 and Figure 5-3) and the 
mean imputation information score for the imputed studies was 0.97. This low-frequency 
synonymous coding variant is in exon 4 of the CYP2R1 and is ~14 kb from the previously identified 
common CYP2R1 variant, rs10741657 (r2 between these two SNVs= 0.03) (Figure 5-2). The 
rs117913124 SNV has not previously been reported to be associated with any vitamin D-related 
traits in humans. 
Figure 5-2: Discovery single-variant meta-analysis. 
 
A. Quantile-quantile plot for the single SNV meta-analysis. B. Manhattan plot of the meta-analysis. The plot 
depicts variants with MAF > 0.5% across the 22 autosomes against the –log10 p-value from the meta-
analysis of 19 cohorts, which included 42,274 individuals. 
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Figure 5-3: Forest plot detailing the per allele effect of rs117913124 on standardised 
log25(OH)D by cohort. 
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N Effect Allele 





ALSPAC Imputed MS 3675 0.028 -0.59 0.07 3.43x10-18 0.99 
ALSPAC WGS MS 1606 0.028 -0.65 0.11 8.23x10-10 NA 
BPROOF MS 2512 0.027 -0.4 0.09 4.99x10-6 0.97 
BMDCS MS 863 0.019 -0.11 0.06 0.058 0.98 
CHS MS 1581 0.022 -0.55 0.11 5.15x10-7 0.88 
FHS CLIA 5402 0.021 -0.45 0.07 2.32x10-10 0.97 
GenerationR MS 1442 0.033 -0.66 0.1 1.78x10-6 1 
GOOD CLIA 921 0.028 -0.14 0.14 0.31 0.96 
MrOS MS 3265 0.018 -0.76 0.09 5.63x10-16 0.96 
MrOS Malmo CLIA 893 0.033 -0.33 0.14 0.016 0.94 
MrOS GBG CLIA 945 0.026 -0.61 0.14 7.87x10-6 1 
NEO MS 5727 0.025 -0.54 0.06 2.73x10-19 1 
PIVUS CLIA 943 0.028 -0.66 0.14 2.56x10-6 0.99 
RSI ECLIA 3320 0.025 -0.19 0.08 0.019 0.98 
RSII ECLIA 2022 0.033 -0.37 0.09 2.38x10-5 0.99 
RSIII ECLIA 2913 0.027 -0.51 0.08 4.61x10-10 0.98 
TUK Imputed CLIA 1919 0.021 -0.1 0.11 0.35 0.98 
TUK WGS CLIA 1013 0.025 -0.39 0.14 0.006 NA 
ULSAM MS 1095 0.025 -0.33 0.14 0.02 1 
* Effect allele is the 25OHD decreasing allele 
# MS: mass spectrometry, CLIA: chemiluminescence immunoassay, ECLIA: electrochemiluminescence immunoassay 
$ Betas represent changes in standard deviations of the standardized log-transformed 25OHD level
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A comparison of the 25(OH)D levels, adjusted for age, sex, BMI and season of measurement, in non-
carriers, heterozygote carriers and homozygous carriers of the A allele of rs117913124 in the ALSPAC 
WGS was performed. The average 25(OH)D levels, adjusted for age, sex, BMI and season of 
measurement were computed in 1,606 individuals from the ALSPAC WGS cohort, among which 
1,516 were not carriers, 89 were heterozygote carriers of the A allele and 1 individual was a 
homozygous carrier of the A allele of rs117913124. A linear regression model with the adjusted 
25(OH)D levels as the dependent variable and the dose of the “A” allele of rs117913124 (numeric 
factor 2, 1 or 0) as the independent variable demonstrated a 11.1 nmol/L decrease in the adjusted 
25(OH)D levels per “A” allele. The mean adjusted 25(OH)D levels were 61.9 nmol/L in non-carriers vs 
51.1 nmol/L in heterozygote carriers vs 27.3 nmol/L in the homozygous carrier (Figure 5-4). 
Figure 5-4: Comparison of 25(OH)D levels in homozygous (AA), heterozygote (AG) and non-
carriers (GG) of the rs117913124 variant in the ALSPAC WGS participants. 
 
25(OH)D levels are adjusted for age, sex, BMI and season of measurement. Thick lines represent the median, 
boxes represent the interquartile range (IQR) and the whiskers indicate +/- 1.5*IQR from the edge of the 
IQR box. 
Two-way conditional analysis between the CYP2R1 common (rs10741657) and low-frequency 
(rs117913124) variants revealed that the two association signals are statistically independent. 
Specifically, after conditioning on rs10741657, rs117913124 remained strongly associated with 
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25(OH)D level remained significant (Pcond= 4.0 x10-33 versus Ppre-cond= 8.8 X 10-45) (Table 5-3). 
Furthermore, no other low frequency variant in the region remained significant when conditioning 
on rs117913124 (Table 5-3). To further disentangle the role of rs117913124 from rs10741657 on 
25(OH)D levels, haplotype analysis based on WGS data from 1,606 individuals from the ALSPAC WGS 
cohort was conducted. It was found that the 25(OH)D decreasing allele A of rs117913124 was rarely 
transmitted in the same haplotype block with the 25(OH)D increasing allele A of the common 
CYP2R1 variant rs10741657 (haplotype frequency = 0.1%). The 25(OH)D levels among carriers of the 
various haplotype blocks was compared. This showed evidence of a decrease in the 25(OH)D levels 
in carriers of the A allele of the rs117913124 compared to non-carriers independent of the presence 
of the effect allele G of the common CYP2R1 variant (Table 5-4).
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Table 5-3: Association results for genome-wide significant low-frequency variants from discovery 25(OH)D meta-analysis, before and after 
conditioning on the lead common CYP2R1 SNP, rs10741657, and the lead low-frequency CYP2R1 variant, rs117913124. 
Genetic 
variant 
Chr Position EA* EAF Candidate 
Gene 
Beta$ P-value  Beta$  P -value  Beta$ P-value N 
                 Conditional on 
rs10741657 









14900931 A 0.025 CYP2R1 -0.43 1.5 x10-88  -0.39 2.4 x10-78  NA NA 41336 




-0.43 2.2 x10-90  -0.40 3.3 x10-80  NA NA 41138 
rs117361591 14861957 T 0.014 -0.44 9.1 x10-51  -0.40 2.2 x10-44  -0.05 0.017 38286 
rs117621176 14861320 G 0.014 -0.44 8.7 x10-51  -0.40 2.1 x10-44  -0.05 0.016 38273 
rs142830933 14838760 C 0.014 -0.44 1.4 x10-48  -0.40 1.7 x10-42  -0.05 0.03 37541 
rs117672174 14746404 T 0.014 -0.43 2.8 x10-45  -0.39 2.9 x10-39  -0.04 0.062 37209 
*Effect allele is the 25OHD decreasing allele 
$ Betas represent changes in standard deviations of the standardized log-transformed 25OHD levels 
Chr = chromosome, EA = effect allele, EAF = effecta allele frequency
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Table 5-4: Effect of different haplotype combinations of the low frequency (rs117913124) 
and the common (rs10741657) CYP2R1 variants on 25OHD levels.  
Haplotype 
 
rare/common*   rare/common* 
Beta$ P-value N (%) 
 
TOTAL = 1,606 
               GA                      GA REF (Mean = 63.51 nmol/L) 254 (15.8) 
               AA                      GG -13.03 2 x10-5 37 (2.3) 
               AG                      GG -12.02 5.8 x10-6 52 (3.2) 
               AG                      AG -36.17 0.038 1 (0.1) 
               GA                      GG -0.51 0.688 718 ( 44.7) 
               GG                      GG -3.93 0.003 544 (33.9) 
* The first allele in each chromatid corresponds to the low-frequency variant rs117913124; the second allele 
corresponds to the common variant rs10741657. The 25(OH)D decreasing allele of the low-frequency variant 
is A, the 25OHD decreasing allele of the common variant is G. 
$ Beta values represent changes in the untransformed 25OHD levels from the mean value in the GA GA 
haplotype. 
No other low-frequency or rare variants were identified in the three previously described vitamin D-
related loci at DHCR7, GC and CYP24A1. The mean effect size of the four previously reported 
common genome-wide significant SNVs (MAF ≥ 5%) from the SUNLIGHT consortium was -0.13 SD 
and the largest effect size was -0.25 SD (for the GC variant) in this meta-analysis (Figure 5-5 and 
Appendix 5.5). The effect size of rs10741657(G), the known common CYP2R1 variant, was -0.09 SD. 
Hence, the observed effect size of rs117913124 is 3-fold larger than the above-mentioned mean, 4-
fold larger that of the common CYP2R1 variant and almost twice that of the largest previously 
reported effect of the GC variant. Last, the percentage of the variance of the 25(OH)D phenotype 
explained by the low-frequency CYP2R1 variant was more than double than the percentage of the 
variance explained by the CYP2R1 common variant (0.9% vs 0.4%). 
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Figure 5-5: Forest-plot of the effect of the four common SUNLIGHT variants and of the 
CYP2R1 low-frequency variant rs117913124 on standardised log-transformed 25(OH)D 
levels. 
 
Eighteen genome-wide significant low-frequency and rare SNVs were also identified on the same 
chromosome 11 region as rs117914124. Six of these were located in the neighbouring PDE3B gene 
and had consistent effect direction in all 19 cohorts (Table 5-3, Figure 5-6B). Signals from these SNVs 
in PDE3B were independent of the common variant at CYP2R1 (Table 5-3). Haplotype blocks with 
rs117913124 and SNVs at PDE3B were generated based on haplotype information from the 1,606 
individuals from the ALSPAC WGS cohorts (Appendix 5.6) It was found that the 25(OH)D decreasing 
allele (A) of the rs117913124 was inherited with the 25(OH)D decreasing allele (A) of its perfect 
proxy rs116970203 (r2=1) in all participants except one. Therefore, rs116970203 is not likely to have 
a distinct effect from rs117913124 on 25(OH)D levels. On the other hand, the 25(OH)D decreasing 
alleles of the remaining four low-frequency variants (all having a MAF of approximately 1.4%) were 
not always inherited in the same haplotype block as the rs117913124 and rs116970203 and were in 
moderate linkage disequilibrium with the rs117913124 (all r2< 0.6, Figure 4B and Figure 4C). Each of 
the four alleles is in almost perfect linkage disequilibrium with the remaining three (all r2 >0.96). This 
implied that these four SNVs might influence 25(OH)D levels independently of the rs117913124. 
Nevertheless, as mentioned above, when conditioning on the lead low-frequency CYP2R1 SNV 
rs117913124, the P-values of the four PDE3B SNVs became non-significant and their betas 
decreased substantially (Table 5-3), demonstrating that they likely do not represent an independent 
signal at the chromosome 11 locus. 
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Figure 5-6: Association Signals from 11p.15.2 
 
A. Snapshot from the UCSC genome-browser including the top low-frequency SNVs (see Table 5-2) and the 
lead common variant rs10741657 at the CYP2R1 locus. The position of rs117913124 is highlighted in light 
blue. B. Regional disequilibrium plot showing the rs117913124 (purple dot), its perfect proxy rs11670203 
(red dot) and the other genome-wide significant SNVs in the same locus (blue and green dots). The plot 
depicts SNVs within 1 Mb of a locus’ lead SNV (x-axis) and their associated meta-analysis p value (-log10). 
SNVs are color coded according to r2 with the lead SNV (labelled, r2 calculated from UK10K whole genome 
sequencing dataset). Recombination rate (blue line), and the position of genes, their exons and the direction 
of transcription are also displayed (below plot). C. Linkage disequilibrium plot indicating the r2 values 
between the SNVs of Table 5-2 (top low-frequency variants) and between these low-frequency SNVs and the 
lead common variant (rs107416570) at the same CYP2R1 locus (r2 calculated from the 1000 Genomes 
dataset). 
5.4.2 Common 25(OH)D-associated SNVs 
Two additional novel loci associated with 25(OH)D levels (Table 5-5) were identified which passed 
the genome-wide significance threshold. Variants leading these associations were common and 
exerted a rather small effect on 25(OH)D: first, a variant in chromosome 12 (rs3819817[C], intronic 
to HAL), with a MAF of 45%, a beta of 0.04 and a P-value of 3.2 x 10-10. Second, a variant in 
chromosome 14 (rs2277458[G], intronic to GEMIN2), with a MAF of 21%, a beta of -0.05 and a P-
value of 6.0 x 10-9. Both variants were present in all 19 studies and with consistent direction of 
effect. Neither the HAL nor the GEMIN2 loci are previously known to be associated with 25(OH)D 
levels. Of note, neither variant was present in the HapMap imputation reference used in the 
SUNLIGHT study. 
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Table 5-5: Main novel findings of the GWAS meta-analysis 






Beta$ P-value N 
rs117913124 11 CYP2R1 A 0.025 -0.43 1.5 x10-88 41,336 
rs3819817 12 HAL C 0.45 0.04 3.2 x10
-10
 41,071 
rs2277458 14 GEMIN2 G 0.21 -0.05 6.0 x10
-09
 39,746 
$ Betas represent changes in standard deviations of the standardized log-transformed 25(OH)D levels, while 
controlling for age, sex, BMI and season of measurement  
5.5 Discussion 
5.5.1 GWAS meta-analysis 
In this meta-analysis of genome-wide association studies for 25(OH)D levels in European 
populations, a low-frequency, synonymous coding genetic variant of large effect that strongly 
associates with 25(OH)D levels was identified. This variant has an effect size four-fold larger than 
that described for the common variant in the same gene (CYP2R1). The biologic plausibility of this 
finding is supported by the fact that the low-frequency variant is located in CYP2R1, the major 
hepatic 25-hydroxylase for vitamin D.84 These findings are of clinical relevance since this study shos 
that approximately 5% of the general European population carry this variant in either the 
homozygous or heterozygous state. 
This study was enabled by large imputation reference panels (UK10K/1000 Genomes and HRC), 
which offer at least 10-fold more European samples than the 1000 Genomes reference panel alone. 
Low-frequency variants of large effect on 25(OH)D were not identified in novel genes in Europeans. 
Although, variants with smaller effects in two loci not previously known to be associated with 
25(OH)D were identified. 
CYP2R1 encodes the enzyme responsible for 25-hydroxylation of vitamin D, and is one of the two 
main enzymes responsible for vitamin D hepatic metabolism.84 Rare mutations in CYP2R1 have 
already been described to cause rickets.84,190 
Two common genetic variants of small effect size were also identified on chromosome 12 (HAL 
gene) and chromosome 14 (GEMIN2 gene) that reached genome-wide level significance in the meta-
analysis. Although there is no existing evidence of implication of GEMIN2 in vitamin D related 
physiologic pathways, HAL is expressed in the skin and is involved in formation of urocanic acid, a 
“natural sunscreen”.191,192 Thus, this could constitute a plausible pathophysiologic mechanism 
implicating HAL in vitamin D synthesis in the skin. Additional functional follow-up of the signals in 
chromosomes 12 and 14 is needed to characterize the genes and/or mechanisms underlying these 
associations. Since the completion of this study a subsequent GWAS has been published which 
aimed to identify only common genetic variants associated with 25(OH)D.193 This study of 
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approximately 80,000 individuals, also found strong evidence for 25(OH)D-associated variants on 
chromosomes 12 and 14. Although these two variants were not the same as those identified in this 
study they were in very similar loci. In European populations, the variant identified in this study on 
chromosome 12 (rs3819817) is in moderate LD (r2 = 0.63) with the variant identified in the newer 
GWAS (rs10745742) and the variant identified in this this study on chromosome 14 (rs2277458) is in 
very high LD (r2 = 0.98) with the variant identified in the newer study (rs8018720). 
These findings may have clinical relevance for several reasons: First, individuals carrying at least one 
copy of the low-frequency CYP2R1 variant have lowered levels of 25(OH)D by a clinically relevant 
degree. Secondly, these findings affect ~5% of individuals of European descent and may have utility 
in predicting individuals at risk of deficiency. 
This study has its limitations. First, although part of the scope of this study was detection of low-
frequency and rare variants, the two whole genome sequencing studies included in this study were 
of relatively low read depth (6.7x), and three studies were imputed to older imputation panels 
(1000Genomes and UK10K). These studies have a limited capacity to capture very rare variants, 
which might explain why such associations were not identified. Since the analysis is restricted to 
populations of European ancestry, no assumptions concerning the effect of rs117913124 in non-
European populations can be made. Nonetheless, based on the 1000Genomes reference, this 
variant is rare in Africans (MAF = 0.3%) and has not been described in East Asians (MAF = 0%). 
Therefore, very large sample sizes of these populations will be required to describe with any 
certainty the effect of this variant on 25(OH)D level in these populations. In the absence of 
functional experiments showing the exact function of the rs117913124 on CYP2R1 and given that 
this synonymous polymorphism does not affect protein sequence, it cannot be unequivocally shown 
that this low-frequency variant is causal, however, given that this is a coding variant in a well-
documented 25(OH)D-associated gene, it seems most likely that it exerts its effect on CYP2R1. In this 
meta-GWAS the phenotype was adjusted for BMI in order to remove any of the variance of 25(OH)D 
explained by BMI. Although this may have slightly improved power to identify genetic variants 
associated with 25(OH)D, it could introduce biases when the summary results are used in 
downstream MR analyses. Specifically, by conditioning on BMI which could be considered a collider 
in the vitamin D – HNC association, collider bias may be introduced however, in reality the 
magnitude of this bias is likely to be very small. Finally, population stratification may have been an 
issue in some of the studies included in the meta-analysis which did not use a linear mixed model to 
account for population structure. Despite this potential limitations, the correction of the issue with 
ancestry informative principal components is unlikely to change the key findings dramatically as only 
genetic variants which were consistent across all 17 studies (included seven where population 
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stratification was corrected for) were considered true findings. In future GWAS efforts of vitamin D 
25(OH)D will not be adjusted for BMI and will be conducted in a method which accounts for 
potential population structure. 
5.5.2 Vitamin D genetic proxy 
This GWAS demonstrates that vitamin D may have an oligogenic architecture. Compared to the 
previous GWAS178, the Jiang et al.193 study includes five times the number of participants in their 
discovery sample and the study in this chapter had twice the sample size and covered four times the 
number of genetic variants in the analysis. Despite this, there have been very few new genetic 
variants discovered which are strongly associated with vitamin D. Although this may partly relate to 
power, it may suggest that serum 25(OH)D biology is tightly controlled by only a few genes and 
pathways. This may have implications on the use of these variants as proxy measures of vitamin D. 
As mentioned, prior to this study there were four genetic variants which had been robustly 
associated with 25(OH)D and had been used in MR analyses. As a result of the low frequency and 
common variants identified in this study, and the similar findings for the two common variants in the 
Jiang et al. (2018) GWAS,193 there are now seven genetic variants with robust associations with 
25(OH)D which can be used as proxy measures of vitamin D. This increase in the number of genetic 
variants will increase power for MR analyses as a larger amount of variance in 25(OH)D will be 
explained by the seven variants than the original four. This increase in power is likely to be modest 
however, with the two novel common variants having only a small effects on the circulating 25(OH)D 
level. Despite the very large effects of rs117913124, it has a MAF of approximately 2.5%, and will 
therefore not explain a large amount of variance in 25(OH)D within the population. 
The low frequency variant (rs117913124), does however have other research benefits due to its 
large effects. Studies in which individuals who are carriers of large effect variants, such as 
rs117913124, are recalled and undergo further testing or more specific phenotyping (either 
physically or in-silico) are referred to as recall-by-genotype studies and can be an efficient and 
powerful adjunct to GWAS. In an extension to the work in this chapter, the effect of this variant on 
multiple sclerosis (MS) risk was investigated. The hypothesis was that as rs117913124 exerts such 
large effects on 25(OH)D, and there is a causal association between 25(OH)D and MS risk, the 
25(OH)D decreasing allele of the variant should predispose carriers to MS. In this work, strong 
evidence for this risk increasing association was identified with Individuals carrying one copy of this 
variant having an increased odds of multiple sclerosis (OR = 1.4 (95% CI = 1.19, 1.64); P = 2.63 
x10−5).194 
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As a continuation of this work, I am contributing to a new GWAS for 25(OH)D. This new study will 
combine the meta-analysis is this chapter with the results of a GWAS in UK Biobank. In total, this will 
include almost 450,000 participants and will therefore be adequately powered to detect genetic 
variants with smaller effect sizes and low frequency variants. This project is discussed further in the 
Future Studies section in Chapter 9. 
The next chapter 
In this chapter several genetic variants were discovered to be associated with 25(OH)D permitting 
their use for genetic proxies of 25(OH)D. In the next chapter I combine these variants with those 
previously identified to generate a genetic risk score for 25(OH)D to use in MR studies. I 
demonstrate how this proxy measure has advantages over serum 25(OH)D for assessing causal 
relationships.
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Chapter 6 :  Assessing genetic variation as a 
potential vitamin D proxy 
6.1 Chapter objectives 
In Chapter 5 genetic variants that are strongly associated with vitamin D were identified. In this 
chapter the suitability for these genetic variants as proxy variables in MR analyses is investigated. 
Associations of the 25(OH)D genetic proxy variable with over 35,000 phenotypic variables are 
assessed and compared to the same associations with serum 25(OH)D. A comparison of the results 
of these studies demonstrates the favourable properties of the proxy variable for causal inference. 
The aim of this chapter is to demonstrate the properties of the 25(OH)D genetic proxy and how they 
allow complementary assessment of causal relationships, alongside the observational estimates 
from Chapter 4. 
6.2 Introduction 
As discussed in Chapter 3, MR utilises genetic variants as instrumental variables to provide estimates 
of association between exposure and outcome, which are, in the right conditions, less affected by 
reverse causality and confounding. Genetic proxies are not necessarily perfect instruments for use in 
instrumental variable analyses such as MR as they often lack power and may not be truly 
independent of other factors. They are however relatively easily identified and readily measured in 
large numbers of individuals and so lend themselves to these types of analyses. Furthermore, they 
are the closest biological examples get to true instrumental variables. 
Phenome scans and PheWAS are hypothesis free approaches which are usually used to assess for 
associations between a variable or genetic variant with many potential outcomes. In this chapter, 
these hypothesis free approaches are repurposed to interrogate the MR assumptions where 
possible and assess the legitimacy of the genetic proxy over and above what can normally be 
achieved in a MR study. An alternative approach could be to select the phenotypes to include in the 
phenome scans as this would lower the multiple testing burden however, this approach would be 
heavily influenced by the variables selected and would not provide much more information to that 
in a standard MR analysis where measured confounders are tested for their association with the 
genetic instrument. 
MR relies on the three assumptions previously discussed in Chapter 3: 
A. The relevance assumption: The genetic variants used within the MR analysis are robustly 
associated with the exposure of interest 
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B. The independence assumption: The genetic variants share no common cause with the 
outcome of interest 
C. The exclusion restriction assumption: The genetic variants only affect the outcome of 
interest through the exposure of interest. 
The first assumption (A) can be readily tested. The identification of genetic proxies using GWAS, as in 
Chapter 5, relies on a hypothesis free approach and has been recognised as a technique able to yield 
reliable associations (through a combination of stringent thresholds to account for multiple testing 
and validation in multiple independent collections). In the case of 25(OH)D, the identified genetic 
variants are mostly found in or near genes which are vitamin D pathway related. Although this is no 
guarantee that the genetic variant is associated with these genes, it does lend further credence to 
their strong association with 25(OH)D. Despite the robust design of the GWAS experiment in Chapter 
5, there remains the possibility that false positive genetic variants, which are not strongly associated 
with 25(OH)D, were identified. To further test the relevance assumption, the genetic variants can be 
assessed for their association with 25(OH)D in an independent study – if the association holds true 
then this provides strong evidence that their association with 25(OH)D is robust. 
As mentioned previously, four of the genetic variants for 25(OH)D have been identified in genetic 
studies of 25(OH)D prior to this thesis178 and the study in Chapter 5 provided further replication of 
these variants. Since the publication of the work in Chapter 5, a larger GWAS of 25(OH)D has been 
published by Jiang et al.193 This more recent GWAS not only re-confirmed the association with the 
four original 25(OH)D variants but confirmed the association with the loci first identified in Chapter 
5, on chromosomes 12 and 14, in both their discovery and replication sets. 
The independence assumption (B) is at first thought easy to assess. Genetic variants which are 
allocated randomly at meiosis should have no common cause with a disease such as HNC. No action 
during an individual’s life can affect their germline genetics and therefore it would seem that this 
assumption is not violated. There are however scenarios in which the assumption is violated, for 
example, where differing ancestry within a sample means that the allele frequencies of the 25(OH)D 
genetic variants are different across ethnic groups. If this coincides with a difference in disease 
prevalence across the same ethnic groups (due to cultural differences and not genetic effects) then 
the MR effect estimate will be biased. Some simple measures can be taken to reduce the 
confounding effect of ancestry including limiting the analysis to a particular ancestral group and/or 
including genetic principal components into the MR model to account for the effect of ancestry. This 
topic is beyond the scope of this thesis, but is discussed further in one of the papers to which I 
contributed to, published during this thesis.144 Another potential source of bias which could violate 
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the independence assumption is ascertainment or collider bias. This is when a selection event 
introduces spurious associations between genetic variants and potential confounders. This topic is 
introduced in more detail in Chapter 3 and its implications investigated in Chapter 8. 
It is challenging to show that the exclusion restriction assumption (C) has not been violated in an MR 
study. In the case of 25(OH)D, there are relatively few genetic variants and all are closely related to 
vitamin D pathway genes. This reduces the likelihood of any of those variants having effects on other 
pathways which may independently affect HNC, a situation referred to as horizontal pleiotropic 
effects. However, there is the possibility that the genetic variants have effects on other pathways or 
metabolites proximal to 25(OH)D in the pathway, which independently of 25(OH)D go on to effect 
HNC. If this is the case, the causal effect from MR will be biased. 
In this chapter two parallel analyses are performed with the aim of systematically evaluating the 
causal effects of vitamin D and of understanding the suitability of the 25(OH)D genetic proxy for MR: 
(1) an observational study analysing the association of serum 25(OH)D with over 35,000 phenotypic 
variables and (2) an MR pheWAS analysis which estimates the causal effect of 25(OH)D on the same 
35,000 measures using the genetic proxy of vitamin D identified in Chapter 5. These parallel studies 
will provide information on whether the 25(OH)D genetic proxy is suitable for use in MR. Firstly, the 
strength of the genetic proxy as a measure of 25(OH)D will be assessed in an independent study to 
evaluate whether the proxy passes the relevance assumption. Secondly, the comparison between 
the observational and MR PheWAS results will provide improved understanding of the confounded 
versus unconfounded effects of vitamin D. This is turn may provide further understanding of any 
disparity between observational and causal estimates of effect in this thesis. As mentioned above, 
assessing the exclusion restriction assumption is complicated. Theoretically, potentially pleiotropic 
phenotypes between vitamin D genetic variants and HNC could be identified however, in reality 
power to detect these pleiotropic pathways will be very low.  
6.3 Methods 
6.3.1 Overview 
In this chapter, an observational phenome scan study and MR pheWAS study analysing the 
association of 25(OH)D with over 35,000 phenotypic variables was conducted. The first stage was to 
generate a 25(OH)D genetic risk score (GRS) by combining the effects of multiple genetic variants 
from those identified in this thesis and the more recent Jiang et al. GWAS.193 This GRS was then 
assessed for associations with over 35,000 phenotypic variables in UK Biobank using a dedicated 
analysis program. For the observational phenome scan, the analyses were then repeated to assess 
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the same associations but using serum 25(OH)D instead of the 25(OH)D GRS. A series of positive and 
negative control look-ups were also conducted. 
6.3.2 Study cohort 
The study was conducted in UK Biobank, a population-based study of approximately 500,000 
participants. A detailed description of this study, genotyping and the 25(OH)D measures are given in 
Chapter 3. 
6.3.3 Generation of exposures 
6.3.3.1 25-hydroxyvitamin D 
To remove the variation in serum 25(OH)D attributable to season, the 25(OH)D measures were 
adjusted as described in Chapter 4. 
6.3.3.2 Genetic risk score for vitamin D 
A weighted genetic risk score (GRS) for vitamin D was generated by combining the genetic variants 
identified in Chapter 5 and the subsequent Jiang et al.193 GWAS studies. Where possible effect 
estimates and standard errors were taken from the Jiang et al. GWAS as this has the largest sample 
size. The low frequency CYP2R1 genetic variant identified in Chapter 5 was not included in the Jiang 
et al. summary results due to its low allele frequency.193 The effect size and standard error of this 
variant was therefore scaled to match that of the variants from the Jiang et al. study. This was 
achieved by taking the four variants that were reported in both GWAS, matching their effect alleles 
and regressing the effect sizes from Jiang et al. on the effect sizes from Chapter 5 (Figure 6-1). The 
resultant linear equation was used to scale the effect of the low frequency CYP2R1 variant. 
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Figure 6-1: Plot of effect size estimates of genetic variants included in both Jiang et al. and 
Chapter 5. 
 
The effect estimates for the variants included in both Jiang et al. and Chapter 5 (rs3755967, rs10741657, 
rs12785878, rs172167070) are plotted against each other (•). The linear equation (y = 0.3662*Beta - 0.0012) 
was used to scale the effect estimate of the low frequency variant rs117913124 (•) in the Chapter 5 GWAS 
that was not reported in the Jiang et al. GWAS. 
!"#$%&'()	+,-.&/0-. = 0.3662	 ∙ 	!"#$8	 − 0.0012 
!"#$%&'()	+,-.&/0-. = 0.3662	 ∙ 	−0.4323 − 0.0012 
!"#$%&'()	+,-.&/0-. = −0.160  
The details of the seven genetic variants included in the GRS are shown in Table 6-1. The GRS was 
weighted by the effect size of the variants from the largest available GWAS (Jiang et al.) as this 
provides the most precise estimates. The weighting takes into account the variant’s relative effect 
size and direction. The GRS is in log 25(OH)D units in nmol/L and is coded such that an increase in 
GRS corresponds to an increase in 25(OH)D. 
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Table 6-1: Effect estimates from GWAS for the genetic variants included in the genetic proxy 
Gene RSID chr:pos Eff/Alt EAF Beta SE P 
GC rs3755967 4:72828262 T/C 0.28 -0.089 0.0023 4.74E–343 
NADSYN1/ DHCR7 rs12785878 11:70845097 T/G 0.75 0.036 0.0022 3.80E–62 































Chapter 5 scale (Standardized log 25-hydroxyvitamin D)
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CYP24A1 rs17216707 20:52165769 T/C 0.79 0.026 0.0027 8.14E–23 
AMDHD1 rs10745742 12:94882660 T/C 0.40 0.017 0.0022 1.88E–14 
SEC23A rs8018720 14:38625936 C/G 0.82 -0.017 0.0029 4.72E–09 
CYP2R1 rs117913124 11:14900931 A/G 0.025 -0.160 0.00645 1.50E–88 
 
6.3.4 Outcome measures 
The data included in these analyses (dataset 29244 in UK Biobank application 16729) includes 3,414 
fields of the following types: integer, continuous, categorical (single) and categorical (multiple). 
These fields contain a wide range of phenotypes including phenotypes derived from health and 
lifestyle questionnaires, clinical assessments, blood and saliva assays (including serum 25(OH)D) and 
linkage to cancer and death registries and hospital episodes. 
The following fields were removed: assessment centre; two fields described by UK Biobank as 
‘polymorphic’, containing values with mixed data types; 26 genetic descriptor fields; one sex field; 
five age fields; 18 fields describing the assessment centre environment, 185 data processing 
indicators, and 21 categorical (single) fields with more than one value recorded per person. This 
resulted in 3,153 fields (591 integer, 1,475 continuous, 934 categorical (single) and 153 categorical 
(multiple)) which form the outcome dataset. 
6.3.5 Covariates 
When assessing the strength of the genetic proxy age, sex and the first 40 genetic principal 
components were included in the model to remove variability in 25(OH)D due to age and sex, and to 
account for potential population stratification. 
For the observational analysis using serum 25(OH)D, age at attendance of UK Biobank assessment 
centre and sex were included as covariates. In the MR analysis using the GRS, age, sex and the first 
40 genetic principal components were included in the model.  
6.3.6 Statistical analysis 
The relevance assumption was assessed by investigating the association between the GRS and 
seasonally adjusted 25(OH)D using linear regression to confirm the strength of the GRS. The effect of 
individual SNPs was also assessed against the seasonally adjusted 25(OH)D measure. 
The PHESANT software (version 0.18), which uses an automated rule based method to assign a 
variable type and hence an analysis method, has been described in detail elsewhere.195 Briefly, 
continuous or integer fields are usually assigned to the continuous type variable, unless there are 
only a few distinct values, in which case they will be assigned as an ordered categorical variable. 
Fields of the categorical (single) type, in which each participant has only a single record, are assigned 
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to either binary, unordered categorical or ordered categorical depending on the type of data the 
field refers to. Fields of the categorical (multiple) type, in which each participant can have multiple 
records, are converted to a series of binary variables – one for each record. For example, a 
participant may be asked whether they ate any of “white bread”, “wholemeal bread” and “other 
bread products” the previous day. As a participant could have conceivably eaten all three, each 
bread type is converted to a binary variable denoting whether each participant had or had not eaten 
that bread type the previous day. In this (hypothetical) example, a single field would result in three 
binary variables, one for each bread type. This rule-based system attempts to provide the best 
available representation of all the phenotypes in UK Biobank. 
The association of the seasonally adjusted 25(OH)D measure and the GRS was tested against all 
outcomes in the outcome dataset to demonstrate the difference in their associations with potential 
confounders. PHESANT estimates the association of the exposure (either the vitamin D GRS or the 
seasonally adjusted 25(OH)D measure) with each outcome variable in the outcome dataset. 
Outcome variables with continuous, binary, unordered categorical and ordered categorical data 
types are analysed using linear, logistic, ordered logistic and multinomial logistic regression 
respectively. To ensure normality of continuous variables each one is inverse normal rank 
transformed prior to running the regression model. Covariates are included in the model as 
described above. 
The strength of evidence for associations was assessed, accounting for the number of statistical tests 
performed using the Bonferroni corrected p-value threshold. This was calculated by dividing 0.05 by 
the number of tests performed.  
To estimate the power in each of the MR PheWAS statistical tests at the Bonferroni corrected P-
value threshold, post-hoc power calculations were conducted based on the size of the observational 
estimate using the methods described by Brion et al. (2013).196 Each calculation took into account 
the variance in 25(OH)D explained by the GRS, the sample size for the specific phenotype and the 
observational effect size. In these power calculations, for phenotypes analysed using linear or 
ordinal regression an estimate of the variance in the exposure and the outcome was taken into 
account, for phenotypes calculated using logistic regression the proportion of cases in the sample 
was taken into account. 
6.3.6.1 Positive and negative control look-ups 
For the MR PheWAS, positive and negative controls were looked up in the results. In these look-ups, 
phenotypes were selected that have been shown to be and not be associated with vitamin D in 
completely independent samples. The PheWAS results are then assessed to see they support these a 
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priori hypotheses. Multiple sclerosis was chosen as a positive control due to the strong evidence for 
a protective effect of 25(OH)D from previous MR studies.197,198 Body mass index was selected as a 
negative control, again due to previous high quality MR studies suggesting there is no evidence of an 
effect of 25(OH)D on body mass index.105 
6.4 Results 
6.4.1 Assessing the GRS 
The GRS was very strongly associated with the seasonally adjusted 25(OH)D measure, with a one 
unit increase in the GRS corresponding to a 24.9 nmol/L (95% CI: 24.3, 25.5) increase in 25(OH)D. 
This supports the genetic proxy does not violate the relevance assumption. The overall distribution 
of seasonally adjusted 25(OH)D with GRS is shown in Figure 6-2, the 25(OH)D level was strongly 
affected by the number of rs117913124 alleles due to the large effects of this variant. The GRS 
explained approximately 3.2% of the variance in seasonally adjusted 25(OH)D. The effect of each 
SNP on seasonally adjusted 25(OH)D was assessed (Table 6-2). All SNPs had effects in the same 
direction and of similar magnitude to those in the most recent 25(OH)D GWAS. 
Figure 6-2: Distribution of seasonally adjusted 25(OH)D with genetic risk score. 
 
Each dot represents an individual with their GRS plotted against their seasonally adjusted 25(OH)D level.  
Dot colour is determined by the number of rs117913124 alleles the individual carries. The groupings reflect 
the large effect size of the rs117913124 variant resulting in it having a large weighting in the GRS. The 
variation in number of dots in each grouping reflects that the variant is rare and so only few participants 
have both vitamin D lowering alleles. 
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Table 6-2: Effect of SNPs on seasonally adjusted 25(OH)D in UK Biobank and Jiang et al. 
(2018). 
  UK Biobank  Jiang et al. 
RSID Eff/Alt EAF Beta SE P  Beta SE 
rs3755967 T/C 0.29 -0.084 0.0012 < 2e-16  -0.089 0.0023 
rs12785878 T/G 0.76 0.051 0.0013 < 2e-16  0.036 0.0022 
rs10741657 A/G 0.40 0.038 0.0011 < 2e-16  0.031 0.0022 
rs17216707 T/C 0.81 0.017 0.0014 < 2e-16  0.026 0.0027 
rs10745742 T/C 0.38 0.013 0.0011 < 2e-16  0.017 0.0022 
rs8018720 C/G 0.82 -0.017 0.0014 < 2e-16  -0.017 0.0029 
rs117913124 A/G 0.027 -0.172 0.0033 < 2e-16  -0.160 0.0065 
 
6.4.2 Phenome scan analysis 
The PHESANT data processing pipeline resulted in 35,109 phenotypes for testing in the observational 
and GRS analyses. A flow diagram detailing how the different data field types were analysed by 
PHESANT is given in Figure 6-3. The Bonferroni corrected p-value threshold accounting for the 
number of statistical tests was 1.42x10-06 (0.05/35,109).
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Figure 6-3: Flow diagram showing details of PHESANT analysis algorithm for both the seasonally adjusted 25(OH)D and exposures. 
 
The flow diagram reflects the decision tree of PHESANT to allocate the four different variable field types, indicated by red triangles (Continuous, Integer, Categorical 
(single), Catigorical (multiple)) to the four different regression approaches (linear regresion, ordinal regression, multinomial logistic regression, logistic regression). The 
first part of the decision tree checks the field type, converts the field to a processable data type and allocates a regression method. The second part of the decision tree 
conducts quality checks on the variable. Red rectangles indicate numbers of phenotypes at each stage of the decision tree. Blue rectangles indicate steps. Grey 
rectangles indicate why phenotypes have been removed from analyses. As an example, take one of the 591 integer variable such as pulse rate (in beats per minute). 
The algorithm checks the number of distinct values (>= 20 for pulse rate) and whether more than 20% of participants have the same value (not true for pulse rate). This 
variable is then considered a continuous variable for the purposes of analyses. The variable is dropped if less than 500 participants have a value (not true for pulse 
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In the observational analyses 3,538 phenotypes passed the Bonferroni corrected p-value threshold. 
Figure 6-4 gives an overview of the results of the observational phenome scan and the top 50 results 
are provided in Appendix 6.1. 
Figure 6-4: Overall graphical view of observational PheWAS results. 
 
This plot gives an overall representation of the effect size and strength of evidence for all results in the 
observational phenome scan. It demonstrates that there are many phenotypes from all regression analyses 
that pass the multiple testing threshold for an association with serum 25(OH)D. Each dot represents a result 
from the PHESANT analysis with the colour corresponding to the type of statistical test used (see legend). 
The y-axis indicates the effect size of 25(OH)D on the phenotype. The x-axis indicates the strength of 
association with stronger evidence towards the right side of the plot. Multinomial-logistic results do not 
have effect sizes, only P values, so are plotted on the x-axis to allow the strength of evidence for the 
association to be visualised. The red line indicates the Bonferroni corrected threshold (P = 0.05/35,109 = 
1.42x10-6). 
In the MR PheWAS analyses, there was greater than 80% power to detect the observational effect in 
58 phenotypes at the Bonferroni corrected P-value threshold using the effect estimates from the 
observational analyses. However, in the MR PheWAS analyses, only two variables passed the 
Bonferroni threshold.  An overview of the results of the MR PheWAS including an indication of the 
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power for each analysis are given in Figure 6-5. The strongest effect of the GRS was seen for the 
serum 25(OH)D measure (PHESANT standardised beta: 0.133 (95% CI: 0.130, 0.137) P< 5x10-324, 
n=306,985). The only other variable to pass the multiple testing threshold was ‘21072’ (UK Biobank 
description: ‘Infection diagnosed alongside IBS [irritable bowel syndrome] when IBS symptoms 
began’ (P =4.78x10-10, n=769). 
Figure 6-5: Overall graphical view of MR PheWAS results. 
 
This plot gives an overall representation of the effect size and strength of evidence for all results in the MR 
PheWAS analyses. It demonstrates that there are very few phenotypes that pass the multiple testing 
threshold for an association with serum 25(OH)D. Although power is limited, even wehere there is sufficient 
power to detect effects, there is limited evidence for causal associations. Each dot represents a result from 
the PHESANT analysis with the colour corresponding to the power to detect the observational estimate 
magnitude, as detected in the observational analyses. The y-axis indicates the effect size of 25(OH)D on the 
phenotype. The x-axis indicates the strength of association with stronger evidence towards the right side of 
the plot. Multinomial-logistic results do not have effect sizes, only P values, so are plotted on the x-axis to 
allow the strength of evidence for the association to be visualised. The red line indicates the Bonferroni 
corrected threshold P = (0.05/35,109 = 1.42x10-6). Phenotypes which pass this threshold are labelled with 
their UK Biobank phenotype description. 
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6.4.2.1 Comparison of estimates of major HNC risk factors between observational and MR 
PheWAS results. 
In the observational PheWAS, consistent with what was expected, there was very strong evidence 
for a lowering effect of 25(OH)D on smoking and alcohol consumption (OR = 0.74  (95% CI: 0.74, 
0.75),  P< 5x10-324; OR = 0.86  (95% CI: 0.85, 0.86),  P< 5x10-324 respectively) however in the MR 
PheWAS the estimates were on the null effect (OR = 1.00  (95% CI: 0.99, 1.01), P=0.62; OR = 1.00  
(95% CI: 0.99, 1.00), P=0.42). There was good power to identify an association with smoking (power 
= 0.93) but less so with alcohol (power = 0.44). 
6.4.2.2 Follow-up of potentially novel causal associations with 25(OH)D 
The only variable identified, in the MR PheWAS, as having a potential causal association with 
25(OH)D, other than serum 25(OH)D, was a questionnaire item asking which type of ‘Infection [was] 
diagnosed alongside IBS when IBS symptoms began’ (field ID 21072). This was one of a series of UK 
Biobank questions around digestive health and this specific question was only asked to participants 
who reported having a diagnosis of IBS and also reported having an infection at the time of that 
diagnosis. The hypothesis that is being tested for this phenotype is does vitamin D cause an 
individual to get one infection over another infection alongside IBS. The analysis result for this 
phenotype came from a multinomial logistic regression analysis in PHESANT and therefore does not 
provide an overall effect estimate. 
To inspect this further, the ‘21072’ field was extracted from the dataset and analyses repeated 
manually. When analysing the results of the multinomial logistic regression, the beta for the shigella 
Infection category is greater than 2000 times the magnitude of the other categories. Of the 769 
participants who reporting having an infection at the onset of IBS symptoms, only 12 had a shigella 
infection. Removing those 12 participants from the analyses removes the strong statistical evidence 
for effect (P-value for model after removing participants with Shigella = 0.71, P-value for model 
including participants with Shigella = 4.8 x10-10-). 
Logistic regression analysis was conducted converting the shigella infection phenotype to a binary 
variable including only those that answered the question (coded 1 = shigella infection, n=12, 0 = 
answered the question but no shigella infection, n=757). This analysis confirmed the false positive 
association with the GRS with the results showing an unrealistic effect size and very wide confidence 
intervals (OR=27.3 (95% CI: 0.0, 35738.2), P=0.88). When this logistic regression analysis was 
repeated for each genetic variant in the GRS individually, the effect was driven entirely by the 
rs117913124 variant which had a very large but very imprecisely estimated effect on the binary 
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shigella variable (Figure 6-6). This extreme effect size is caused by all 12 shigella infection 
participants have the same number of risk alleles of the rs117913124 variant. 
Figure 6-6: Effect of individual variants in the GRS on having a shigella infection at the time 
of IBS diagnosis. 
 
When the individual genetic variant effects were meta-analysed the rs117913124 had a negligible 
effect on the pooled estimate due to its large standard error. The pooled effect therefore represents 
the effect estimate for the binary shigella variable when the rs117913124 variant has been removed 
(Figure 6-6).  
6.4.2.3 Positive and negative control look-ups 
The point estimate effect of the MR analysis on multiple sclerosis showed a protective effect of 
increased 25(OH)D in line with results from previous MR experiments (OR=0.66 (95% CI: 0.38, 1.15)). 
The analysis however was underpowered and confidence intervals crossed the null. The 
corresponding observational estimate showed strong evidence for a larger protective effect of 
vitamin D (OR=0.57 (95% CI: 0.49, 0.66)). 
In the MR PheWAS, there was little evidence of an effect of 25(OH)D on body mass index which is in 
line with previous MR experiments (PHESANT standardised beta: -0.000 (95% CI: -0.004, 0.003)). This 
is in strong contrast to the observational analysis which showed very strong evidence for an inverse 
association between 25(OH)D and BMI (PHESANT standardised beta: -0.169 (95% CI: -0.173, -0.166)). 
6.5 Discussion 
The observational phenome scan identified over 3,500 phenotypes that were strongly associated 
with 25(OH)D after correcting for multiple testing. This was in contrast to there being no suggestive 
causal associations identified in the MR PheWAS analysis after discounting 25(OH)D itself and the 
false positive IBS infection variable. There was however a very strong association between the 
genetic proxy and 25(OH)D which provides further evidence that the proxy is robust and the 
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In general, the observational results demonstrate the highly confounded nature of vitamin D with an 
increase in its level being strongly associated with positive heath phenotypes such as lower BMI, less 
smoking and alcohol consumption as well many others. This is important as it may explain how 
confounding could explain observational associations between vitamin D and HNC, even after 
correcting for the most obvious confounders. For example, analyses looking at the risk of HNC have 
not routinely corrected for BMI but it is likely that this may confound the vitamin D-HNC risk 
association. 
One aim of this chapter was to assess whether the vitamin D GRS, a combination of vitamin D 
genetic variants, was more robust to confounding that the serum 25(OH)D measure. When the 
results of the observational and MR PheWAS are compared it demonstrates the GRS is related to 
very few phenotypes, other than 25(OH)D itself. However, it must be considered that there was not 
power to detect effects for the majority of variables. Where power was high to detect effects in the 
MR PheWAS analyses, there were some clear demonstrations that the GRS is not related to potential 
confounders which would be strongly associated with the serum vitamin D measure. For example 
power was high to detect effects on sunbed use (PHESANT standardised beta: 0.00; 95% CI: -0.02, 
0.02; P=1.0, power = 1) and vitamin D supplementation (PHESANT standardised beta: -0.01; 95% CI: -
0.03, 0.00; P=0.2, power = 1) but the MR PheWAS estimates were very close to the null. This is 
important as these variables, although clearly important in serum vitamin D levels, are likely to be 
correlated with other behaviours which cause HNC and would therefore bias observational 
associations but, as they are not related to the GRS, will not bias MR estimates. 
It is worth considering whether the stark difference between the MR PheWAS results and the 
observational phenome scan results are a result of chance. It could be that if repeated the 
observational and MR PheWAS associations would be much more similar, either with more 
associations identified in the MR PheWAS, less in the observational analyses or both. However, given 
the expectation that the GRS would be associated with less variables than the serum 25(OH)D 
measure matching the actual results, it is unlikely that this finding was only by chance. One way to 
confirm this would be to run a simulation study but that is beyond the scope of this thesis. 
The results of this study can be used to look up whether the genetic proxy is independent of the 
known confounders in the vitamin D HNC association. For both smoking status and alcohol 
consumption frequency, there was strong evidence of serum 25(OH)D having observational 
associations with smoking and drinking. However, in the MR PheWAS results the causal effect 
estimates for these phenotypes were precisely estimated around the null (OR = 1). Therefore, in MR 
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analyses that assess the causal effect of vitamin D on HNC, the estimate will be minimally affected 
by any confounding by these two major HNC risk factors. 
MR PheWAS has several limitations which must be considered when interpreting these results. 
Firstly, despite the PHESANT algorithm (depicted in Figure 6-3) including steps to quality control 
each variable under investigation, it cannot be as rigorous as would be expected if conducting a 
study into a single association. This can lead to problems, such as statistical assumptions being 
violated, which may lead to false positives. One example of this is the finding in this chapter relating 
to the type of infection coincident with an IBS diagnosis, where too few individuals in a strata of the 
variable led to a strong false positive association. This demonstrates the importance of following up 
any PheWAS result with complementary analyses to assess its validity. Secondly, there are a large 
number of variables which are likely to suffer different types of error. For example, self-reported 
data may be biased by recall whereas cancer registry data will not. Li et al.199 show that, in a PheWAS 
of uric acid genetic variants, the effect size on gout depends on the source of the information. 
However, in their study, the uric acid genetic variants showed strong evidence for an association 
with both data sources (self-reported gout and hospital diagnosed gout). Finally, the main limitation 
of PheWAS is the large multiple testing burden – particularly when investigating such a large number 
of phenotypes as in this study. In this work the large number of statistical tests combined with a GRS 
which does not explain a large amount of variance in vitamin D meant there was limited power to 
detect effects for the majority of the variables assessed. However, power for the observational 
analyses were high and comparing the MR PheWAS and observational results can be informative 
when assessing whether a variable should be followed up with subsequent studies. In this study, the 
Bonferroni multiple testing threshold was used to provide an indication of where the null value 
might lie, this is likely to be over-stringent. The limited power in this study precludes the possibility 
of ruling out horizontal pleiotropy as even if the GRS has pleiotropic effects, these are likely to be 
small and therefore not pass the multiple testing burden.   
6.5.1 Conclusions 
In summary, this chapter demonstrates the highly confounded nature of serum vitamin D measures 
and highlights that in observational studies of vitamin D on HNC, there is likely to be substantial 
residual confounding by factors that may not traditionally be measured as potential confounders. 
This chapter also shows that the vitamin D GRS is largely unconfounded and therefore lends itself to 
be used in MR analyses assessing the effect of vitamin D on HNC risk and prognosis. 
The next chapter 
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In this chapter I have demonstrated that the vitamin D genetic variants identified in Chapter 5 are a 
strong proxy of vitamin D and are largely unconfounded. In the following two chapters, I apply MR to 
assess the causal association of vitamin D on HNC risk and prognosis, using the GRS tested in this 
chapter.  
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Chapter 7 :  Assessing the causal association 
between vitamin D and HNC 
7.1 Chapter objectives 
In Chapter 4 the observational association between 25(OH)D and HNC incidence was investigated 
and strong protective associations were identified however these estimates are likely biased by 
confounding. In this chapter, an MR analysis is conducted using the genetic proxy identified and 
tested in the previous chapter. The aim of this chapter is to estimate the causal association between 
vitamin D and HNC incidence using MR. 
7.2 Introduction 
An increase in 25(OH)D was associated with a large reduction in the odds of oral cavity cancer (OR 
per doubling of 25(OH)D = 0.71 (95% CI: 0.57, 0.88)) and a moderate reduction in odds of 
oropharyngeal cancer (OR per doubling of 25(OH)D = 0.80 (95% CI: 0.65, 0.98)), even after correction 
for measured confounders. These estimates were similar in magnitude to those in a previous 
prospective observational study conducted in EPIC126 and together they represent the best estimate 
of the effect of 25(OH)D on HNC risk to date. 
As detailed previously, observational estimates are often biased by residual confounding even after 
careful correction for measured confounders using multivariable regression or stratification. 
Residual confounding and reverse causality often bias away from the null meaning effects estimates 
from observational studies are larger than the true causal effect. Furthermore, reverse causality can 
also be an issue as the development of cancer is a slow process and even undiagnosed cancers may 
affect an individual’s exposure to factors such as vitamin D.  
The study described in Chapter 4, and the previous study by Fanidi et al.126, are case-cohort in design 
and are therefore likely to be affected by the biases mentioned above, residual confounding and 
reverse causality. Bias by confounding may not have been fully accounted for in Chapter 4 during 
multivariable regression analyses because of unmeasured confounding factors or due to error in the 
measurement of the confounders accounted for. One example of this is confounding by smoking 
status which, is often recorded at the time of diagnosis and is commonly recorded as current 
smoker, ex-smoker or never smoker. It is unlikely that these broad categories fully capture the 
influence of smoking, as they do not take into account smoking intensity, duration or type of 
smoking or variability in any of these aspects. As a result of this confounder measurement error, the 
effect estimate of 25(OH)D on HNC may still be biased by smoking even after correcting for it. 
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Reverse causality may have also contributed to biased estimates in the observational studies, 
although this is less likely as 25(OH)D measures were taken prior to any HNC diagnosis and 
sensitivity analyses including only those with 25(OH)D measures five years prior to diagnosis show 
similar results. 
As previously described in Chapter 3, MR reduces the impact of bias by confounding due to the 
randomised allocation of genetic alleles at gamete formation and segregation. This randomisation 
event results in confounders being approximately equal across exposure groups irrespective of 
whether they are perfectly measured, measured with error or unmeasured. Reverse causality is also 
not an issue in MR as the development of a HNC cannot alter germline genetics. 
In this chapter, MR is utilised to provide an estimate of the effect of 25(OH)D on HNC risk which is 
minimally affected by confounding bias or reverse causality. 
7.3 Methods 
7.3.1 Overview 
Genetic variants which proxy 25(OH)D levels were utilised in this chapter to conduct an MR study 
assessing the causal effect of 25(OH)D on oral and oropharyngeal cancer risk (laryngeal cancers were 
not available in the included studies and so were not investigated). As serum 25(OH)D, genetic and 
HNC outcome measures were not available in a large enough sample, a two-sample MR approach 
was adopted and modified to make the best of individual level HNC outcome data. 
The genetic variants identified in the 25(OH)D GWAS in Chapter 5 were used as 25(OH)D proxies. 
The genotypes of these variants were identified in individuals of two studies with HNC cases and 
controls (GAME-ON and UK Biobank) and combined to make a relative 25(OH)D measure. To assess 
the assumption that this relative 25(OH)D measure was unconfounded, associations between the 
relative measure and available confounders was assessed in each of the studies. 
The relative 25(OH)D measure was then included in regression analyses to provide an estimate of 
the causal effect of 25(OH)D on HNC risk. Finally, a bootstrap approach was used to adjust the 
standard errors of these effect estimates so that they took into account the imprecision of the 
genetic variant effects on 25(OH)D. Failure to conduct this last step could lead to false positive 
findings. 
7.3.2 Proxy variant selection  
Common genetic variants strongly related to serum 25(OH)D levels have been identified in 
GWAS98,178,193 including the work described in Chapter 5. For this MR study, genetic variants that 
passed a genome wide association threshold in these GWAS studies (p<5x10-8) were selected. Five of 
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these genetic proxies, including the low-frequency variant identified in Chapter 5, were located in or 
near 25(OH)D related genes: Group-Specific Component (GC), Cytochrome P450 family 2, subfamily 
R, polypeptide 1 (CYP2R1), 7-Dehydrocholesterol Reductase (DHCR7) and Cytochrome P450, family 
24, polypeptide 1 (CYP24A1). The two common variants near HAL (rs3819817) and GEMIN2 
(rs2277458) identified in Chapter 5 were also included as strong proxies of 25(OH)D. 
To provide the most precise estimate of the causal association of 25(OH)D on HNC, effect estimates 
for SNP associations with serum 25(OH)D concentrations were taken from the largest 25(OH)D 
GWAS available (Jiang et al. (2018), published shortly after the study in Chapter 5). Where the 
variants identified in Chapter 5 were not available in the Jiang et al. summary results, the effect size 
from Chapter 5 was scaled to match the Jiang et al. paper, as in the pheWAS study reported in 
Chapter 6. 
To be valid proxies of 25(OH)D in MR analyses, the genetic variants must be independent of each 
other. To assess independence, variants on the same chromosome were assessed for linkage 
disequilibrium (LD) using SNAP (http://archive.broadinstitute.org/mpg/snap/ldsearchpw.php) in 
Europeans from the 1000 Genomes (Pilot 1) project. 
In total, seven variants were identified for the 25(OH)D proxy from GWAS (Table 7-1). rs4588 in GC, 
rs10741657 in CYP2R1 and rs6013897 in CYP24A1 have been used as genetic proxies for 25(OH)D in 
MR studies before. rs4423214 near DHCR7 is in perfect LD with rs12785878, identified in the original 
SUNLIGHT consortium 25(OH)D GWAS.178 Finally, rs116970203 near CYP2R1, rs3819817 near HAL 
and rs2277458 near GEMIN2 were identified in Chapter 5 with the latter two (or variants highly 
correlated with them) being replicated in the Jiang et al. GWAS. 
For each individual the seven 25(OH)D variants were combined into a genetic risk score weighted by 
the beta coefficients derived from GWAS. To ease clinical interpretation and to allow easy 
comparison with observational estimates, this score was converted from a per allele scale to a log2 
25(OH)D scale. Therefore, each unit increase in this variable (hereafter referred to as relative 
25(OH)D) represented a doubling of 25(OH)D.
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Table 7-1: 25-Hydroxyvitamin D genetic variant details 
            Vitamin D GWAS   GAME ON  UK Biobank 
RSID Chrom
osome 











EAF  Info 
(snptest) 
EAF 
rs4588 4 72618323 GC G T 0.717 0.089 0.0023 1.68E-263 
 
Genotyped 0.722  Genotyped 0.712 
rs116970203 11 14876718 PDE3B G A 0.975 0.157 0.0064 2.29E-90 
 
0.98 0.978  0.99 0.973 
rs4423214 11 71173254 DHCR7 T C 0.697 0.036 0.0023 1.39E-40 
 
0.99 0.718  1.00 0.761 
rs10741657 11 14914878 CYP2R1 A G 0.415 0.031 0.0022 8.76E-45 
 
Genotyped 0.383  Genotyped 0.398 
rs3819817 12 96378771 HAL C T 0.451 0.014 0.0024 1.88E-14  1.00 0.539  0.997 0.422 
rs2277458 14 39583481 GEMIN2 A G 0.214 0.017 0.0031 4.72E-09  Genotyped 0.825  0.998 0.824 
rs6013897 20 52742479 CYP24A1 T A 0.791 0.021 0.0024 9.06E-16   0.74 0.781   1.00 0.805 
EAF = effect allele frequency, Rsq = R squared, SE = standard error 
 




An overall description of the GAME-ON study including the genetic data are provided in Chapter 3. 
For this study cancer cases of interest comprised the following ICD codes: oral cavity (C02.0–C02.9, 
C03.0–C03.9, C04.0–C04.9, C05.0–C06.9) and oropharynx (C01.9, C02.4, C09.0–C10.9). DNA 
extraction, genotyping, quality control and imputation has been described previously.22 The study 
population included participants from Europe, North America and South America. To reduce the 
effect of heterogeneity across these regions only participants with >70% CEU ancestry were included 
in analyses (n=11,117). 
7.3.3.2 UK Biobank 
An overall description of the UK Biobank study including the genetic data are provided in Chapter 3. 
Age on 31 December 2010 (coinciding with the approximate end of baseline data collection) was 
used as the age variable and not age at cancer diagnosis. Prevalent and incident oral and 
oropharyngeal cancers (ICD10 codes matched to GAME-ON) were identified from linked cancer 
registry data. To reduce selection bias in allocating controls, all remaining participants, after 
removing those participants with other HNC, were used as controls. A full description of the UK 
Biobank study design, participants and quality control (QC) methods have been described in detail 
previously.154 UK Biobank received ethical approval from the Research Ethics Committee (REC 
reference for UK Biobank is 11/NW/0382). 161 In UK Biobank analyses were restricted to individuals 
of white British ancestry who self-report as “White British” and who have very similar ancestral 
backgrounds according to the principal component analysis, as described by Bycroft.160 The full data 
release contains the cohort of successfully genotyped samples (n=488,377). 
7.3.4 DNA extraction genotyping and imputation 
DNA extraction, genotyping, imputation and the generation of genetic principal components for 
GAME-ON and UK Biobank is described in Chapter 3. 
7.3.5 Assessment of potential confounders 
One of the principals of MR is that as alleles are assigned randomly during gamete formation and 
segregation. The genetic proxy is therefore not associated with factors that typically confound the 
association in observational analyses. To test this assumption, associations between relative 
25(OH)D and measured potential confounders were investigated. Sex, smoking status (never, ever, 
current) and alcohol use (never, ever) were recorded by questionnaire in both cohorts. In GAME-ON 
only, sub-study and study country were also considered potential confounders. The associations of 
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relative  25(OH)D with strata of these potential confounders was examined in boxplots of range and 
means +/- one standard deviation. Tests of associations were made using linear regression with 
categorical variables as factor variables, the overall P-value for the model was shown on the 
boxplots. Where evidence of an association exists, there was the potential that the relative 25(OH)D 
measure is associated with confounders, violating the independence assumption of MR. 
7.3.6 Statistical analysis 
The relative 25(OH)D measure was used in logistic regression models to estimate a causal OR for a 
unit increase in log2 25(OH)D. To correct for within region population structure, region specific 
principal components were added to the logistic regression models. 
The standard error of this estimate was corrected to account for the imprecision of the effect of the 
genetic variant on 25(OH)D using a bootstrap approach in the ‘boot’ package in R.200 Five hundred 
imputed relative 25(OH)D values were generated from a sampling distribution based on the beta 
coefficient and standard error from the 25(OH)D GWAS study. This set of newly imputed relative 
25(OH)D values were used in logistic regression models, with cancer case status as the outcome, to 
generate a distribution of causal estimates. The standard deviation of this distribution was added to 
the standard error of the original causal OR to give a corrected standard error. 
1. STAGE 1: Create estimate of vitamin D (referred to as relative vitamin D) in each participant 
using Beta from GWAS and dosage of variant 
!"…$ = &'()	+,-.	/012	+-,	3),4)5("…$ 
67 = 	8-9):'	+-,	3),4)5("…$	45	45;434;<)= 
>?7 = '9(4.)('	-+	<54(	@ℎ)5:'	45 log225(HI)8 	<945:	3),4)5("…$ 
>?7 = 	!"6"7 + ⋯+ !$6$7  
 
2. STAGE 2: Estimate causal odds ratio of relative vitamin D on OC/OPC risk as the coefficient 
of the below logistic regression 
M7 = M,-N)N4=4(O	-+	IPQ	45	4;434;<)= 
=-:4((M7) = 	RS + T>?7  
3. CORRECTED STANDARD ERRORS: The SE from stage 2 does not consider the error in a1…j, a 
bootstrap method was used to generate corrected SE for the second stage regression. 
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7.3.6.1 GAME-ON 
MR analyses were performed within each geographic region of the GAME-ON consortium 
accounting for age, sex and the first 15 population specific principal components. As there were 
likely to be differences between the causal estimates across regions, a random-effects meta-analysis 
was used to combine GAME-ON causal estimates using the R package ‘meta’.201 Heterogeneity 
between study populations was assessed using I2.202 Meta analyses were repeated excluding 
geographical regions that were outliers to assess for their influence on the overall estimate. 
7.3.6.2 Replication in UK Biobank and meta-analysis 
MR analyses were repeated in UK Biobank. GAME-ON and UK Biobank estimates were compared 
and then combined using meta-analysis. This employed a random-effects model and was conducted 
using the ‘meta’ package in R.201 Heterogeneity between studies was assessed using I2.202 
7.3.6.3 Stratification by smoking status 
In the observational analyses in Chapter 4, the effect of 25(OH)D on HNC risk differed depending on 
whether the participants smoked or not, with the effect only seen in current or former smokers. To 
assess whether the heterogeneity in effect size across smoking strata reflects true heterogeneity in 
the causal effect, MR analyses were repeated within each smoking strata in the GAME-ON study. 
7.3.6.4 Sensitivity analyses 
In order to assess whether any single genetic variant was driving a causal estimate, which could be 
driven by events such as horizontal pleiotropy which invalidate the exclusion restriction MR 
assumptions, a leave-one out method was applied. In this approach, the analysis is sequentially 
repeated, each time removing one variant from the genetic proxy used to derive relative 25(OH)D. 
To demonstrate this further, where a variant overtly influenced an association, each possible genetic 
proxy from combinations of the seven 25(OH)D variants, was used to estimate relative 25(OH)D and 
thereafter a causal OR. These OR were plotted as histograms highlighting those that include the 
highly influential variant to see if there was an obvious grouping of these estimates. 
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A UK Biobank nested focus study (UKBiLEVE),203 investigating lung disease, preferentially selected 
and genotyped heavy and non-smokers using a different array to the remainder of the participants. 
49,979 individuals were genotyped using the UKBiLEVE array and 438,398 using the UK Biobank 
axiom array. UK Biobank analyses were repeated removing UKBiLEVE participants. 
7.4 Results 
7.4.1 Study participants 
In the GAME-ON study, after removing participants with <70% CEU ancestry, there were 5,133 cases 
(oral n=2,700, oropharyngeal n=2,433) and 5,984 controls). Participants from Europe and North 
America represented approximately 90% of cases and controls. In UK Biobank, after removing 
related and non-White British participants, there were 337,108 eligible participants, consisting of 
585 cases (oral n=294, oropharyngeal n=291) and 336,523 controls. In GAME-ON the cases and 
controls were well matched for age whereas in UK Biobank, the cases were on average older than 
the controls. In both GAME-ON and UK Biobank there were more males and current smokers in the 
cases than there were in the controls (Table 7-2). 
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Table 7-2: GAME-ON and UK Biobank participant summaries 
 GAME-ON  UK Biobank  
All n (%) Case n (%) Control n (%)  All n (%) Case n (%) Control n (%) 
  N=11117 N=5133 N=5984  N=337108 N=585 N=336523 
Site 
   
    




  294 (50.3)  




  291 (49.7)  
Age 
   
    
    =<50 2217 (19.9%) 1071 (20.9%) 1146 (19.2%)  65349 (19.4%) 51 (8.72%) 65298 (19.4%) 
    50-<60 3443 (31.0%) 1696 (33.0%) 1747 (29.2%)  94102 (27.9%) 180 (30.8%) 93922 (27.9%) 
    60-<70 3348 (30.1%) 1504 (29.3%) 1844 (30.8%)  153829 (45.6%) 298 (50.9%) 153531 (45.6%) 
    >=70 2108 (19.0%) 861 (16.8%) 1247 (20.8%)  23828 (7.07%) 56 (9.57%) 23772 (7.06%) 
    Missing 1 (0.01%) 1 (0.02%) 0 (0.00%)     
Sex 
   
    
    Male 7680 (69.1%) 3798 (74.0%) 3882 (64.9%)  155747 (46.2%) 387 (66.2%) 155360 (46.2%) 
    Female 3437 (30.9%) 1335 (26.0%) 2102 (35.1%)  181361 (53.8%) 198 (33.8%) 181163 (53.8%) 
Smoking status 
   
    
    Never 3302 (29.7%) 1002 (19.5%) 2300 (38.4%)  184081 (54.6%) 208 (35.6%) 183873 (54.6%) 
    Previous 3655 (32.9%) 1590 (31.0%) 2065 (34.5%)  118478 (35.1%) 267 (45.6%) 118211 (35.1%) 
    Current 3300 (29.7%) 2019 (39.3%) 1281 (21.4%)  33364 (9.90%) 107 (18.3%) 33257 (9.88%) 
    Missing 860 (7.74%) 522 (10.2%) 338 (5.65%)  1185 (0.35%) 3 (0.51%) 1182 (0.35%) 
Alcohol use 
   
    
    Never 1825 (16.4%) 767 (14.9%) 1058 (17.7%)  10406 (3.09%) 10 (1.71%) 10396 (3.09%) 
    Ever 8422 (75.8%) 4030 (78.5%) 4392 (73.4%)  326467 (96.8%) 575 (98.3%) 325892 (96.8%) 
    Missing 870 (7.83%) 336 (6.55%) 534 (8.92%)  235 (0.07%) 0 (0.00%) 235 (0.07%) 
Geographic region 
   
    
    Europe 5251 (47.2%) 2323 (45.3%) 2928 (48.9%)     
    North America 4583 (41.2%) 2254 (43.9%) 2329 (38.9%)     
    South America 1283 (11.5%) 556 (10.8%) 727 (12.1%)     
        
Chapter 7: Assessing the causal association between vitamin D and HNC 
 131 
7.4.2 SNP Selection 
Of the seven SNPs included in the analyses, rs4588 and  rs10741657 were directly genotyped in both 
the GAME-ON and UK Biobank studies, rs2277458 was genotyped in the GAME-ON consortium . All 
other SNPs were imputed and the imputation quality metric (Minimac3 r2 for GAME-ON; SNPTEST 
info score for UK Biobank) was greater than 0.98, except rs6013897 in the GAME-ON study which 
had an r2 of 0.74 (Table 7-1) . No two SNPs on the same chromosome had an LD r2 greater than 0.01.  
7.4.3 Assessment of confounders 
In the GAME-ON study there was no strong evidence of association of the 25(OH)D relative  measure 
with sex, smoking status or drinking status after taking multiple testing into account. However, there 
was evidence for a difference in the 25(OH)D genetic proxy across regions and sub-studies in GAME-
ON (Figure 7-1). 
Figure 7-1: Mean (+/- standard deviation) and range of relative 25-hydroxyvitamin D across 
strata of potential confounders for GAMEON. 
 
Overall mean relative 25-hydroxyvitamin D for those included in plot indicated by red line. 25OHD = 25 
hydroxyvitamin D,  p=p value for linear model 
The region showing deviation from the others was South America and any differences across 
confounders were no longer seen when the South American region was excluded from analyses 
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between the 25(OH)D genetic proxy and confounders (Appendix 7.1). In UK Biobank there was no 
evidence for a difference in relative 25(OH)D across strata of sex, smoking status or drinking status 
(Figure 7-3). These findings provide some evidence that the independence assumption is not 
violated by the relative 25(OH)D measure across the European and North American regions or within 
the South American region. However, there is some evidence that allele frequencies may differ in 
South America compared to North American and Europe, although these differences are small. This 
finding supports the decision to conduct the main analyses within each region and meta-analyse the 
effect estimates. 
Figure 7-2: Mean (+/- standard deviation) and range of relative 25-hydroxyvitamin D across 
strata of potential confounders for GAMEON with the South American studies removed. 
 
Overall mean relative 25-hydroxyvitamin D for those included in plot indicated by red line. 25OHD = 25 
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Figure 7-3: Mean (+/- standard deviation) and range of relative 25-hydroxyvitamin D across 
strata of potential confounders UK Biobank. 
 
Overall mean relative 25-hydroxyvitamin D for those included in plot indicated by red line. 25OHD = 25 
hydroxyvitamin D,  p=p value for linear model 
7.4.4 Causal association between 25(OH)D and oral and oropharyngeal cancer 
In GAME-ON, for oral and oropharyngeal cancer there was little evidence for a causal association 
with relative 25(OH)D when the three geographic regions were meta-analysed, OR for a doubling of 
25(OH)D = 0.77 (95% CI: 0.49, 1.20), P=0.25 and OR = 1.65 (95% CI: 0.55, 5.00), P=0.37 respectively. 
For oral sites, estimates were homogenous across geographic regions (I2=0% (95% CI: 0, 87), 
Phet=0.44) but due to only having three estimates to meta-analyse, power to detect heterogeneity 
between regions was low. Despite this, there was evidence of heterogeneity between regions for 
the oropharyngeal sites (I2=75% (95% CI: 17, 92), Phet=0.02). This was also reflected when all sites 
were examined together (I2=58% (95% CI: 0, 88), Phet=0.09) and was most likely driven by the strong 
risk increasing association with oropharyngeal cancer identified in the South American region (OR = 
13.81 (95% CI: 2.29, 83.09), P<0.01) compared to null associations in both European (OR = 0.98 (95% 
CI: 0.47, 2.03), P=0.95) and North American regions (OR = 0.90 (95% CI: 0.47, 1.84), P=0.76) (Figure 
7-4). 
When replicated in UK Biobank, estimates for oral cavity cancer (OR=0.69 (95% CI: 0.24, 1.99), 
P=0.49) were similar to those from the GAME-ON study. For oropharyngeal sites (OR=0.78 (95% CI: 
0.27, 2.47), P=0.65) point estimates differed between GAME-ON and UK Biobank although 
confidence intervals overlapped. When the two studies were meta-analysed using random-effects 
there was no convincing evidence of a causal association with either cancer or when all sites were 
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Figure 7-4: Odds ratio (95% CI) for developing cancer for D doubling in 25-hydroxyvitamin D 
for (A) oral cavity cancer, (B) oropharyngeal cancer and (C) all sites combined in Mendelian 
randomization analysis. 
 
7.4.5 Stratification by smoking status 
When stratified by smoking status, there was no clear pattern of effect across strata of smoking 
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never smokers and the estimate for current smokers was on or near the null (Figure 7-5). This is the 
opposite of the observational findings which see any protective effect of 25(OH)D on HNCs driven by 
the current smoking strata (Chapter 4). 
Figure 7-5: Odds ratio (95% CI) for developing cancer for doubling in 25-hydroxyvitamin D 
stratified by smoking in (A) oral cavity cancer and (B) oropharyngeal cancer. 
 
7.4.6 Sensitivity analyses 
In leave one out analyses, sequentially omitting each of the seven variants provided similar causal 
estimates for any site within the European and North American regions of GAME-ON. This is 
demonstrated in Figure 7-6 A and B, where the effect estimates differ very little when each of the 
genetic variants are left out of the analysis. However, in the South American region of the GAME-ON 
study, the risk increasing association between 25(OH)D and oropharyngeal cancer was most strongly 
influenced by the rs4588 variant. This is demonstrated clearly in Figure 7-6 C, where the effect 
estimate not including rs4588, is substantially closer to the null compared to the estimates leaving 
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Figure 7-6: Leave-one-out plots for the three GAME-ON regions. 
 
To investigate the influence of the rs4588 variant further, analyses were repeated using the relative 
25(OH)D measure consisting of all possible combinations of the 25(OH)D variants with one variant, 
then two variants then three variants, all the way to seven variants. In the South American region, 
for oropharyngeal cancer, whenever the rs4588 variant was included, there was a much stronger 
odds increasing effect of 25(OH)D compared to when it was not included in the relative 25(OH)D 
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association for oropharyngeal cancer in the South American region (Figure 7-7). Removing the South 
American region from the oropharyngeal analyses reduced heterogeneity between the GAME-ON 
regions with the effect estimate suggesting little evidence of a causal effect of 25(OH)D on 
oropharyngeal cancer (OR = 0.93 (95% CI: 0.56, 1.56), P=0.80; I2 = 0, Phet=0.87). When combined with 
the UK Biobank estimate, the pooled estimate made little difference to the interpretation (OR = 0.90 
(95% CI: 0.57, 1.43), P=0.67; I2 = 0, Phet=0.77). 
Figure 7-7: Histograms of OR for MR analyses repeated for each possible combination of 25-
hydroxyvitamin D genetic proxies. 
 
Proxies including rs4588 variant ( • ), proxies not including rs4588 variant ( • ). 
7.5 Discussion 
This study set out to investigate the causal association between 25(OH)D and oral and 
oropharyngeal cancer risk. Given the lack of 25(OH)D measures in large scale oral and oropharyngeal 
cancer studies a two-sample MR approach was adopted204 that allowed genetic variants to be used 
as largely unconfounded measures of 25(OH)D. Strong evidence of a causal association was not 
identified with oral or oropharyngeal cancer. The point estimate for the association of 25(OH)D with 
oral cavity cancer (OR = 0.75 (95% CI: 0.50, 1.14)) was smaller but had some consistency with the 
observational estimates identified in Chapter 4 (OR = 0.71 (95% CI: 0.57, 0.88)) however, confidence 
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intervals were wide in these MR analyses and include the null. The MR estimate for oropharyngeal 
cancer form the meta-analysis of GAME-ON and UK Biobank (OR = 1.12 (95% CI: 0.52, 2.39)), was in 
the opposite direction to that of the observational results in Chapter 4 (OR = 0.80 (95% CI: 0.65, 
0.98), however there was clear heterogeneity across the regions of the GAME-ON study. When 
removing the estimate from the South American participants the pooled GAME-ON, UK Biobank MR 
estimate was imprecisely estimated but, similar to the oral cavity cancer result, smaller but 
potentially consistent with the observational estimate. 
The lack of strong evidence for a causal association between 25(OH)D and cancer risk mirrors a 
recently published MR study of colorectal, breast, prostate, ovarian, lung and pancreatic cancer, and 
neuroblastoma that did not support a causal role of 25(OH)D cancer risk.205 Similar to the inference 
from this work on oral and oropharyngeal cancer, the authors of the previous study state that 
although they are unable to rule out clinically relevant effects of small magnitude, their study 
combined with previous literature, “provide evidence that population-wide screening for vitamin D 
deficiency and subsequent widespread vitamin D supplementation should not currently be 
recommended as a strategy for primary cancer prevention”. Recent RCTs, including the large VITAL 
study, examining the effect of vitamin D on cancer incidence do not show strong evidence of a 
protective effect and support the findings from MR studies.206,207 Contrary to this however, Ong et al. 
(2016)208 did demonstrate a protective role for 25(OH)D in ovarian cancer in a well powered MR 
study but the more recent pan-cancer MR study seems to refute this. Despite the body of evidence 
that does not support a protective effect of 25(OH)D on cancer incidence there is some evidence to 
support the hypothesis that vitamin D has an effect on cancer prognosis54,126 and this is supported by 
the observational results in Chapter 4. Recently a large meta-analysis of RCTs for vitamin D 
supplementation on all-cancer mortality demonstrated a protective effect with supplementation (RR 
= 0.84 (95% CI: 0.74, 0.95)).209 Given the lack of RCT and MR evidence supporting a strong role for 
vitamin D on cancer risk, it may be that the effect on mortality seen in this recent meta-analysis is 
driven by the effect of 25(OH)D on cancer prognosis. The role of 25(OH)D on HNC prognosis is 
examined in Chapter 8. 
The genetic relative 25(OH)D measure used in this study specifically proxies average total (free and 
bound) circulating 25(OH)D. This measure does not necessarily predict the concentrations of free 
25(OH)D available at the tissues or concentrations of free or bound 1,25(OH)2D in circulation or at 
the tissue level. Potential anti-cancer effects of vitamin D are via free 1,25(OH)2D interacting with 
the vitamin D receptor within tissues resulting in reduced angiogenesis, metastasis, cell invasion, 
inflammation, and proliferation, as well as upregulation of apoptosis.54 Levels of 1,25(OH)2D are 
assumed to be correlated with circulating 25(OH)D, but this is not necessarily the case. Although it is 
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unlikely, the genetic proxy may not be a valid measure for 25(OH)D and this is discussed further in 
Chapter 9. However, as the genetic variants used here as genetic proxies for 25(OH)D have robust 
associations with 25(OH)D and are mainly in genes known to affect this metabolite they are likely to 
be valid for the purposes of instrumenting serum 25(OH)D in MR. 
As highlighted previously, in order to be valid the genetic measure must proxy circulating 25(OH)D 
without affecting cancer risk through other causal pathways (violation of this assumption is referred 
to as horizontal pleiotropy). The SNPs used in this proxy are in genes with known effects on vitamin 
D pathways and have been consistently associated with circulating levels of 25(OH)D in GWA98,178 
and MR studies,105 reducing the chance of horizontal pleiotropy. Sensitivity analyses such as MR 
Egger6 and the weighted median method150 can detect or correct for the presence of directional 
pleiotropy but have low power with few SNPs comprising the genetic proxy, as in this case. Here, 
causal estimates in the European and North American populations are largely consistent across all 
five SNPs, providing some evidence against the presence of strong pleiotropy that could bias 
findings. 
In the South American population, some evidence for a large risk increasing association was 
identified between 25(OH)D and oropharyngeal cancer. Use of individual level data in this study 
allowed scrutiny of the genetic proxy-confounder independence assumption and showed that the 
25(OH)D proxy generally held up to this assumption however there was some evidence the genetic 
proxy was associated with region and sub-study, driven by the South American region. As mentioned 
above it is unlikely then that pleiotropy can explain the large risk increased effect seen for 
oropharyngeal cancer in the South American region. There is also little evidence that the genetic 
proxy for 25(OH)D is associated with potential confounders, as demonstrated in this work and in the 
PheWAS in Chapter 6. However, as the risk increasing association seen between 25(OH)D and 
oropharyngeal cancer in the South American region, is inconsistent with observational effect 
directions and MR estimates from other geographic regions, it is unlikely to be truly causal: it most 
likely represents structure within this population that is by chance associated with oropharyngeal 
cancer risk. To assess the impact of this potentially biased estimate on the overall causal OR, the 
analyses were repeated with the South American individuals removed, resulting in more consistent 
estimates. Future studies could firstly use GWAS results for 25(OH)D which are specific to the South 
American population which would reduce problems with the genetic instrument potentially not 
being relevant to this population. Furthermore increasing the numbers of participants from the 
South American regions would improve power to produce a more precise estimate of the causal 
effect and therefore help to clarify whether these interesting finding are real or not. 
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In observational studies (including work from this thesis), the HNC risk decreasing effects of 25(OH)D 
are seen to be strongest in current smokers, with no evidence of an effect seen in never smokers. 
Despite being underpowered to show clear differences across smoking strata, the trend of effect 
sizes in this study does not match the observational analyses and shows no clear pattern. This result 
does not support the theory that smoking and vitamin D interact to make vitamin D protective but 
only in smokers. 
The genetic 25(OH)D relative measure is a good proxy for circulating total 25(OH)D, the same 
metabolite that is used in supplementation and is measured in the observational studies. Despite 
the improved proxy identified in Chapter 5 which has been shown to be robustly associated with 
25(OH)D, the genetic variants used here only explain a relatively small amount of variance in 
25(OH)D. This means that causal effects of small magnitude cannot be ruled out. A new GWAS, 
currently being conducted, has identified a large number of new genetic variants that are associated 
with 25(OH)D. These variants will improve the proxy 25(OH)D measure beyond that of this thesis 
and increase power for future MR analyses. Furthermore, a larger case-control HNC study with 
genetic data will also help to provide more precise causal estimates from MR and, a collaborative 
effort is underway to achieve this. These new initiatives, to which I am contributing, are both 
discussed in the Future Work section in Chapter 9. 
Using MR, it cannot be determined whether 25(OH)D has an effect on cancer risk in individuals 
below a certain 25(OH)D concentration threshold. Where inference is likely to be useful clinically is 
in relation to supplementation. Supplementation increases total circulating 25(OH)D and is 
presumed to subsequently increase free 1,25(OH)2D availability at the tissues. The effect sizes in this 
chapter reflect a doubling in 25(OH)D to mirror those in previous observational studies. In the 
general population (with normal 25(OH)D levels), this would reflect a very large increase in 25(OH)D, 
likely to be larger than would be achieved by vitamin D supplementation. The 25(OH)D difference in 
this study is genetically determined and will have a relative effect on total 25(OH)D across the whole 
life course. If this long-term difference in relative 25(OH)D does not produce a detectable and 
clinically useful effect in this study, any 25(OH)D causal effect is unlikely to be of a magnitude that 
would warrant long-term supplementation in the general population. 
7.6 Conclusion 
This chapter does not support the large size of the observational association between 25(OH)D and 
oral cavity cancer risk and is consistent with evidence that a causal, clinically relevant protective 
effect of 25(OH)D on oropharyngeal cancer risk is unlikely.  
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The next chapter 
As detailed above there is a growing body of evidence from observational and randomised studies 
that 25(OH)D has an effect on cancer mortality, even if not on cancer risk. The effect of 25(OH)D on 
oral and oropharyngeal cancer prognosis was not assessed in this chapter due to the lack of 
prognosis data in the GAME-ON contributing studies. In the next chapter, a study assessing the 
causal effect of 25(OH)D on HNC prognosis is conducted on the currently available data. 
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Chapter 8 :  Assessing the causal association 
of vitamin D with HNC progression 
8.1 Chapter objectives 
In Chapter 4 the observational association between 25(OH)D and HNC prognosis was investigated 
and strong protective associations were identified however these estimates are likely biased by 
confounding and other biases specific to case only analyses. In this chapter, an MR analysis is 
conducted using the genetic proxy identified and tested in Chapter 5 and 6. The aim of this chapter 
is to estimate the causal association between vitamin D and HNC prognosis using MR. 
8.2 Introduction 
As reported in the summary of previous observational evidence in Chapter 2 and demonstrated in 
the study described in Chapter 4, there is a growing body of observational evidence that higher 
25(OH)D confers a survival advantage in HNC patients. This protective effect is robust to correction 
by confounding and when 25(OH)D measures are recorded before the onset of cancer (for example 
five years prior to diagnosis). Despite these results, these estimates from observational studies are 
likely to be affected by the issues of residual confounding that were described above for the 
association with HNC incidence. MR can be used to investigate the association between 25(OH)D 
and HNC prognosis but statistical and logistical issues exist which make this less straight forward. 
One major concern in case only analyses, including MR, is that when selecting on case status an 
ascertainment or selection event occurs which can introduce bias into any subsequent analyses. This 
type of bias, referred to as ascertainment or collider bias, is explained in more detail in Chapter 3. In 
the context of this chapter, any factors which cause an individual to develop HNC will become 
correlated in case only analyses of HNC. Therefore, if vitamin D does cause HNC then, in the case 
only setting, there will be induced correlations between vitamin D and any other cause of HNC. As 
will be discussed in Chapter 9, it is not clear whether there is a causal association between vitamin D 
and HNC risk and so the implication of collider bias is unknown. 
In this example, vitamin D is assumed to be causally related to HNC incidence and smoking is used as 
a common cause of HNC. In an observational study, we would expect there to be associations 
between vitamin D and factors such as smoking, even in the non-ascertained (case-control or 
cohort) study but, in the ascertained (case-only) study these associations may be altered in 
magnitude and or direction. The collider bias from this induced or altered association with smoking 
can be unpredictable but can be partially mitigated by correcting for smoking in the analyses. 
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However, much like when correcting for confounding, there can be residual bias if there is error in 
the measurement of smoking. One of the major benefits of MR analyses over observational studies 
is the genetic proxies are uncorrelated with the potential confounders of the exposure-outcome 
relationship. However, in the case only setting, genotypes which proxy causal risk factors will 
become correlated, inducing associations between the genetic proxies, of vitamin D in this case, and 
other risk factors such a smoking. In an MR study of vitamin D on HNC prognosis, this creates a 
pathway between the genetic variants for vitamin D and HNC prognosis, which is not via vitamin D, 
violating the independence assumption of MR (Figure 8-1). 
Figure 8-1: Collider bias in the context of an MR study assessing the causal association 
between 25(OH)D and HNC prognosis. 
 
The genetic variant for 25(OH)D (G25(OH)D) is causally related to the incidence of HNC (IHNC) through 25(OH)D. 
Smoking also causes IHNC, is unrelated to G25(OH)D but also affects HNC prognosis (PHNC). To investigate the 
effect of 25(OH)D on the prognosis of the disease (PHNC), an MR analysis in conducted in cases only 
(indicated by the square around IHNC). In the cases only G25(OH)D is non-randomly assigned and a spurious 
association is induced between G25(OH)D and smoking (red dotted arrow). In the case only MR analysis, the 
causal effect of 25(OH)D – P25(OH)D is biased via the aternative route from G25(OH)D through smoking. 
One problem in all studies which assess the process of disease, is what measure to use to as the 
prognosis outcome. The most commonly used measure is survival and this will be used here.  It is 
routinely recorded from death registry data and so available on all participants. One method is to 
generate a binary variable of survived versus not survived at a set timepoint. The approach has the 
advantage of being more amenable to current MR methods but there is a large amount of 
information loss as the amount of time in the study is not taken into account. In this study time to 
death will be used as it makes the best use of available information but MR methods using this type 
of data are less developed. 
There are very few instances in the literature of MR analyses being applied to survival data. One 
study used MR to assess the effect of BMI on all-cause mortality in UK Biobank,210 using a genetic 
risk score (GRS) in an instrumental variable ratio method. In this study, the authors calculated the 
effect of the GRS on the exposure (BMI) as the denominator of the ratio and the GRS was used in a 
cox-proportional hazards model to calculate the effect of the GRS on all-cause mortality, as the 
G25(OH)D PHNC 25(OH)D 
IHNC 
Smoking 
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numerator of the ratio. The causal hazards ratio (HR) was calculated as the exponential of the ratio 
of the GRS effect on mortality to the GRS effect on BMI. Confidence intervals were calculated using a 
Taylor series expansion. 
A more recent paper assessed the effect of BMI on breast cancer survival.211 In this study two MR 
methods were used to assess the causal association, both estimating a HR. The first method used a 
weighted GRS in a Cox proportional hazards model, similar to that used in the previous chapter for 
HNC risk. The second method used a two-sample approach in which GWAS summary statistics for 
BMI and breast cancer progression were utilised in a method identical to that which would be used 
to generate an OR. 
The main logistical challenge is that there are limited sample sizes available for well powered studies 
due to the difficulty in getting long-term HNC follow-up data in large enough samples. Genetic data 
and 25(OH)D measures are not both available in HNC specific studies with HNC follow data, and due 
to the relatively rare incidence of HNC, there are few cases in large population-based studies which 
do have 25(OH)D and genetic data. These issues make single sample MR impractical. Furthermore, 
studies with HNC follow up data and genetics are limited and there are no published GWAS of HNC 
prognosis which, would allow for a two-sample MR approach using summary level data. Given the 
relatively small proportion of variance in 25(OH)D explained by the 25(OH)D genetic variants and the 
small samples with genetics and HNC follow-up data available, a well powered MR study is not 
possible at this time. 
Despite the issue of power, there are advantages to conducting an MR study looking at the effect of 
25(OH)D on HNC prognosis. A study of this type will provide preliminary estimates of effect to 
inform sample size calculations for well powered MR studies and allow testing of the methodologies 
discussed above which have not been formally compared. 
In this chapter several MR methods will be utilised to study the effect of 25(OH)D on HNC prognosis 
using available data in Head and Neck 5000 and UK Biobank. The reader is pointed to the Future 
Work section of Chapter 9, for a description of how this study will be developed in the future. 
8.3 Methods 
8.3.1 Overview 
Genetic variants which proxy 25(OH)D levels were utilised in this chapter to conduct an MR study 
assessing the causal effect of 25(OH)D on oral and oropharyngeal cancer prognosis in two case only 
studies using three MR methods. All methods estimate the causal effect as a HR, two using individual 
level data and one using summary level data. 
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As in the previous chapter, genetic variants identified in the 25(OH)D GWAS in Chapter 5 were used 
as 25(OH)D proxies. The genotypes of these variants were identified in individuals of two studies 
with follow up of HNC cases (HN5000 and UK Biobank) and combined to make a 25(OH)D genetic 
risk score (GRS). To assess the assumption that this 25(OH)D GRS was unconfounded in the 
ascertained (case only) setting, the association between the GRS and available confounders was 
assessed in UK Biobank in both the whole cohort and the ascertained, HNC case only, participants.  
The first MR method was conducted in both HN5000 and UK Biobank as serum 25(OH)D levels were 
not required. The 25(OH)D GRS was scaled to match 25(OH)D on the log2 scale then used in a Cox-
proportional hazards survival regression model to estimate a HR for a log2 increase in 25(OH)D. 
The second method applied the ratio method discussed above to assess the effect of BMI on all-
cause mortality in UK Biobank. As serum 25(OH)D levels were required this was only conducted in 
UK Biobank, and not HN5000. 
In the final method, a two sample MR analysis was used to estimate a causal HR using summary level 
data. Summary level data for 25(OH)D was used from published GWAS and summary level data for 
HNC prognosis was used from a GWAS of HNC survival conducted in UK Biobank and HN5000 for the 
purposes of this chapter. 
8.3.2 Studies 
8.3.2.1 Head and neck 5000 
HN5000 is a large collection of HNC cases with detailed phenotyping and follow-up. An overall 
description of the HN5000 study is provided in Chapter 3. 
8.3.2.2 UK Biobank 
UK Biobank is a population-based study of approximately 500,000 participants. A detailed 
description of this study, genotyping and the 25(OH)D measures is given in Chapter 3. 
8.3.3 DNA extraction genotyping and imputation 
DNA extraction, genotyping and imputation for UK Biobank and HN5000 is described in Chapter 3. 
8.3.4 Follow-up of HNC cases 
Cancer cases were followed up in both studies using death registry data to identify the date of 
death. All-cause mortality was identified from death registry data as a death of a participant from 
any cause. Due to the limited sample size (UK Biobank) and data-availability (HN5000), HNC-specific 
cause of death was not assessed in this study. 
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Survival time was calculated from date of diagnosis to date of death. Those participants alive at the 
end of follow up were censored. Censoring was on 31st March 2018 in HN5000 (last data capture 
from death registry) and 14th February 2018 in UK Biobank (last recorded death in the UK Biobank 
data freeze used for this study). 
8.3.5 Vitamin D genetic variants for MR analysis 
The seven genetic variants used in Chapter 7 were used as a genetic proxy for 25(OH)D in MR 
analyses. As in Chapter 7, for each individual the seven 25(OH)D variants were combined into a GRS 
weighted by the beta coefficients of the genetic variant’s effect on 25(OH)D levels, derived from 
GWAS.  
For the assessment of confounders and the first MR method the GRS was converted from a per allele 
scale to a log2 25(OH)D scale. Therefore, each unit increase in this variable represented a doubling 
of 25(OH)D. For the second MR method, the GRS was used on the per allele scale. 
For the summary level data the same seven genetic variants were identified from the largest 
published GWAS of 25(OH)D.193 Effect estimates and standard errors were scaled to match the log 2 
scale. As the low frequency variant in  frequency variant in CYP2R1, identified in Chapter 5, was not 
available in this GWAS, the effect estimate identified in this thesis was used and scaled to match that 
of the other six variants, as done in previous chapters. 
8.3.6 GWAS of HNC prognosis to generate summary level outcome data 
A GWAS was conducted for HNC survival in HN5000 and UK Biobank using the SurvivalGWAS_Sv 
program.212 Full details of the method are described in Appendix 8.1. Briefly, a Cox proportional 
hazards regression model was run for each genetic variant. The number of risk alleles at each variant 
was used as the exposure and time to event data for all HNC sites combined (as detailed above) was 
used as the outcome, age and sex were used as covariates in the regression model. Results from the 
two studies were meta-analyses using a fixed effect in GWAMA.187 Summary effect estimates (log 
HR) and standard errors were extracted for the seven 25(OH)D genetic variants for the pooled 
results and the individual studies. 
8.3.7 Statistical analysis 
8.3.7.1 Assessment of GRS in UK Biobank 
The strength of the GRS as a proxy measure for 25(OH)D was assessed using the F-statistic from a 
linear regression model of the GRS on seasonally adjusted 25(OH)D. The F-statistic gives a measure 
of the strength of an instrumental variable in MR analyses. As discussed in Chapter 3, where an 
instrumental variable is weak the analyses can be affected by weak instrument bias. This is where 
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chance associations between the instrumental variable and confounders outweigh the direct effect 
of the instrumental variable on the outcome and can bias the causal estimate. The R2 was used to 
assess the proportion of variance in 25(OH)D which is explained by the GRS. This was performed in 
the HNC case only sample and compared to the same metrics in the whole UK Biobank dataset. A 
scatter plot was used to demonstrate the correlation between individual level log2 25(OH)D and the 
GRS with the linear relationship indicated. 
8.3.7.2 Assessment of confounding in case only setting 
To investigate the potential impact selecting only a set of HNC cases has on further analyses, the 
association between vitamin D and a series of variables was assessed in both the full UK Biobank 
cohort and the selected HNC cases. Smoking status and self-reported number of sexual partners (a 
proxy measure of HPV status) were selected as they are strong risk factors for HNC and have been 
shown to influence survival.213,214 The association between these variables and both 25(OH)D and 
the GRS was assessed using a linear regression model. The magnitude and direction of effects was 
compared between the full and selected study samples. 
8.3.7.3 MR method 1: GRS analysis in HN5000 and UK Biobank 
In both studies the GRS was dichotomised at the median value and Kaplan Meier survival plots were 
generated to graphically represent the survival in “high” and “low” GRS individuals. This was 
repeated for the 25(OH)D levels in UK Biobank, again using the median 25(OH)D level as the cut 
point. 
In both HN5000 and UK Biobank, the effect of the GRS on survival in the HNC cases was assessed 
using a cox-proportional hazards model using the ‘survival’ package in R.215 Age at diagnosis and sex 
were included as the only covariables in the regression models as the GRS had been shown to be 
unrelated to potential confounders. In UK Biobank, including genetic principal components in the 
model made minimal impact on the effect estimates and were not included in further analyses for 
either cohort. In UK Biobank where 25(OH)D was available, the observational estimate in those 
included in the GRS analysis was calculated using the same regression model. 
The estimates from HN5000 and UK Biobank, generated using the GRS, were meta-analysed using 
fixed effects in the ’meta’ R package.201 
8.3.7.4 MR method 2: Two-stage ratio method in UK Biobank 
The second method involved two stages and was only conducted in UK Biobank as serum 25(OH)D 
levels were required. In this method, a GRS was generated for 25(OH)D scaled to a per allele effect. 
In the first stage, a beta and standard error for the effect of the GRS on 25(OH)D were estimated 
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from a linear regression model. In the second stage the beta and standard error for the effect of the 
GRS on HNC survival were estimated from a Cox proportional hazards model. The causal HR was 
generated by dividing the beta from the second stage by the first stage. Standard errors for the 
causal estimate were estimated using a Taylor series expansion which takes into account the 
imprecision of both stages of the method. 
8.3.7.5 MR Method 3: Two-sample MR using summary statistics 
The R package ‘TwoSampleMR’216 was used to conduct the MR analyses with option “2” used to 
harmonise the data. With this option, positive strand alleles were inferred using allele frequencies 
for palindromic variants. An inverse variant weighted method was used to provide the causal 
estimate which was compared to the observational and MR estimates from the first method. The 
MR analysis was conducted for the pooled HN5000 and UK Biobank GWAS summary results and then 
the studies individually. This was to allow direct comparison between the different MR methods in 
the same studies. 
8.3.7.6 Sensitivity analyses 
To assess whether any one genetic variant is overtly influencing the causal estimate a leave one out 
sensitivity analysis was performed for both the GRS and two-sample MR methods. This repeats the 
primary analysis sequentially removing one of the seven genetic variants. If any of the resulting 
estimates differ substantially from the others, this may provide evidence that the genetic variant is 
pleiotropic. 
8.4 Results 
8.4.1 Study participants 
In the HN5000 study, there were 1,020 cases (oral n=395, oropharyngeal n=577, larynx = 6, other 
HNC=41) with follow-up and genetic data. Median follow up was 4.5 years (range: 11 days, to 6.4 
years) and there were 335 (32.8%) deaths from any cause during this period. This corresponds to a 
follow period of 3,918.7 person-years. In UK Biobank, there were 457 cases (oral n=136, 
oropharyngeal n=212, larynx = 83, other HNC=27) with follow up and genetic data. Median follow up 
was 4.4 years (range: 1 day to 10.3 years) and there were 111 (24.3) deaths from any cause during 
this period. This corresponds to a follow period of 2,035.2 person-years. 
8.4.2 SNP selection 
Of the seven SNPs included in the analyses, rs117913124, rs10741657 and rs12785878 were directly 
genotyped in HN5000 and rs10741657, rs12785878 and rs8018720 were directly genotyped in UK 
Biobank. All other SNPs were imputed and the imputation quality metric (Minimac3 r2 for HN5000; 
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SNPTEST info score for UK Biobank) was greater than 0.96, except rs6013897 which in the HN5000 
study had an r2 of 0.75 (Table 8-1). No two SNPs on the same chromosome had an LD r2 greater than 
0.01.
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Table 8-1: 25-Hydroxyvitamin D genetic variant details 
 
            Vitamin D GWAS   HN5000  UK Biobank 
RSID Chrom
osome 








EAF  Info 
(snptest) 
EAF 
rs3755967 4 72609398 GC C T 0.713 0.128 0.0033 4.74E-343 
 
1.0 0.702  1.0 0.713 
rs117913124 11 14900931 CYP2R1 G A 0.973 0.227 0.0093 2.29E-88 
 
Genotyped 0.965  0.99 0.973 
rs10741657 11 14914878 CYP2R1 A G 0.398 0.045 0.0032 2.05E-46 
 
Genotyped 0.393  Genotyped 0.398 
rs12785878 11 71167449 DHCR7 T G 0.758 0.052 0.0032 3.80E-62 
 
Genotyped 0.777  Genotyped 0.758 
rs10745742 12 96358529 AMDHD1 T C 0.384 0.025 0.0017 1.88E-14  0.98 0.363  1.00 0.384 
rs8018720 14 39556185 SEC23A G C 0.178 0.025 0.0042 4.72E-09  0.99 0.187  Genotyped 0.178 
rs17216707 20 52732362 CYP24A1 T C 0.812 0.038 0.0039 8.14E-23   0.75 0.817   0.96 0.812 
Beta = per allele effect on 25(OH)D on log2 scale, EAF = effect allele frequency, Rsq = R squared, SE = standard error 
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8.4.3 Assessment of GRS 
The strength of the GRS, as a proxy measure of 25(OH)D, was assessed in UK Biobank. The F-statistic 
from the linear model of the GRS on seasonally adjusted 25(OH)D was 28.2, in the sample included 
in survival analyses with the GRS explained approximately 5.8% of the variance in 25(OH)D. Figure 
8-2 demonstrates the relationship between the GRS and actual 25(OH)D levels in the analysed 
samples. In the full UK Biobank sample, the F statistic was much higher (F=1,453) due to the larger 
sample size (n= 421,686) but the variance in 25(OH)D explained by the GRS in the full UK Biobank 
sample was lower (3.3%). 
Figure 8-2: Scatter plot demonstrating the relationship between GRS and 25(OH)D levels. 
 
8.4.4 Assessment of confounding in case only setting 
To assess how selecting only cases may influence further analyses, the association between vitamin 
D and smoking, number of sexual partners and mean corpuscular haemoglobin concentration was 
compared in the case-only and full UK Biobank samples. When using the serum 25(OH)D measure, 
there was strong evidence for lower 25(OH)D in former and current smokers compared to never 
smokers in the full UK Biobank sample and in the case only sample. However, the effect of smoking 
on 25(OH)D was of a larger magnitude in the case only sample compared to the full UK Biobank 
sample. When assessing the association between the GRS and smoking there was little evidence that 
the GRS differed across smoking strata in either the case-only or full UK Biobank samples, with 
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Table 8-2: Association of 25(OH)D and smoking in full and selected UK Biobank samples. 
  Full UK Biobank sample Case only sample 
 Smoking 
status 








D Never REF   REF   
Former -0.138 -0.142, -0.133 <2x10-16 -0.401 -0.519, -0.283 8.31x10-11 








Never REF   REF   
Former -0.001 -0.001, 0.000 0.22 -0.011 -0.032, 0.010 0.31 
Current -0.001 -0.001, 0.000 0.09 0.006 -0.013, 0.026 0.52 
 
The association of 25(OH)D with number of sexual partners was weaker than the association with 
smoking. There was no obvious alteration in effect size or direction between the full and case only 
samples. There was strong evidence that the GRS was not associated with number of sexual partners 
in the full sample however, in the case only study there was some weak evidence that the GRS was 
higher in individuals who had more than two sexual partners compared to less than two. Due to the 
limited sample size and multiple tests used here, this result could be a false positive and should be 
viewed with caution (Table 8-3). 
Table 8-3: Association of 25(OH)D and number of sexual partners in full and selected UK 
Biobank samples. 
  Full UK Biobank sample Case only sample 
 No. of sexual 
partners 








D 0-1 REF   REF   
2-4 -0.015 -0.018, -0.112 <2x10-16 -0.040 -0.163, 0.083 0.327 








0-1 REF   REF   
2-4 -0.000 -0.000, 0.001 0.496 0.024 0.002, 0.046 0.025 
5+ -0.000 -0.000, 0.001 0.439 0.014 -0.225, 0.523 0.244 
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8.4.5 Survival analyses 
8.4.5.1 MR method 1: GRS analysis in HN5000 and UK Biobank 
The GRS was dichotamised into a high-25(OH)D and a low-25(OH)D GRS in each study. In UK 
Biobank, where 25(OH)D measures were available, the high-25(OH)D GRS group had a mean 
25(OH)D level of 49.7 nmol/L and the low-25(OH)D GRS group has a mean 25(OH)D of 42.1 nmol/L. 
In these analyses, there was little evidence from graphical representations that either group has a 
survival benefit over the follow up period in either UK Biobank or HN5000.  
Figure 8-3: Kaplan Meier curves for high- and low-25(OH)D genetic risk scores in (A) HN5000 
and (B) UK Biobank and (C) high- and low-25(OH)D levels in UK Biobank. 
 
High-25(OH)D GRS = GRS above the median value in each cohort, Low-25(OH)D GRS = GRS below the median 
value in each cohort. Shaded area represent the 95% confidence interval of line. Vertical lines represent 
censoring. P = P-value for the log-rank test assessing whether there is a difference in survival between the 
two groups. 
In survival analyses using cox-proportional hazards regression, the UK Biobank effect estimate was 
very imprecisely estimated. The point estimate corresponded to a large hazard increasing effect for 
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hazard increasing effect (HR=2.14 (95% CI: 0.46, 9.97)). The HN5000 estimate was more precise but 
confidence intervals still spanned the null effect (HR=0.64 (95% CI: 0.26, 1.58)), the point estimate 
was similar to that of the UK Biobank observational analysis (HR=0.64 (95% CI: 0.50, 0.81). When 
meta-analysed together, the combined estimate was HR=0.87 (95% CI: 0.40, 1.91) (Figure 8-4). 
8.4.5.2 MR method 2: Two-stage ratio method in UK Biobank 
Using the ratio based method the causal estimate for a log2 increase in 25(OH)D was in the same 
direction but of a smaller magnitude and slightly more precise than method 1 (HR= 1.71 (95% CI: 
0.57, 5.16)) (Figure 8-4). 
8.4.5.3 MR method 3: Two-sample MR using summary statistics 
In the two-sample MR method, the effect estimates for both studies combined was HR = 0.90 (95% 
CI: 0.51, 1.57) which is similar to the pooled estimate from method 1. However, when the analyses 
were run within the individual studies the direction of effect in UK Biobank was not consistent with 
the previous two estimates (Figure 8-4). 
Figure 8-4: Hazard ratio for death from any cause for a doubling in 25(OH)D from 
observational and three MR methods. 
 
8.4.6 Sensitivity analyses 
8.4.6.1 Leave-one-out 
In both Methods 1 and 3, a leave-one-out sensitivity analysis was performed to see if any one 
variant was overtly affecting the causal estimate. In both methods, the removal of each genetic 
variant in turn did not substantially change the effect estimate, suggesting that no one variant was 
driving the effect in a particular direction. The results of this sensitivity analysis are presented for 
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Figure 8-5: Leave-one-out sensitivity analysis plots for method 1. 
 
Each line represents a hazard ratio and 95% confidence interval. The top line represents the overall estimate 
with all genetic variants included. The esitmates below are the those which exclude the variant labelled on 
the left of the plot. 
8.5 Discussion 
This study demonstrates three MR methods to investigate the effect of 25(OH)D on HNC prognosis. 
These MR methods have several advantages over a serum measure of 25(OH)D. Firstly, these 
approaches are less affected by confounding factors than serum 25(OH)D, meaning that causality 
can be inferred. Secondly, two of the methods allow the association to be investigated in studies 
that do not have serum 25(OH)D measures, such as HN5000. Furthermore, if genome-wide genetic 
data are available in studies such as HN5000, these methods can be used to investigate other factors 
of interest that can be effectively proxied by genetic variants. This ultimately provides a cost-
effective means of investigating a large range of factors in comparison to measuring them all 
individually. 
The causal estimates from all three methods and across the two studies were imprecisely estimated. 
The point estimate for two studies showed opposite effect directions for Method 1, the GRS based 
method. These differing effect sizes and directions may represent the random spread of effects 
around the true estimate due to error and it is difficult to say with any certainty where the true 
causal estimate lies without improved power. The most precise estimate was from Method 3, the 
two-sample summary statistic method. However, when using the summary data from UK Biobank 
and HN5000 combined, the estimate is still consistent with a moderate survival advantage, no effect 
or indeed a survival disadvantage. When compared to estimates from observational studies, 
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observational estimates are an overestimation but again it is difficult to say with any certainty as the 
MR effects sizes are imprecisely estimated. A well powered study is required to identify the exact 
causal effect and how this compares with the precise but likely-confounded observational estimates. 
As discussed in previous chapters, the genetic variants used as a proxy measure of 25(OH)D in this 
study are likely to be a valid measure of circulating 25(OH)D levels. This was demonstrated by the 
relatively large F-statistic for the GRS in UK Biobank, despite the small sample size. The amount of 
variance in 25(OH)D explained in the HNC cases (5.8%) was interesting. This proportion of variance 
explained was almost double the value than in the full UK Biobank cohort. Although this may reflect 
a chance finding it could be that those with HNC are different, with regard to vitamin D, to the 
general population. For example, they may acquire less 25(OH)D from sunlight and their diet, 
meaning that the impact of the genetic variants for vitamin D in this group is higher. In Chapter 4, 
Table 4-2 shows that those participants who went on to get HNC had lower dietary 25(OH)D which 
may support this hypothesis. 
The MR analyses in this study are conducted in a selected, case only scenario. The use of UK Biobank 
means some impacts of this selection can be interrogated. To do this, the associations between 
25(OH)D and smoking and 25(OH)D and number of sexual partners were used as examples. In the 
case-only setting, the association between smoking and 25(OH)D was substantially exaggerated in 
terms of effect size which, may have implications on observational analyses: Any bias by residual 
confounding in the case-only analysis of 25(OH)D on HNC survival may be increased by the 
exaggerated association between smoking and 25(OH)D. As the GRS for 25(OH)D is uncorrelated 
with smoking there should be no exaggeration of confounding when a GRS is used in a case only 
context, however this is not always the case. Using a GRS (or other MR related method), would be 
problematic if the factor of interest (25(OH)D here) is causally related to HNC risk. In this scenario, 
when selecting on case (and therefore the 25(OH)D genetic variants) the 25(OH)D variants would 
become correlated with other HNC risk factors and would then introduce bias into the causal 
estimates – this is the issue previously referred to as ascertainment or collider bias. 
In the assessment of the association of 25(OH)D and the 25(OH)D GRS with number of sexual 
partners, there was weak evidence for an association between the GRS and number of sexual 
partners in the case only scenario. Although this likely represents a chance finding, it could 
theoretically be the result of collider bias. If this is the case it could invalidate the independence 
assumption of MR. However, this study does demonstrate that the GRS for 25(OH)D is not 
associated with smoking in either the full UK Biobank or the case-only datasets. This has two 
important implications. Firstly, it suggests the estimates are unbiased with respect to confounding 
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by smoking and secondly it provides some evidence that 25(OH)D is not causally related to HNC risk 
as if it were an association between the 25(OH)D GRS and smoking would be induced in the case 
only setting. 
Statistical methods to conduct MR in time to event analyses are much less established than those for 
continuous or binary variables in case-control or cohort designs. In this work three methods which 
have been reported in the literature were used.  The first method used a GRS to estimate the causal 
effect of a unit increase in the GRS (scaled to a log2 increase in 25(OH)D). This method does not take 
into account the imprecision of the effect of the genetic variant on 25(OH)D and so may produce 
confidence intervals which are artificially narrowed. The second method, the ratio method, requires 
serum 25(OH)D in addition to the genetic variants and survival data. This method produces similar 
but slightly more precise estimates than Method 1. This increased precision likely comes from the 
GRS explaining a greater amount of variance in serum 25(OH)D in the case only scenario than in 
population-based studies. The final method which uses summary level data produced the most 
precise estimates and these were consistently closer to the null than the estimates from the other 
methods. This summary level method has the disadvantage that if only summary level data are 
available, no assessment of the independence assumption is possible. Summary level MR has 
attracted much attention over the past few years and many statistical approaches have been 
generated which can assess the exclusion restriction assumption such as MR-Egger.150 However, 
these have little power to detect pleiotropy with low numbers of genetic variants and their utility is 
unknown in time to event MR contexts. 
The outcome used in these analyses was all-cause mortality. This was due to limited data in HN5000 
and limited numbers in UK Biobank. In future studies it would be interesting to see if estimates of 
HNC specific death differ from all-cause death. 
Finally, the estimates generated in this study can be used to plan future MR studies of 25(OH)D on 
HNC prognosis. The best available causal estimate for the effect of 25(OH)D on HNC prognosis, 
provided by the meta-analysis of HN5000 and UK Biobank, is closer to the null than observational 
estimates. This implies that future studies should be powered to detect effects smaller than that of 
the observational estimate if estimate precision is to be clinically useful. 
8.6 Conclusion 
MR is likely to provide a useful method for assessing causality in situations where time to event data 
are available and in case-only scenarios however, refinement of methods is required. This study 
Chapter 8: Assessing the causal association of vitamin D with HNC progression 
 158 
demonstrates the utility of using population-based studies to nest case-only analyse within, allowing 
certain methodological issues such as collider bias, to be assessed. 
The next chapter 
The final chapter of this thesis will summarise the main findings of this work and discuss the 
important strengths and weaknesses of the body of work. Finally, plans for future work that hopes 
to address some of the issues highlighted will be provided.  
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Chapter 9 :  Discussion 
In this thesis, I describe my work attempting to estimate the true causal effect of vitamin D on the 
risk and prognosis of head and neck cancer. I did this by generating a precise estimate of the effect 
of vitamin D on HNC risk and prognosis from observational epidemiology. I then identified a robust 
genetic proxy for vitamin D which was minimally affected by confounding and reverse causality and 
used this genetic proxy in MR studies to estimate the causal effect of vitamin D on HNC risk and 
prognosis. 
In this discussion I summarise the evidence gained as to whether there is a true causal link between 
vitamin D and HNC risk and prognosis by synthesising evidence from various chapters as well as 
previous studies. I use the Bradford Hill framework of causation,140 detailed in Chapter 3, to assess 
this body of evidence. From this evidence I provide my conclusions on the association of vitamin D 
and HNC risk and prognosis and discuss these conclusions in the context of its clinical application. I 
discuss the strengths and limitations of the work in this thesis and how they may help support or 
reduce confidence in the main conclusions. Finally, I outline current work and planned research that 
will help to address some of the limitations raised. 
9.1 Synthesis of findings 
In this section I will assess the evidence presented in this thesis in the context of previously 
published research using the Bradford-Hill criteria which are described in detail in Chapter 3. A 
summary of findings from this thesis is presented in Table 9-1. As I have explained in the 
introductory chapters, cancer risk and prognosis should be considered separately and I will use that 
strategy here. It is also important to consider the heterogeneity between HNC sites as it could be 
that vitamin D has an effect which is dependent on the anatomical site of the cancer. In this section, 
I will where possible, summarise the evidence for oral and oropharyngeal cancers separately. The 
evidence for laryngeal cancer is limited to the observational chapter and so will not be discussed in 
detail. For HNC prognosis, stratification by site was not possible in the MR study therefore the 
association between vitamin D and all HNC combined will be discussed. 
Table 9-1: Summary of results. 





CHAPTER 4: Observational 
(unconditional minimally adjusted) 0.61 (0.50, 0.76) 0.75 (0.61, 0.91) 0.63 (0.56, 0.71) 
CHAPTER 7: Mendelian randomization 









 CHAPTER 4: Observational 
(unadjusted) 0.74 (0.50, 1.10) 0.66 (0.50, 0.88) 0.64 (0.53, 0.77) 
CHAPTER 8: Mendelian randomization 
(method 3: 2-sample) - - 0.90 (0.51, 1.57) 
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9.1.1 Vitamin D and HNC risk 
9.1.1.1 Strength of evidence 
Strength of evidence is the first of the Bradford-Hill criteria that I will use to assess causality in the 
association between vitamin D and HNCs. For oral cavity cancers, the effect size estimated from the 
observational study in this thesis was moderate, with a doubling of vitamin D relating to a 41% 
reduction in odds (95% CI: 24%, 50%) from the minimally adjusted model. This estimate was slightly 
smaller in magnitude than previous studies and attenuated slightly after correcting for known 
confounders.126 Although the MR estimate was imprecise, the point estimate was smaller again but 
would also have been consistent with no effect or one more extreme than the observational (OR = 
0.75 (95% CI: 0.50, 1.10). The oropharyngeal effects were consistently smaller than the oral cavity 
cancer estimates in both observational and MR studies. The observational study in Chapter 4 
estimated a modest protective effect for oropharyngeal cancer (0.75 (95% CI: 0.61, 0.91)), and this 
effect was closer to the null when meta-analysed with the Fanidi et al. study.126 In the MR analysis 
the effect estimate was OR = 1.12 (95% CI: 0.52, 2.39). The South American region suffered potential 
population stratification issues which led to the risk increasing effect in this region being unreliable. 
After excluding this region the effect size was even closer to the null for oropharyngeal cancer (OR = 
0.93 (95% CI: 0.56, 1.56)). To put these effect sizes in context, the effect of not smoking compared to 
smoking, in the same UK Biobank sample used in the observational study in Chapter 4, reduces the 
odds of HNC by approximately 94%. In terms of causality, it is conceivable that residual confounding 
factors could account for modest or small observational effects, particularly when considering the 
large effect size of known confounders such as smoking. 
9.1.1.2 Consistency and specificity of evidence 
As discussed in Chapter 3, the concept of consistency is similar to the triangulation approach to 
assessing causality. Despite the effect sizes being fairly modest, there is consistency in effect sizes 
particularly between the observational study in Chapter 4 and the Fanidi et al paper.126 Furthermore, 
if you include older studies that report effects for the same change in vitamin D,124 the effect size for 
all HNC sites was again consistent. It is unlikely that the confounding structures in these studies are 
identical and so consistency across these studies lends some support to a causal association. When 
including the MR studies, there is again some consistency across the sites – there is a consistent 
pattern in both observational and MR analyses that the effect in oropharyngeal cancer risk is smaller 
than in oral cavity cancer risk. This latter point relates also to specificity, as it appears that the effect 
of vitamin D on oral cavity cancer risk is greater than the effect on oropharyngeal cancer but the 
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difference in effect size is small. It is known that many of the oropharyngeal cancers will be HPV 
driven cancers and one explanation for the difference in vitamin D effect magnitude is that HPV 
cancers have a different association with vitamin D than non-HPV cancers. Although it is likely to be 
true that vitamin D has a different association with HPV driven cancer, this does not imply that 
associations with vitamin D in non-HPV driven cancers are causal. It is just as likely that the 
confounding structures of these cancers are different. For example, HPV related cancer is more 
common in non-smokers than non-HPV related cancers and, as we have seen in the observational 
results in Chapter 4 and several previous studies, 121,122,125,126 the effect of vitamin D on HNC risk in 
non-smokers is close to the null. It may be that there is less residual confounding by smoking in HPV-
oropharyngeal cancers as less are driven by smoking. Unfortunately, there was not data on HPV 
related cancer in either the observational or MR studies in this thesis and so this could not be 
investigated further. 
9.1.1.3 Temporality 
Temporality is important when considering causality of vitamin D and cancer. The diagnosis of a HNC 
will almost certainly change patients’ lifestyle which may reduce time outside, alter diet and 
ultimately affect vitamin D levels. In this thesis, the design of both the observational and MR studies 
adequately deal with the concept of temporality. In the observational study, only incident cancers, 
after measurement of serum 25(OH)D, were included in the analysis. Furthermore, when assessing 
the effect of vitamin D on HNC stratified by time since blood draw there was no strong evidence of 
an attenuation of effect as the time since blood draw increased, as would be expected if there was a 
reverse causal effect of cancer on vitamin D. In the MR analyses, genetic proxies were used as 
measures of vitamin D and these genetic variants are unchanged by the process of cancer and are 
therefore unaffected by temporality. 
9.1.1.4 Dose-response relationship 
In the observational analyses, a dose-response relationship was investigated by assessing the 
association of vitamin D with HNC risk in quintiles of 25(OH)D. There was no evidence of a dose 
response relationship, with effect sizes consistent across all 25(OH)D quintiles. If the association 
between vitamin D and HNC was causal, the most likely intervention would be to increase serum 
25(OH)D with supplementation. The lack of a dose-response however, suggests that those with 
higher 25(OH)D are not at a lower risk and this does not support a causal relationship. MR analyses 
do not lend themselves to the investigation of dose-response relationships and so cannot provide 
further insight. 
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9.1.1.5 Plausibility and coherence 
The plausibility and coherence of the association between vitamin D and HNC risk was not 
investigated in this thesis. A summary of the evidence supporting the biological explanation for the 
association between vitamin D and HNC is provided in the introductory chapters. It is worth noting 
that there are likely to be many unknown aspects of the biological relationship and as these are 
discovered they may support or refute the association of vitamin D with HNC risk. 
9.1.1.6 Experimental evidence and analogy 
Experimental evidence can provide strong evidence of causality. In the introduction I have discussed 
why a randomised controlled trial specific for vitamin D in HNC would be problematic. It would be 
extremely expensive requiring large numbers and long follow up periods. However, MR can be 
considered a quasi-experimental method as long as its assumptions hold. The MR study of vitamin D 
on HNC risk in this thesis suggests that the effect estimates of vitamin D are likely smaller than those 
from the observational studies but more precise MR estimates are required to provide clarity. The 
risk of more common cancers such as colorectal cancers have been investigated in large RCTs of 
vitamin D supplementation with all results finding no strong evidence of a protective effect of 
supplementation.206,217 Given that the observational evidence for the association between vitamin D 
and colorectal cancer is considered much stronger than for HNCs,9 considering the concept of 
analogy an RCT of vitamin D supplementation for HNC risk would be unlikely to support a protective 
association. 
9.1.1.7 Triangulation of evidence 
Applying the Bradford-Hill criteria to the evidence presented in this thesis, it is not completely clear 
whether the association between vitamin D and HNC risk is causal. A triangulation approach to 
assessing causality involves assessing the strength and direction of the particular biases from each 
set of evidence and using this to help clarify if an association could be causal. In this thesis, there are 
two main sources of evidence, the prospective observational evidence and the MR evidence. 
As mentioned, neither method is likely to be affected by reverse causality. However, the 
observational study conducted in Chapter 4 and those that have gone before are likely to be 
affected by confounding. This is clearly demonstrated in Chapter 4, where effect estimates adjusted 
for confounders attenuate towards the null compared to the unadjusted effect estimates. This 
suggests the direction of the confounding for the variables corrected for in the regression models 
(ethnicity, smoking status, alcohol consumption frequency, highest educational attainment, BMI and 
latitude) is away from the null in a protective direction. Therefore, any residual confounding by 
these variables, not explained by their measurement, is likely to be acting in the same direction. The 
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magnitude of the residual confounding is unknown but there are several indications which may 
provide an approximation. Smoking is likely to be one of the main confounders in this association so, 
like in previous chapters, it will be used in these examples. 
Firstly, the Fanidi et al. study,126 recognised residual confounding by smoking as a potential issue. 
They used urinary cotinine, an objective measure of current smoking exposure in their regression 
analysis. In these analyses there was a very modest attenuation in effect size (OR = 0.54 unadjusted, 
OR = 0.55 cotinine adjusted) suggesting smoking at the time of 25(OH)D measurement was not a 
strong confounder of the vitamin D – HNC risk association. However, it is important to note that 
cotinine is only an objective measure of recent smoking (less than one week218) and so would not 
account for smoking history before this point. Future studies that wish to remove the effect of long-
term smoking should consider alternative measures of smoking such as epigenetic profiles, which 
have been demonstrated to predict previous smoking over longer periods.219 
Secondly, if smoking is to be considered the main confounder of the vitamin D – HNC risk association 
and there is limited mis-classification by self-reported current smoking (as indicated by the cotinine 
adjustment in the first point) then there should not be residual confounding by smoking status. 
However, it is unlikely that simply smoking or not smoking captures the true confounding effect of 
smoking and that the intensity and duration of smoking will play a large part. If this is true, there will 
be disparity across smoking strata as to the magnitude of the residual confounding effect. In true 
never-smokers there will be no error in the measurement of intensity or duration as both will be 
zero. In current smokers there will be a vast range of smoking intensities and durations and this will 
not be captured by the “current smoker” status and thus may lead to greater residual confounding 
in smokers than non-smokers. When considering an estimate of the causal effect from observational 
studies, the most robust estimate will be one with the least error in the measurement of the 
confounders and in the scenario above this would be the non-smoking strata. As highlighted in the 
introductory chapters121,122,125,126 and shown in Chapter 4, there is a consistent near-null effect of 
vitamin D on HNC risk in non-smokers which can be considered the best estimate of the causal effect 
from the observational work presented here. An alternative explanation to this is that vitamin D 
interacts with smoking to provide a protective effect but only in smokers. There is some weak 
evidence to support this in the observational study in Chapter 4 and the Fanidi et al. study126 but 
even with these relatively large samples there is limited power to distinguish an interaction from 
residual confounding.  
Finally, one of the main advantages of MR is that the effect estimate from this approach is largely 
unaffected by confounding. In this thesis, the genetic proxy used in the MR analyses has been 
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demonstrated to be unrelated to smoking in both the hypothesis free MR PheWAS analyses in 
Chapter 6 and in the MR study in Chapter 7, whereas the serum 25(OH)D measure was strongly 
associated with smoking status in both the observational study in Chapter 4 and the phenome wide 
scan in Chapter 6. The MR estimate therefore provides the best estimate of the unconfounded 
effect however, due to the issues of power the estimate is imprecise. Because of this, it is not 
completely clear where the unconfounded effect estimate lies but the comparison of effect 
estimates from this thesis suggests some degree of residual confounding as the MR estimates are 
consistently smaller in magnitude than the adjusted observational estimates. 
The issue of confounding is not limited to smoking. The phenome scans in Chapter 6 demonstrate 
that the serum 25(OH)D measure is strongly associated with a wide range of factors which may be 
causally related to HNC risk – either directly or by covariation with other causal factors. If this is the 
case, even if smoking is adequately corrected for, the observational effects will be confounded by 
these other, unmeasured, factors. Again, as demonstrated in the MR PheWAS, the genetic proxy of 
vitamin D was unrelated to these potential confounders and so the MR effect estimate is robust to 
them. 
Considering these examples, it is likely that the magnitude of residual confounding could be as large 
as the full observational effect size (as suggested by the observational estimate in non-smokers) but 
may be smaller than this (as demonstrated by the consistently smaller but imprecisely estimated MR 
effect sizes). 
When synthesising this evidence, I feel it is unlikely that low vitamin D can explain some of the 
recent patterns in HNC incidence or the unexplained population attributable risk discussed in 
Chapter 2. It seems doubtful that vitamin D supplementation provides genuine potential to reduce 
the risk of HNCs in the general public. It is still unclear whether vitamin D does have a causal 
association with HNC risk but if it does, the effect is likely to be small and potentially limited to 
specific groups, such as smokers or specific cancer types, such as oral or  non-HPV oropharyngeal 
cancers. Before an expensive population-wide intervention could be considered, robust evidence 
from intervention studies would be required but the work of this thesis suggests we do not have the 
required threshold of evidence for a RCT to be considered. A more sensible approach would be to 
conduct a well powered MR study to provide more precise minimally confounded estimates, before 
even considering a trial. I am involved with several projects that will allow a subsequent MR study 
with greater power and these projects are described in the future work section below. 
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9.1.2 Vitamin D and HNC prognosis 
9.1.2.1 Strength and consistency of evidence 
The observational effect of vitamin D on HNC prognosis is approximately a 33% reduction in hazards 
of death. Given the high mortality of HNCs, this relative effect corresponds to a clinically important 
outcome that would have clear benefit for patients if real. In observational studies, when assessing 
the effect on HNC-specific deaths, there is some attenuation of the effect size but the majority of the 
effect is driven by HNC-related deaths. However, MR estimates suggest this effect size is smaller 
than that reported in the observational work but these MR estimates are very imprecise due to the 
relatively small sample sizes. There is consistency of effect size between the observational study in 
Chapter 4 and the Fanidi et al.126 study but these are not consistent with the MR estimates which are 
smaller in size and, in the case of the UK Biobank MR estimate, in the opposite direction to the 
observational estimates. 
9.1.2.2 Temporality 
The temporality of the effect of vitamin D on HNC prognosis is important to consider. Several studies 
discussed in the introduction used 25(OH)D measures at diagnosis and there is the potential that the 
process of cancer will be affecting 25(OH)D levels in these studies. In this thesis, I use pre-diagnosis 
25(OH)D levels to avoid this issue in the observational analyses. Furthermore, in stratifying by time 
from blood draw to diagnosis, I was able to assess if undiagnosed cancer was potentially having an 
effect on 25(OH)D levels. In these stratified analyses, the effect of vitamin D on HNC prognosis 
completely attenuated in those with vitamin D measures more than six years before diagnosis, 
which may be evidence that HNC is lowering 25(OH)D levels. However, in this greater than six-year 
strata, there are few participants and very few deaths limiting power to reliably detect an effect. 
Additionally, if there is a true causal relationship between 25(OH)D and HNC prognosis, a single 
measure of 25(OH)D greater than six years before diagnosis is unlikely to represent a valid measure 
of 25(OH)D during the HNC cancer process and this would also explain the null result in this stratum. 
Similar to HNC risk, the vitamin D proxy measure used in MR analyses is unaffected by the cancer 
process and estimates from MR should be robust to it. 
9.1.2.3 Dose-response relationship 
There is limited evidence from this thesis that there is a dose response relationship between vitamin 
D and HNC prognosis. The Fanidi et al.126 study did model the effect of increasing 25(OH)D on the 
hazards of all-cause mortality and this demonstrated a U-shaped association with both very low and 
very high levels of 25(OH)D being associated with greater hazards of dying. This U-shaped 
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association was not investigated in this thesis but is not necessarily supported by current biological 
understanding. 
As in the case of HNC risk, it is unclear from the work in this thesis whether a causal relationship 
does exist between vitamin D and HNC prognosis partly due to limited power from MR analyses. 
However, unlike for HNC risk, there does appear to be potential clinical utility if a causal association 
exists. For that reason, it is important that this topic is revisited in better powered observational 
studies and MR studies with approaches that are specific to the application on MR in case only data. 
Some of these approaches which I am involved in are discussed below. 
9.2 Strengths and limitations 
9.2.1 Power 
In this thesis there was generally sufficient power for observational approaches, particularly in the 
assessment of the association with HNC risk. In these approaches, stratification by certain key 
factors was possible allowing heterogeneity between smoking strata to be identified. Power was  
moderate in observational studies of prognosis meaning there was limited inference from results 
stratified by site or potential confounders. 
In the GWAS analyses, there was good power to detect common genetic variants with moderate to 
large associations with 25(OH)D and two novel associations were identified which were later 
replicated in a larger GWAS. One of the aims of the GWAS was to identify lower frequency variants 
with larger effects and one such variant was identified which had a large effect on 25(OH)D. Other 
variants of similar frequency may exist but are likely to have smaller effects. There was limited 
power to identify these variants.  
Despite the discoveries in Chapter 5, there are few genetic variants which can be used as reliable 
genetic proxies of 25(OH)D which has two implications in MR analyses. Firstly, the genetic proxy 
explains a small amount of the variance in 25(OH)D limiting the power for MR. Secondly, with few 
variants many of the MR approaches which have been designed to be robust to pleiotropy are 
underpowered and would be uninformative. The power in MR studies also relies heavily on the size 
of the outcome sample and very large HNC datasets are currently unavailable. Work I am 
contributing to which will hopefully address both these power issues is described in the Future Work 
section below. 
9.2.2 Head and neck cancer data 
As mentioned in the section above there is limited HNC data available for approaches such as MR 
which required very large sample sizes. Collaborative efforts such as the International Head and 
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Neck Cancer Epidemiology Consortium (INHANCE), a collaboration of over 40 studies with 
approximately 40,000 cases and a similar number of controls, do provide an opportunity to conduct 
large observational studies but there is limited recording of phenotypes such as vitamin D across 
these collections. If genetic data are available on samples of this size, MR will allow a range of 
potential risk and prognostic factors to be investigated even if they are not measured across these 
studies. However, many of the studies contributing to the INHANCE consortium are relatively old 
and genotyping in newer collections such as HN5000 should be encouraged.   
9.2.3 Vitamin D genetic proxy 
In this thesis MR is used to estimate the causal effect of vitamin D on HNC risk and prognosis. For the 
MR estimates to be valid, the genetic proxy for vitamin D must not violate the three core MR 
assumptions. I will discuss each of these three assumptions below in the context of this thesis 
highlighting where limitations or potential violation exist and how future work may be able to 
overcome these. 
9.2.3.1 The relevance assumption 
The relevance assumption relates to the genetic proxy being robustly associated with the exposure 
of interest, here vitamin D or more specifically serum 25(OH)D levels. Under this assumption there 
are two aspects that should be considered, the strength of the association between the proxy and 
the exposure and the appropriateness of the proxy for that exposure. 
In this thesis I have demonstrated that the seven genetic variants used as proxy measures of vitamin 
D are strongly and consistently associated with 25(OH)D. This is demonstrated in Chapter 5 where in 
the GWAS, the four previously identified 25(OH)D genetic variants showed strong associations with 
25(OH)D and the three novel variants passed the genome-wide threshold in the meta-analysis and 
were consistent in the direction of effect across the 19 studies. The relevance assumption was also 
tested in Chapter 6 and Chapter 8, where the genetic variants were combined into a GRS and shown 
to have very strong associations with 25(OH)D in an independent sample, UK Biobank. The strength 
of a genetic proxy is often discussed in terms of the F-statistic which depends on both the 
percentage of variance in the exposure explained and the sample size where the association is being 
tested. The smallest sample where the GRS was assessed for its strength to proxy 25(OH)D was in 
the prognosis MR analyses in Chapter 8. Even in this relatively small sample the genetic proxy had an 
F-statistic of 28.2 and would seem strong enough to exclude weak instrument bias. Despite this 
strength, the genetic proxy only accounted for between 3% and 5% of the variance in 25(OH)D. 
Although this is large for the relatively low number of genetic variants used in the GRS, this means 
that power for MR analyses is low as discussed above. 
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The second important point to consider is the appropriateness of the genetic proxy for investigating 
the association between 25(OH)D and HNC risk and prognosis. The previously identified genetic 
variants, and the low-frequency variant identified in Chapter 5, which were used as proxies in this 
thesis, are in or near genes that are close to vitamin D related biology. Although it must be 
considered that being physically close to a gene is no guarantee that the variant affects that gene, it 
does support the relevance assumption as there is biological plausibility for how these variants could 
influence serum 25(OH)D. The two novel common variants identified in Chapter 5 have less clear 
links with vitamin D biology but were successfully replicated in a subsequent GWAS193 and at least 
one of these may be involved in the utilisation of UV light in the skin which again demonstrates a 
biologically plausible mechanism for influencing serum 25(OH)D. 
Despite the GRS being a strong proxy of serum 25(OH)D levels it must be considered whether this is 
appropriate for investigating the effect of vitamin D in HNC risk and prognosis. As highlighted in the 
introduction, serum 25(OH)D assays measure total 25(OH)D, a combination of free 25(OH)D and 
bound (to vitamin D binding protein (DBP) and albumin) 25(OH)D. Additionally, the GRS is a proxy for 
25(OH)D and not the active metabolite, 1,25(OH)2D. It is not completely clear whether a proxy of the 
total inactive form is suitable when investigating the effect of vitamin D on cancer, as it has been 
demonstrated that the anti-cancer effects are via free-1,25(OH)2D acting at the tissues.133 Despite 
these points, the most common form of vitamin D intervention is by supplementation with 25(OH)D, 
which will act to increase total 25(OH)D in the first instance. Therefore, in order to estimate the 
effects of this intervention using MR, it makes sense to have a genetic proxy which has the same 
influence. However, there is one genetic proxy used in this thesis which may be problematic even 
when trying to mirror 25(OH)D supplementation, this is discussed below. 
In the kidney, 25(OH)D is transported into the cell using a megalin-mediated transport system, 
bound to DBP. It is likely that the effect of vitamin D on cancer is extra-renal and, outside of the 
kidney, 25(OH)D is likely to enter the cell in its free state and therefore there is controversy within 
the field as to whether the total or free level is the most important.68 Although there is strong 
evidence to suggest free and total levels are highly correlated, it may be that the amount of DBP and 
its affinity to bind free 25(OH)D, dictates the availability of free 25(OH)D at peripheral sites such as 
the oral cavity and oropharynx. If this is the case an increase in DBP or its affinity for 25(OH)D will 
increase total 25(OH)D but may limit how much free 25(OH)D is available to provide the potential 
anti-cancer actions at the tissue level. 
This issue is important because the genetic variant in GC (rs3755967) used as a proxy in this thesis 
has been linked with altered levels of DBP and binding affinity for 25(OH)D178 and this may be 
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problematic. When GC variants are included in the genetic proxy which increase DBP concentration 
or its affinity for 25(OH)D, they will be robustly associated with increased total 25(OH)D as more 
25(OH)D will be bound and therefore captured by the assay. However, this may also result in 
reduced free 25(OH)D at the peripheral tissues as more is in the bound form, particularly when 
25(OH)D levels are low.69 If so, the effect of the GC variant on free vitamin D may be in the opposite 
direction to that of total 25(OH)D and therefore GC may not be a suitable variant for the purposes of 
investigating the effect of 25(OH)D on cancer. 
To assess the potential impact of this issue, leave-one-out approaches can be informative. Across 
the MR studies in this thesis, leaving the GC variant out does not impact the MR estimates in a 
consistent and systematic way. This indicates above GC issues are not influencing the causal 
estimates. Finally, megalin-mediated transport in extra-renal tissues such as the breast220 and 
prostate221 has been discovered so there is the potential that this transport process is also occurring 
in the oral and oropharyngeal mucosal cells which reduce the impact of this concern with the GC 
variant. 
9.2.3.2 The independence assumption 
The independence assumption relates to the genetic proxy being unrelated to potential confounders 
of the exposure – outcome association. In situations where this assumption is violated, the effect 
estimate can be biased in a similar way to a confounded observational effect estimate. 
In this thesis, I have demonstrated that the vitamin D genetic proxy is unrelated to the measured 
confounders in the two MR chapters (Chapter 7 and Chapter 8) but have gone further than this by 
conducting the MR PheWAS in Chapter 6. In Chapter 6, I showed that compared to the serum 
25(OH)D measure, the vitamin D GRS is unrelated to other factors in the UK Biobank study including 
phenotypes that would be the most likely confounders of the vitamin D – HNC risk and prognosis 
association such as smoking and alcohol use. 
In Chapter 7, there was some evidence that the GRS was associated with geographic region and this 
may be a result of population stratification which was not accounted for by the addition of genetic 
principal components in the regression model. This population stratification could lead to a violation 
of the independence assumption and to account for this, analyses were repeated removing 
individuals from this geographic region in sensitivity analyses. 
The independence assumption relies on genetic variants being randomly allocated at gamete 
formation and segregation in the population of interest. Where an ascertained population is under 
investigation this may not hold and the independence assumption may be violated. In Chapter 8, a 
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case only sample of HNC patients was selected. In this selected sample, the vitamin D genetic 
variants will not be randomly distributed with respect to confounders, if vitamin D (and hence those 
genetic variants) causally influence whether an individual develops HNC. As detailed above, it is not 
completely clear whether vitamin D is a cause of HNC so the implication of ascertainment or collider 
bias is unknown in the MR analyses assessing the association of vitamin D on HNC prognosis. In 
Chapter 8, I was able to compare GRS – confounder associations in both the unselected and selected 
samples to assess whether they differed. The strategy of comparing the effect of genetic variants in 
selected and un-selected populations is likely to be informative in future case-only MR analyses by 
allowing the identification of genetic variants that may lead to collider bias. These approaches may 
also be able to be extended so that they can correct for any identified bias. 
9.2.3.3 The exclusion restriction assumption 
The exclusion restriction assumption relates to the genetic proxy acting on the outcome only 
through the exposure of interest and not via alternative pathways. As mentioned this is hard to 
assess particularly when there are few genetic variants included as proxy measures. 
As mentioned above, the majority of the genetic variants are near or within genes that are involved 
in vitamin D related pathways but this is no guarantee that they are acting on that gene or not acting 
on other (horizontally) pleiotropic pathways. For example, the DHCR7 genetic variant used in this 
thesis (rs12785878) codes for the protein responsible for converting 7-dehydrocholesterol into 
cholesterol, therefore removing it from the vitamin D synthesis pathway. It might be expected that 
this variant also has roles in other cholesterol related pathways and therefore may be pleiotropic. 
However, in this example this is unlikely to be the case as it has been shown that the DHCR7 variant 
is not related to cholesterol levels in at least two well conducted studies.222,223 This example 
demonstrates how difficult it would be to rule out all potential pleiotropic pathways. In reality, we 
will only look for evidence of pleiotropy in biologically plausible pathways but this relies on adequate 
knowledge of such pathways. Furthermore, if potentially pleiotropic pathways are selected we also 
need the availability of correct data and adequate power to detect if a potential pleiotropic 
association is real. 
MR sensitivity approaches which estimate causal effects which are robust to pleiotropy have been 
developed and provide a more realistic way of identifying the presence of pleiotropy.150,151 
Unfortunately, these methods have little power when only a small number of genetic variants are 
available as proxies for the exposure of interest. As discussed below, future effects to identify more 
genetic proxies of vitamin D will increase the number of genetic variants allowing these approaches 
to be used to assess the presence of pleiotropy. 
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9.3 Next steps 
Despite this thesis adding to the body of evidence assessing the association between vitamin D and 
HNC, the MR aspects of the thesis would benefit from improved genetic proxies for vitamin D and 
larger genotyped HNC resources. During the latter part of this thesis, I have been working to 
establish these to further the investigation of the vitamin D – HNC association. Below I briefly 
describe these projects.  
9.3.1 GWAS of 25(OH)D in UK Biobank 
I am currently contributing to a meta-analysis of the GWAS in Chapter 5 with a new GWAS analysis 
of 25(OH)D in UK Biobank. This work which has a sample size of over 400,000 participants has 
potentially identified over 100 novel 25(OH)D related variants. This work will have two impacts on 
future MR studies assessing the effect of vitamin D on HNC. Firstly, these novel variants can be 
included in the genetic proxy of vitamin D and will increase the proportion of variance explained 
directly improving power for MR analyses. Secondly, a larger number of variants will allow the use of 
pleiotropy robust MR approaches. 
9.3.2 Genotyped HNC resources 
I have been involved in two projects which aim to increase the size of HNC case – control datasets 
with genome-wide genetic coverage. In the first of these I have obtained funding to complete 
genotyping of over 2,500 HNC (oral, oropharyngeal and laryngeal cancers) cases from HN5000 and 
to perform technical validation checks so that these cases can be linked to over 10,000 population-
based controls. In the second project I have worked closely with collaborators at the International 
Agency for Research on Cancer (IARC) to obtain funding to genotype a further 5,351 HNC cases and 
4,351 controls. 
These two projects are run in parallel and when combined with the previously genotyped HNC 
datasets (described as GAME-ON in this thesis) there will be over 14,000 cases and 26,000 controls. 
This more than doubles the sample size which will be available for MR analyses of HNC risk and will 
also include a large number of laryngeal cancer samples, allowing MR analyses of this cancer site for 
the first time. 
MR analyses of HNC prognosis will also benefit from the above projects. All of the HNC cases that are 
newly genotyped and some of the samples in the GAME-ON genotyping round have high quality 
follow-up data. In total there will be at least 8,000 HNC cases with genetic and follow up data. 
The genotyped HNC resources discussed here not only provide the opportunity to conduct MR 
analyses assessing the effect of vitamin D on HNC risk and prognosis but also any other exposure 
which has valid genetic proxies. 
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9.4 Concluding remarks 
In summary, this thesis cannot rule out small effects of 25(OH)D on HNC risk but suggests that 
effects as large as those reported in observational studies are unlikely. Given this, it would not be a 
sensible strategy to pursue a RCT of 25(OH)D supplementation unless more precise MR estimates 
suggest clinically relevant causal effects. The effect of 25(OH)D prognosis may be more clinically 
important, as even small effects will have clinical benefit but, larger samples and more established 
MR approaches are required before causality can be established using the methods in this thesis. 
The genetic proxy for 25(OH)D has been improved by the work of this thesis but questions remain 
about how appropriate a genetic proxy for 25(OH)D may be in studies of cancer. Future work will 
help to improve power in both studies of HNC risk and prognosis by further improving the genetic 
proxy for vitamin D and increasing the size of genotyped HNC resources.
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Appendix 4.1: Odds ratio for HNC across quintiles of 25 hydroxyvitamin D. 
A      B 
   
 
C      D 
 
A = All HNC sites, B = Oral cavity cancer, C = Oropharyngeal cancer, D = Laryngeal cancer. Levels = quintiles of 
























































































































































Detection limits for 
25OHD measurement 
ALSPAC 
Imp HRC SNPtest v2.5.0 1.0133 8247588 3679 HPLC/Tandem mass spec 
64.2 
(23.5) 9.8 (1.3) 17.6 (2.8) 1909/1770 2.5 to 624 nmol/L 
ALSPAC 
WGS - SNPtest v2.5.0 0.999 9886094 1606 HPLC/Tandem mass spec 
61.8 
(19.9) 10.1 (0.8) 17.6 (2.9) 789/817 2.5 to 624 nmol/L 
BPROOF UK10K/1000G GEMMA 0.9991 9857390 2514 SLC-MS/Ms/tandem mass spec 56.2(24.6) 73.5(6.5) 27.1 (4.0) 1271/1243 
The inter-assay 
coefficient of variation 
was 9% at 25 nmol/L 
and 6% at 62.4 nmol/L 
MROS UK10K/1000G GEMMA 1.0111 10012764 3266 Mass spec 
62.1 
(20.8) 74.1(5.8) 27.4(3.8) 3266/0 1.6nmol/L 
TUK 
Imputed UK10K/1000G GEMMA 1.0076 9614367 1920 
chemiluminescence immunoassay 
(DIASORIN) 76.5(42.4) 49.2(13.8) 25.5(4.8) 1744/176 4 to 10 nmol/L 






(11.7) 25.3 (4.8) 953/0 4 to 10 nmol/L 
CHS 1000G Custom R program 0.9951 8569308 1792 HPLC/Tandem mass spec 
66.6 
(27.0) 74.1(4.7) 26.4(4.5) 1250/542 2.0 to 200 nmol/L 




(19.7) 70.1 (0.2) 27.0(4.4) 471/472 10 nmol/L 
ULSAM HRC SNPTEST 0.9949 8879176 1095 HPLC-APSI-MS 
68.7 
(19.1) 71.0 (0.6) 26.3(3.4) 1095/0 1 to 4 nmol/L 
NEO 1000G PROBABEL 1.0146 8454808 5744 LC-MS/MS  
68.9 
(23.6) 56.0 (5.9) 30.0 (4.8) 2757/2987 1.6nmol/L 
MROS 




(24.3) 75.6 (3.2) 26.5 (3.6) 893/0 10 nmol/L 
MROS GBG UK10K/1000G PLINK 1.015 10311274 947 
chemiluminescence immunoassay  
DIASORIN) 
66.7 
(18.8) 75.2 (3.2) 26.2 (3.5) 947/0 10 nmol/L 




(21.7) 18.9 (0.6) 22.4 (3.2) 921/0 10 nmol/L 
BMDCS  UK10K GEMMA 1.0032 9537533 863 Tandem mass spec  
49.3 
(15.4) 14.9 (4.7) 21.1 (4.1) 420/443 1.6-285 nmol/L 






(13.1) 27.0 (5.3) 2539/2863 4 to 10 nmol/L 
Generation 
R UK10K/1000G SNPTEST 1.0222 9555270 1442 LC-MS/MS 
76.5 
(26.4) 6.11(0.4) 15.9(1.5) 731/711 4 nmol/L 
RSI UK10K/1000G SNPTEST 1.0117 9540518 3320 
electrochemiluminescence immunoassay 
(COBAS, Roche Diagnostics GmbH) 
49.4 
(25.3) 73.4 (7.6) 26.9(4.0) 1390/1930 3 nmol/L 
RSII UK10K/1000G SNPTEST 0.9936 9554142 2022 
electrochemiluminescence immunoassay 
(COBAS, Roche Diagnostics GmbH) 62.4(28.3) 64.7(8.0) 27.3(4.0) 919/1103 3 nmol/L 
RSIII UK10K/1000G SNPTEST 1.0037 9558464 2913 
electrochemiluminescence immunoassay 
(COBAS, Roche Diagnostics GmbH) 61.9(27.6) 57.1(6.8) 27.7(4.6) 1277/1636 3 nmol/L 
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Appendix 5.2: Participating Cohorts: study designs and locations 
Short name Full name Study design Study Type Country of Origin Ethnicity 
ALSPAC The Avon Longitudinal Study of Parents and Children Cohort Population-based, family-based United Kingdom North-western European 
TUK TwinsUK Cohort Population-based, family-based United Kingdom North-western European 
FHS Framingham Heart Study Cohort Population-based, family-based United States of America European American 
MrOS Osteoporotic Fractures in Men USA Cohort General population United States of America Non-Hispanic white 
BPROOF 
B-Vitamins for the PRvention Of Osteoporotic 
Fractures Cohort Population-based, family-based     
MrOS GBG Osteoporotic Fractures in Men Gothenburg Cohort Population-based Sweden North-western European 
MrOS MALMO Osteoporotic Fractures in Men Malmo Cohort Population-based Sweden North-western European 
GOOD Gothenburg Osteoporosis and Obesity Determinants Cohort Population-based Sweden North-western European 
CHS Cardiovascular Health Study Cohort Population-based United States European American 
RSI Rotterdam Study-I Cohort Population-based, family-based The Netherlands North-western European 
RSII Rotterdam Study-II Cohort Population-based, family-based The Netherlands North-western European 
RSIII Rotterdam Study-III Cohort Population-based, family-based The Netherlands North-western European 
PIVUS 
Prospective Investigation of the Vasculature in Upssala 
Seniors Cohort 
Population-based sample from the general 
population Sweden North-western European 
ULSAM Upssala Longitudinal Study of Adult Men Cohort 
Population-based sample from the general 
population Sweden North-western European 
Generation R The Generation R Study Cohort Population-based, family-based The Netherlands Admixed 
BMDCS Bone Mineral Density in Childhood Study Cohort population-based United States of America European American 
NEO Netherlands Epidemiology of Obesity Cohort 
Population-based, oversampling of 
individuals with overweight The Netherlands European American 





Appendix 5.3: Metrics for Sequencing-Based Cohorts 






Variant QC Calling 
method 
Additional variant QC 
filters pre-association 






1934 6x Singletons 
included 
VQSR (with standard 
GATK parameters), only 





Subsequent to conversion 
to binary GEN format, 
variants were filtered by 
removing variants with 
INFO < 0.4 and HWE p-
value < 1e-6. 






1976 6x Singletons 
included 
VQSR (with standard 
GATK parameters), only 





Subsequent to conversion 
to binary GEN format, 
variants were filtered by 
removing variants with 
INFO < 0.4 and HWE p-




Appendix 5.4: Info Scores for Imputed SNVs per Participating Cohort 
Cohort  Imputation reference panel Average Info Score 
Average Info score according to MAF Number of SNVs according to MAF 
0.5%-1% 1%-5% >5% 0.5%-1% 1%-5% >5% total 
ALSPAC Imputed HRC 0.953898 0.86779 0.929003 0.983156 1039739 2240923 4966926 8247588 
BMDCS UK10K 0.9337 0.813959 0.8921 0.97537 1170457 2508752 5864874 9544083 
BPROOF UK10K/1000G 0.903492 0.761488 0.851148 0.957815 1269564 2683536 5904456 9857556 
CHS 1000G 0.861307 0.695624 0.764028 0.912802 636475 1989577 5806416 8432468 
FHS UK10K/1000G 0.901056 0.761261 0.856422 0.952144 1308922 2515245 5779103 9603270 
GenerationR UK10K/1000G 0.991865 0.99749 0.993785 0.979851 1065474 2130392 2963012 6158878 
GOOD UK10K/1000G 0.963843 0.855494 0.930359 1.00184 1365394 2699130 6272408 10336932 
MrOS UK10K/1000G 0.906883 0.777368 0.843646 0.958579 1057189 2608734 5839794 9505717 
MROS MALMO UK10K/1000G 0.969319 0.861881 0.93872 1.00542 1338140 2691611 6262995 10292746 
MROS GBG UK10K/1000G 0.973695 0.871793 0.945207 1.00796 1350188 2700557 6260530 10311275 
NEO 1000G 0.860829 0.67615 0.778314 0.924774 900228 2163238 5391343 8454809 
PIVUS HRC 0.963494 0.883933 0.94073 0.989421 1096722 2326148 5407710 8830580 
RSI UK10K/1000G 0.992253 0.997564 0.99386 0.980092 1106406 2065041 2828682 6000129 
RSII UK10K/1000G 0.991956 0.997524 0.993753 0.979589 1103454 2099961 2883101 6086516 
RSII UK10K/1000G 0.992352 0.997571 0.993931 0.980243 1092398 2042174 2826194 5960766 
TUK Imputed UK10K/1000G 0.936431 0.830858 0.89187 0.973654 923412 2599834 5731415 9254661 
USLAM HRC 0.976243 0.913023 0.963587 0.994818 1122991 2339719 5416466 8879176 
MAF = minor allele frequency  
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        P-value beta P-value 
rs2282679 G 0.28 GC 1.9x10-109 -0.25 2.6 x10-258 
rs12785878 G 0.3 DHCR7 2.1x10-27 -0.1 3.2 x10-40 
rs10741657 G 0.58 CYP2R1 3.3x10-20 -0.09 8.8x10-45 
rs6013897 A 0.21 CYP24A1 6.0 x10-10 -0.07 9.1x10-16 
*effect allele is the 25OHD decreasing allele  
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Appendix 5.6: Haplotype Counts in the ALSPAC WGS Study for the Six SNVs of the Same Chromosome 11 Locus. 
N of chromatids 
Gene/SNV 
PDE3B PDE3B PDE3B PDE3B PDE3B CYP2R1 
all chromatid2 chromatid1 rs117672174 rs142830933 rs117621176 rs117361591 rs116970203 rs117913124 
7341 1516 1605 C A A G G G 
111 51 0 C A A G A A 
75 37 1 T C G T A A 
14 1 0 C C G T A A 
1 1 0 T C G T G A 
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Appendix 6.1: Top 50 results (by p-value) for observational 25(OH)D phenome scan 
varName varType n beta lower upper P resType description 
48 CONTINUOUS 306489 -0.175754407 -0.178803462 -0.172705353 0 LINEAR Waist circumference 
49 CONTINUOUS 306451 -0.157643996 -0.161148576 -0.154139415 0 LINEAR Hip circumference 
670-1 CAT-SIN 279740/306249 -999 -999 -999 0 MULTINOMIAL-LOGISTIC Type of accommodation lived in 
680-1 CAT-SIN 165316/303268 -999 -999 -999 0 MULTINOMIAL-LOGISTIC Own or rent accommodation lived in 
728 CAT-SIN 305191 0.256794482 0.249967627 0.263621338 0 ORDERED-LOGISTIC Number of vehicles in household 
864 INTEGER 302066 0.135211317 0.128596412 0.141826222 0 ORDERED-LOGISTIC Number of days/week walked 10+ minutes 
884 INTEGER 292622 0.188947452 0.182424402 0.195470502 0 ORDERED-LOGISTIC Number of days/week of moderate physical activity 10+ minutes 
904 INTEGER 292796 0.307301383 0.300464504 0.314138263 0 ORDERED-LOGISTIC Number of days/week of vigorous physical activity 10+ minutes 
924 CAT-SIN 305360 0.227605588 0.220426912 0.234784263 0 ORDERED-LOGISTIC Usual walking pace 
102 INTEGER 289255 -0.150934017 -0.154536185 -0.147331849 0 LINEAR Pulse rate, automated reading 
189 CONTINUOUS 306624 -0.122308471 -0.125827624 -0.118789318 0 LINEAR Townsend deprivation index at recruitment 
914 INTEGER 168444 0.100654627 0.095594106 0.105715148 0 LINEAR Duration of vigorous activity 
1418-2 CAT-SIN 200299/306835 -999 -999 -999 0 MULTINOMIAL-LOGISTIC Milk type used 
1428-3 CAT-SIN 164383/306685 -999 -999 -999 0 MULTINOMIAL-LOGISTIC Spread type 
1050 INTEGER 279370 0.272977265 0.265555694 0.280398836 0 ORDERED-LOGISTIC Time spend outdoors in summer 
1090 INTEGER 204779 0.16487138 0.15666761 0.17307515 0 ORDERED-LOGISTIC Time spent driving 
1239 CAT-SIN 306826 -0.296045976 -0.307381124 -0.284710829 0 ORDERED-LOGISTIC Current tobacco smoking 
1329 CAT-SIN 305626 0.192251789 0.185643682 0.198859897 0 ORDERED-LOGISTIC Oily fish intake 
1558 CAT-SIN 306770 -0.156142573 -0.162560472 -0.149724674 0 ORDERED-LOGISTIC Alcohol intake frequency. 
1717 CAT-SIN 303242 0.231474636 0.223436374 0.239512898 0 ORDERED-LOGISTIC Skin colour 
1727 CAT-SIN 301139 -0.287464016 -0.294138657 -0.280789374 0 ORDERED-LOGISTIC Ease of skin tanning 
2050 CAT-SIN 294320 -0.174462601 -0.182984364 -0.165940838 0 ORDERED-LOGISTIC Frequency of depressed mood in last 2 weeks 
2060 CAT-SIN 297464 -0.19738052 -0.206215313 -0.188545726 0 ORDERED-LOGISTIC Frequency of unenthusiasm / disinterest in last 2 weeks 
2080 CAT-SIN 298262 -0.213030766 -0.220017353 -0.206044179 0 ORDERED-LOGISTIC Frequency of tiredness / lethargy in last 2 weeks 
2188 CAT-SIN 202852/97316(300168) -0.193801949 -0.201567342 -0.18604043 0 LOGISTIC-BINARY Long-standing illness, disability or infirmity 
2316 CAT-SIN 239762/61889(301651) -0.177903734 -0.186605653 -0.16920025 0 LOGISTIC-BINARY Wheeze or whistling in the chest in last year 
2443 CAT-SIN 291189/15096(306285) -0.308404292 -0.323702047 -0.293074295 0 LOGISTIC-BINARY Diabetes diagnosed by doctor 
2178 CAT-SIN 305934 -0.294071875 -0.301144621 -0.286999129 0 ORDERED-LOGISTIC Overall health rating 
2267 CAT-SIN 305323 0.159430799 0.15272301 0.166138588 0 ORDERED-LOGISTIC Use of sun/uv protection 
2277 INTEGER 289968 1.029646469 1.007372112 1.051920826 0 ORDERED-LOGISTIC Frequency of solarium/sunlamp use 
3062 CONTINUOUS 279762 0.070531398 0.067841152 0.073221643 0 LINEAR Forced vital capacity (FVC) 
3063 CONTINUOUS 279762 0.069737647 0.066985902 0.072489392 0 LINEAR Forced expiratory volume in 1-second (FEV1) 
3064 INTEGER 279762 0.065110813 0.06209445 0.068127176 0 LINEAR Peak expiratory flow (PEF) 
3143 CONTINUOUS 177345 -0.103598869 -0.107618772 -0.099578966 0 LINEAR Ankle spacing width 
3637 CAT-SIN 147724 0.211638156 0.201613089 0.221663223 0 ORDERED-LOGISTIC Frequency of other exercises in last 4 weeks 
4194 INTEGER 99605 -0.145886783 -0.152122018 -0.139651547 0 LINEAR Pulse rate 
4717 CAT-SIN 88851/10215(99066) -0.388752912 -0.408579652 -0.368929006 0 LOGISTIC-BINARY Shortness of breath walking on level ground 
4548 CAT-SIN 100348 -0.26728787 -0.27946725 -0.255108491 0 ORDERED-LOGISTIC Health satisfaction 
6141#1 CAT-MUL 77190/228009(305199) 0.263728018 0.2555961 0.271864664 0 LOGISTIC-BINARY How are people in household related to participant: Husband, wife or partner 
6142#2 CAT-MUL 192885/113233(306118) 0.216318398 0.20534117 0.227305726 0 LOGISTIC-BINARY Current employment status: Retired 
6142#4 CAT-MUL 295010/11108(306118) -0.370747378 -0.387704492 -0.353748459 0 LOGISTIC-BINARY Current employment status: Unable to work because of sickness or disability 
6143#3 CAT-MUL 130255/33034(163289) -0.228728321 -0.240614883 -0.216845675 0 LOGISTIC-BINARY Transport type for commuting to job workplace: Public transport 
6145#6 CAT-MUL 271610/33858(305468) -0.280661302 -0.291602496 -0.269715927 0 LOGISTIC-BINARY Illness, injury, bereavement, stress in last 2 years: Financial difficulties 
6146#100 CAT-MUL 17170/287882(305052) 0.320633608 0.306385723 0.334859128 0 LOGISTIC-BINARY Attendance/disability/mobility allowance 
6146#2 CAT-MUL 292206/12846(305052) -0.34646434 -0.362409564 -0.330483965 0 LOGISTIC-BINARY Attendance/disability/mobility allowance: Disability living allowance 
6155#100 CAT-MUL 95200/210619(305819) -0.415549718 -0.424054816 -0.40705948 0 LOGISTIC-BINARY Vitamin and mineral supplements 
6155#7 CAT-MUL 240196/65623(305819) 0.478724694 0.468930364 0.488538765 0 LOGISTIC-BINARY Vitamin and mineral supplements: Multivitamins +/- minerals 
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Appendix 7.1: Mean (+/- standard deviation) and range of relative 25-hydroxyvitamin D across 















































































































Appendix 8.1: Methods for HNC prognosis GWAS 
Studies 
Head and neck 5000 
HN5000 is a large collection of HNC cases with detailed phenotyping and follow-up. An overall 
description of the HN5000 study is provided in Chapter 3. 
UK Biobank 
UK Biobank is a population-based study of approximately 500,000 participants. A detailed 
description of UK Biobank study is provided in Chapter 3. 
DNA extraction genotyping and imputation 
DNA extraction, genotyping and imputation for UK Biobank and HN5000 is described in Chapter 3. 
Follow-up of HNC cases 
Cancer cases were followed up in both studies using death registry data to identify the date of 
death. All-cause mortality was identified from death registry data as a death of a participant from 
any cause. Due to the limited sample size (UK Biobank) and data-availability (HN5000), HNC-specific 
cause of death was not assessed in this study. 
Survival time was calculated from date of diagnosis to date of death. Those participants alive at the 
end of follow up were censored. Censoring was on 31st March 2018 in HN5000 (last data capture 
from death registry) and 14th February 2018 in UK Biobank (last recorded death in the UK Biobank 
data freeze used for this study). 
Statistical analysis 
GWAS analysis 
A GWAS was conducted for HNC survival in HN5000 and UK Biobank separately using the 
SurvivalGWAS_Sv program.212 This program applies a Cox proportional hazards regression model at 
each genetic variant. The number of risk alleles at each variant was used as the exposure and time to 
event data for all HNC sites combined was used as the outcome, age and sex were used as covariates 
in the regression model. A large number of genetic variants in both studies have minor allele 
frequencies less than 1%. Due to the relatively small sample sizes available these low frequency 
alleles would not be present in enough cases to allow meaningful analyses and were removed prior 
to running the GWAS. Genetic variants with imputation quality scores less than 0.3 were also 




Results from the two studies were meta-analyses using a fixed effect in GWAMA.187 This approach 
includes automated quality control steps which identify strand problems, incorrect alleles, 
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Vitamin D insufficiency is common, correctable, and influenced by genetic factors, and it has been associated with risk of several dis-
eases. We sought to identify low-frequency genetic variants that strongly increase the risk of vitamin D insufficiency and tested their
effect on risk of multiple sclerosis, a disease influenced by low vitamin D concentrations. We used whole-genome sequencing data
from 2,619 individuals through the UK10K program and deep-imputation data from 39,655 individuals genotyped genome-wide.
Meta-analysis of the summary statistics from 19 cohorts identified in CYP2R1 the low-frequency (minor allele frequency ¼ 2.5%) syn-
onymous coding variant g.14900931G>A (p.Asp120Asp) (rs117913124[A]), which conferred a large effect on 25-hydroxyvitamin D
(25OHD) levels ("0.43 SD of standardized natural log-transformed 25OHD per A allele; p value ¼ 1.5 3 10"88). The effect on 25OHD
was four times larger and independent of the effect of a previously described common variant near CYP2R1. By analyzing 8,711 indi-
viduals, we showed that heterozygote carriers of this low-frequency variant have an increased risk of vitamin D insufficiency (odds ratio
[OR]¼ 2.2, 95% confidence interval [CI]¼ 1.78–2.78, p¼ 1.263 10"12). Individuals carrying one copy of this variant also had increased
odds of multiple sclerosis (OR ¼ 1.4, 95% CI ¼ 1.19–1.64, p ¼ 2.63 3 10"5) in a sample of 5,927 case and 5,599 control subjects.
In conclusion, we describe a low-frequency CYP2R1 coding variant that exerts the largest effect upon 25OHD levels identified to date
in the general European population and implicates vitamin D in the etiology of multiple sclerosis.
Introduction
Vitamin D insufficiency affects approximately 40% of the
general population in developed countries.1 This could
have important public health consequences, given that
vitamin D insufficiency has been associated with muscu-
loskeletal consequences and several common diseases,
such as multiple sclerosis (MIM: 126200), type 1 diabetes
(MIM: 222100), type 2 diabetes (MIM: 125853), and
several cancers.2 Further, repletion of vitamin D status
can be achieved safely and inexpensively. Thus, under-
standing the determinants of vitamin D insufficiency,
and their effects, can provide a better understanding of
the role of vitamin D in disease susceptibility with poten-
tially important public health benefits.
Approximately half of the variability in the concentra-
tion of the widely accepted biomarker for vitamin D sta-
tus, 25-hydroxyvitamin D (25OHD), has been attributed
to genetic factors in twin and family studies.3,4 Four com-
mon (minor allele frequency [MAF] > 5%) genetic vari-
ants in loci near four genes known to be involved in
cholesterol synthesis (DHCR7 [MIM: 602858]), hydroxyl-
ation (CYP2R1 [MIM: 608713]), vitamin D transport
(GC [MIM: 139200]), and catabolism (CYP24A1 [MIM:
126065]) are strongly associated with 25OHD levels
yet explain little of its heritability.5 Low-frequency and
rare genetic variants (defined as those with a MAF %
5% and 1%, respectively) have recently been found
to have large effects on clinically relevant traits,6–8
providing an opportunity to better understand the
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biologic mechanisms influencing disease susceptibility in
the general population.
Therefore, the principal objective of the present study
was to detect low-frequency and rare variants with large ef-
fects on 25OHD levels through a large-scale meta-analysis
and describe their biological and clinical relevance. Similar
to an earlier genome-wide association study (GWAS) exam-
ining common (MAF R 5%) genetic variation by the
SUNLIGHT consortium,5 we sought to increase under-
standing of the genetic etiology of vitamin D variation
within the general population; however, our current study
focused on genetic variation with a MAF < 5%. This has
only recently been made possible through whole-genome
sequencing (WGS) and the use of improved genotype
imputation for low-frequency and rare variants with the
recent availability of large WGS reference panels.9 The sec-
ond objective of this study was to better understand
whether low-frequency genetic variants with large effects
on 25OHD could predict a higher risk of vitamin D insuf-
ficiency in their carriers and whether vitamin D intake
through diet might interact with such genetic factors to
prevent, or magnify, vitamin D insufficiency. Finally, we
sought to understand whether these genetic determinants
of 25OHD levels are implicated in multiple sclerosis, a dis-
ease influenced by low 25OHD levels.10
To do so, we first undertook an association study ofWGS
data and deeply imputed genome-wide genotypes to iden-
tify novel genetic determinants of vitamin D in 42,274
individuals. We next tested if these genetic variants
conferred a higher risk of vitamin D insufficiency in
8,711 subjects and whether this insufficiency showed ef-
fect modification by dietary intake. Last we assessed their
effect on multiple sclerosis in a separate sample of 5,927
case and 5,599 control subjects.
Material and Methods
Cohorts
Allhumanstudieswereapprovedbyeach respective institutional or
national ethics review committee, and all participants provided
written informed consent. To investigate the role of rare and low-
frequency genetic variation on 25OHD levels in individuals of Eu-
ropean descent, we usedWGS data at amean read depth of 6.73 in
2,619 subjects from twocohortswith available25OHDphenotypes
in theUK10Kproject11 (Table1).Wealsoused imputation reference
panels to impute variants that were missing, or poorly captured,
from previous GWASs of 39,655 subjects (Table 1 and Figure 1).
The participating individuals were drawn from independent co-
horts of individuals of European descent. A detailed description
of each of the participating studies is provided in Table S1.
25OHD Measurements
The methods applied for measuring 25OHD levels differed among
the participating cohorts (Tables S1 and S6). The four methods
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used were tandem mass spectrometry (in the Bone Mineral Den-
sity in Childhood Study [BMDCS], Osteoporotic Fractures in
Men USA [MrOS], and B-Vitamins for the Prevention of Osteopo-
rotic Fractures [BPROOF]), combined high-performance liquid
chromatography and mass spectrometry (in the Avon Longitudi-
nal Study of Parents and Children [ALSPAC], BPROOF, Cardiovas-
cular Health Study [CHS], Upssala Longitudinal Study of Adult
Men [ULSAM], Netherlands Epidemiology of Obesity [NEO], and
Generation R Study [Generation R]), chemiluminescence immu-
noassay (DiaSorin) (in TwinsUK [TUK], the Prospective Investiga-
tion of the Vasculature in Upssala Seniors [PIVUS], the Framing-
ham Heart Study [FHS], Osteoporotic Fractures in Men Malmo
[MrOS Malmo], Osteoporotic Fractures in Men Gothenburg
[MrOS GBG], and Gothenburg Osteoporosis and Obesity Determi-
nants [GOOD]), and electrochemiluminescence immunoassay
(COBAS, Roche Diagnostics) (in Rotterdam Studies I [RSI], II
[RSII], and III [RSIII]). Detection limits for the different methods
are provided in Table S6.
WGS, Genotyping, and Imputation
ALSPAC WGS and TUK WGS cohorts had been sequenced at an
average read depth of 6.73 through the UK10K consortium on
the Illumina HiSeq platform and aligned to the GRCh37 human
reference sequence with Burrows-Wheeler Aligner 31.12 Single-
nucleotide variant (SNV) calls were completed with SAMtools/
BCFtools,13 and VQSR14 and GATK were used to recall these vari-
ants. WGS for the ALSPAC and TUK cohorts has been described
in detail in a previous publication from our group.7 Table S8 sum-
marizes the data-generationmethod for sequencing-based cohorts.
Participating studies separately genotyped samples and imputed
them toWGS-based reference panels. The most recent imputation
panels, such as the UK10K and 1000 Genomes Project (v.3) com-
bined panel (7,562 haplotypes from the UK10K project and
2,184 haplotypes from the 1000 Genomes Project9) and the
Haplotype Reference Consortium (HRC) panel (64,976 haplo-
types15), enabled more accurate imputation of low-frequency var-
iants than the UK10K or 1000 Genomes reference panel alone.9
Specifically, 11 of the 17 participating cohorts were imputed to
the combined UK10K and 1000 Genomes reference panel (total
number of imputed individuals included in the meta-analysis ¼
25,589). Three of the participating cohorts were imputed with
the HRC panel (n ¼ 5,717). Finally, two cohorts were imputed to
the 1000Genomes panel (n¼ 7,536), and one cohort was imputed
to the UK10K panel (n ¼ 863) (Table S1). Details on genotyping
methods and imputation for the 17 participating cohorts are pre-
sented in Table S6. Info scores for the imputed SNVs per partici-
pating cohort are presented in Table S7. To assess the quality of
imputation, we tested the non-reference discordance rate for the
low-frequency genome-wide-significant SNVs and found this to
be 0% (Table S9).
Association Testing for 25OHD Levels and Meta-analysis
We conducted a GWAS separately for each cohort by using an addi-
tive genetic model for 25OHD levels. Because 25OHD concentra-
tions were measured by different methods, log-transformed
25OHD levels were standardized to Z scores after adjustment for
age, sex, BMI, and season of measurement. Specifically, the pheno-
type for each GWASwas prepared according to the following steps:
(1) We log transformed 25OHD levels to ensure normality. (2) We
used linear regression models to generate cohort-specific residuals
of log-transformed 25OHD levels adjusted for covariates (age, sex,
BMI, and season). Season was treated as a non-ordinal categorical
variable (summer: July to September; fall: October to December;
winter: January to March; and spring: April to June). (3) We added
themeanof log-transformed25OHDlevels to the residuals to create
the adjusted 25OHDphenotype. (4)We thennormalized the above
phenotype within each cohort (mean of 0 with 1 SD) to make the
phenotype consistent across cohorts, given that our consortium
has measured 25OHD levels in different cohorts by different
methods. (5) Finally, we removed outliers beyond 5 SD from step 4.
For comparison purposes, we computed the average 25OHD
levels, adjusted for age, sex, BMI, and season of measurement, in
one cohort of our meta-analysis (TUK WGS) in carriers and non-
carriers of the lead SNV(s).
The software used for each cohort’s GWAS is listed in Table S1.
We performed single-variant tests for variants with MAF > 0.1%
by using an additive effect of the minor allele at each variant in
each cohort. The type of software employed for single-variant
testing for each cohort is shown in Table S1. Studies with related
individuals used software that accounted for relatedness. Cohort-
specific genomic inflation factors (lambda values) are also shown
in Table S1 (the mean lambda value was 1.015).
We then meta-analyzed association results from all discovery
cohorts (n ¼ 42,274). This stage included validation of the
results file format, filtering files by the above quality-control
(QC) criteria, comparison of trait distributions among different
studies, and identification of potential biases (large beta values
and/or standard errors, inconsistent effect allele frequencies,
and/or extreme lambda values). Meta-analysis QC of the GWAS
data included the following SNV-level exclusion criteria: (1) infor-
mation score < 0.4, (2) Hardy-Weinberg equilibrium (HWE)
p value < 10"6, (3) missingness > 0.05, and (4) MAF < 0.5%.
















MrOS GBG 945 –
GOOD 921 –





The American Journal of Human Genetics 101, 227–238, August 3, 2017 229
SNValignment across studies was done with the chromosome and
position information for each variant according to genome build
hg19 (UCSC Genome Browser). SNVs in the X chromosome
were not included in the meta-analysis. Fixed-effects meta-anal-
ysis was performed with the software package GWAMA16 with
adjustment for genomic control. We tested bi-allelic SNVs with
MAF R 0.5% for association and declared genome-wide statistical
significance at p % 1.2 3 10"8 for variants present in more than
one study. This stringent p value threshold was set to adjust for
all independent SNVs above the MAF threshold of 0.5%.17
Conditional analysis was undertaken for the four previously
described lead vitamin D SNVs from the SUNLIGHT consortium
with the Genome-wide Complex Trait Analysis (GCTA) pack-
age.18 This method uses an approximate conditional-analysis
approach from summary-level statistics from the meta-analysis
and inter-SNV linkage-disequilibrium corrections estimated from
a reference sample. We used UK10K individuals as the reference
sample to calculate the linkage disequilibrium of SNVs. The
associated regions flanking within 400 kb of the top SNVs from
SUNLIGHTwere extracted, and the conditional analyses were con-
ducted within these regions. Conditional analyses of individual
variants presented in Tables 2 and S5 were conducted with
GCTA v.0.93.9 and default parameters.
We used analyses of haplotype blocks for the candidate variants
of interest by deriving phased haplotypes from 1,013 individuals
from the TUK WGS cohort with a custom R package.
Effects on Vitamin D Insufficiency
To investigate the effect of genome-wide-significant SNVs on
vitamin D insufficiency (defined as 25OHD levels below
50 nmol/L), we used data from four cohorts: TUK imputed, TUK
WGS, BPROOF, and MrOS (n ¼ 8,711). We performed logistic
regression of this binary phenotype against the SNVs by adjusting
for the following covariates: age, sex, BMI, and season of measure-
ment. Meta-analysis of cohort-level summary statistics was per-
formed in R19 with the epitools20 and metafor21 packages.
Interaction Analysis with Vitamin D Intake
We analyzed interactions between our candidate SNV(s) and
vitaminDdietary intake (continuous and tertiles) in 9,224 individ-
Figure 1. Schematic of the Discovery
Single-Variant Meta-analysis
uals from five of the cohorts (FHS, PIVUS,
ULSAM, BPROOF, and RSIII) participating
in our discovery phase. A detailed descrip-
tion of the method for capturing vitamin
D intake in each of the participating co-
horts appears in Table S6. Linear regression
was conducted in each of these studies
under an additive genetic model. The
following variables and co-variables were
included in the model: log-transformed
serum 25OHD as the dependent variable;
SNV genotype (coded as 0, 1, or 2) as an
independent variable; SNV (genotype) 3
dietary vitamin D intake (continuous or
tertiles) as an interaction term; and age,
sex, BMI, season of 25OHD measurement,
dietary vitamin D intake (continuous or tertiles), supplemented
vitaminD (yes or no), and total energy intake as covariates. The re-
sults from the five studies were meta-analyzed by a fixed-effects
model with the metafor tool of the R statistical package.
Effects on Multiple Sclerosis
We tested the effect of the genome-wide-significant SNVs on the
risk of multiple sclerosis in 5,927 case and 5,599 control samples
by assuming an additive genetic model. Control samples were
obtained from the UK Biobank22 by random selection of partici-
pants without multiple sclerosis. Case samples were obtained
from the UK Biobank,22 previously published multiple sclerosis
GWASs,23,24 and newly genotyped UK subjects. Before genotype
imputation of the genotyped case samples, we applied
numerous QC criteria to ensure unbiased genotype calls between
cohorts. These included retaining only SNVs with a MAF > 1%
and excluding SNVs or samples with high missingness.25
Further, samples were assessed for population stratification with
EIGENSTRAT,26,27 and outliers were removed. Genotype data
were then imputed by the Sanger Imputation Service15 with
the combined UK10K and 1000 Genomes Phase 3 reference
panels,9,28 the same reference panel used for the UK Biobank con-
trol samples. Genotype data were phased with EAGLE229 and
imputed with PBWT.30 SNPTEST31 was used for association testing
on the combined case-control dataset, which included testing the
additive effect of each allele on multiple sclerosis status and using
the top ten principal components from EIGENSTRAT26,27 to adjust
for population stratification and batch effects.
Results
GWAS
After strict QC, the genomic inflation factor for the meta-
analysis of 19 GWASs was 0.99, suggesting a lack of bias
due to population stratification (Figure 2). Through meta-
analysis of 11,026,511 sequenced and imputed variants
from our discovery cohorts (Table 1), we identified a signal
at the chromosomal locus 11p.15.2, which harbors vari-
ants associated with 25OHD levels (lead low-frequency
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SNV g.14900931G>A [p.Asp120Asp] [rs117913124(A)]
[GenBank: NC_000011.9]; MAF ¼ 2.5%, allelic effect
size ¼ "0.43 SD of the standardized log-transformed
25OHD levels [SD], p ¼ 1.5 3 10"88; Figure 3 and Table 2).
The direction of effect was consistent across all discovery
cohorts (Table 3 and Figure 3A), and the mean imputation
information score for the imputed studies was 0.97. This
low-frequency synonymous coding variant is in exon 4
of CYP2R1 and is #14 kb from the previously identified
common CYP2R1 variant rs10741657 (r2 between these
two SNVs ¼ 0.03) (Figure 4). To our knowledge,
rs117913124 has not previously been associated with any
vitamin-D-related traits in humans.
Figure S1 shows a comparison of the average 25OHD
levels, adjusted for age, sex, BMI, and season of measure-
ment, in non-carriers and heterozygous carriers of the A
allele of rs117913124 in the TUKWGS cohort. The average
25OHD levels, adjusted for age, sex, BMI, and season of
measurement were computed in 542 individuals from
the TUK WGS cohort, among which 510 were not carriers
and 32 were heterozygous carriers of the A allele of
rs117913124 (no homozygous carriers were present in
this cohort). After removing outliers (adjusted 25OHD
levels 53 SD from the mean), we included in our analysis
449 non-carriers and 30 heterozygous carriers (for a total
of 479 individuals). A linear-regression model with the
adjusted 25OHD levels as the dependent variable and
the dose of the A allele of rs117913124 (numeric factor 1
or 0) as the independent variable demonstrated an
8.3 nmol/L decrease in the adjusted 25OHD levels per A
allele. The mean adjusted 25OHD levels were 64.3 nmol/L
in non-carriers and 56.0 nmol/L in heterozygous carriers.
Two-way conditional analysis between the CYP2R1
common (rs10741657) and low-frequency (rs117913124)
variants revealed that the two association signals are
largely independent. Specifically, after conditioning on
rs10741657, rs117913124 remained strongly associated
with 25OHD levels (pcond ¼ 2.4 3 10"78); after condition-
ing on rs11791324, the effect of rs10741657 on 25OHD
levels remained significant (pcond ¼ 4.0 3 10"33 versus
ppre-cond ¼ 8.8 3 10"45; Tables 2 and S5). Further, no
other low-frequency variant in the region remained signif-
icant after conditioning on rs117913124 (Table 2). To
further disentangle the role of rs117913124 from that
of rs10741657 on 25OHD levels, we undertook a
haplotype analysis based on WGS data from 3,781 indi-
viduals from the TUK WGS and ALSPAC WGS cohorts.
We found that the 25OHD decreasing A allele of
rs117913124 was always transmitted in the same haplo-
type block with the 25OHD decreasing G allele of the com-
mon CYP2R1 variant rs10741657. By using 25OHD data
from the TUK WGS cohort, we compared the 25OHD
levels among carriers of the various haplotype blocks. We
observed lower levels of 25OHD in carriers of the A allele
of rs117913124 than in non-carriers, independently of
the presence of the effect allele G of the common
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No other low-frequency or rare variants were identified
in the three previously described vitamin-D-related loci
at DHCR7, GC, and CYP24A1. The mean effect size of the
four previously reported common (MAF R 5%) genome-
wide-significant SNVs from the SUNLIGHT consortium
was "0.13 SD, and the largest effect size was "0.25 SD
(for the GC variant) in our meta-analysis (Table S3 and
Figure 3B). The effect size of rs10741657(G), the known
common CYP2R1 variant, was "0.09 SD. Hence, the
observed effect size of rs117913124 is 3-fold larger than
the above mean, 4-fold larger than that of the common
CYP2R1 variant, and almost twice that of the largest previ-
ously reported effect of theGC variant. Last, the percentage
of the 25OHD phenotype variance explained by the low-
frequency CYP2R1 variant (0.9%) was more than double
the percentage of the variance explained by the CYP2R1
common variant (0.4%).
We also identified 18 genome-wide-significant low-fre-
quency and rare SNVs on the same chromosome 11 region
as rs117914124 in the neighboring PDE3B (MIM: 602047)
Figure 2. Discovery Single-Variant Meta-analysis
(A) Quantile-quantile plot for the single SNV meta-analysis.
(B) Manhattan plot of the meta-analysis depicts variants with MAF > 0.5% across the 22 autosomes against the "log10 p value from the



















































Figure 3. Forest Plot by Cohort for rs117913124 and Forest Plot for rs117913124 and the Previously Described Common 25OHD-
Related Variants from Discovery Meta-analysis
(A) Forest plot of estimates from all 19 studies for the low-frequency CYP2R1 variant rs117913124.
(B) Forest plot of the effect of the four common SUNLIGHT variants and the CYP2R1 low-frequency variant rs117913124 on log-trans-
formed 25OHD levels.
Squares represent beta values in the 19 studies, and bars around the squares represent 95% confidence intervals (CIs).
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(Tables 2 and S4 and Figure 4B). Signals from these SNVs
in PDE3B were independent of the common variant at
CYP2R1 (Table 2). We then created haplotype blocks with
rs117913124 and SNVs at PDE3B on the basis of haplotype
information from the 3,781 individuals from the TUKWGS
and ALSPAC WGS cohorts (Table S2). We found that the
25OHD decreasing allele (A) of rs117913124 was always in-
herited with the 25OHD decreasing allele (A) of its perfect
proxy rs116970203 (r2 ¼ 1). Therefore, rs116970203 is not
likely to have a distinct effect from that of rs117913124
on 25OHD levels. On the other hand, the 25OHD
decreasing alleles of the remaining four low-frequency
variants (all with a MAF of approximately 1.4%) were
not always inherited in the same haplotype block as
rs117913124 and rs116970203 and were in moderate link-
age disequilibrium with rs117913124 (all r2 < 0.6; Figures
4B and 4C). Each of the four alleles was in almost perfect
linkage disequilibrium with the remaining three (all r2 >
0.96). This implies that these four SNVs might influence
25OHD levels independently of rs117913124. Neverthe-
less, as mentioned above, after conditioning on the lead
low-frequency CYP2R1 SNV rs117913124, the p values of
the four PDE3B SNVs became non-significant and their
betavaluesdecreased substantially (Table 2), demonstrating
that they probably do not represent an independent signal
at the chromosome 11 locus.
rs117913124 and Risk of Vitamin D Insufficiency
To further investigate the clinical significance of the low-
frequency CYP2R1 variant rs117913124, we tested its ef-
fect on a binary outcome for vitamin D insufficiency
(defined as 25OHD levels < 50 nmol/L) in 8,711 individ-
uals from four studies (TUK WGS, TUK IMP, BPROOF,
and MrOS). rs117913124 was strongly associated with
an increased risk of vitamin D insufficiency (odds ratio
[OR] ¼ 2.20, 95% confidence interval [CI] ¼ 1.8–2.8, p ¼
1.2 3 10"12) (Figure 5) after control for relevant covariates
as described in the Material and Methods.
Common 25OHD-Associated SNVs
We report two additional loci associated with 25OHD
levels (Table 5). Variants leading these associations were
common and exerted a rather small effect on 25OHD: (1)
a variant in chromosome 12 (rs3819817[C], intronic to
HAL [MIM: 609457]) with a MAF of 45%, a beta value of
0.04, and a p value of 3.23 10"10; and (2) a variant in chro-
mosome 14 (rs2277458[G], intronic to GEMIN2 [MIM:
602595]) with a MAF of 21%, a beta value of "0.05, and
Table 3. Summary Statistics for the CYP2R1 Low-Frequency Variant, rs117913124, from 19 Studies
Study
25OHD Measurement
Method n EAF (A Allelea) Betab Standard Error p Value Information Score
ALSPAC imputed MS 3,675 0.028 "0.59 0.07 3.43 3 10"18 0.99
ALSPAC WGS MS 1,606 0.028 "0.65 0.11 8.23 3 10"10 NA
BPROOF MS 2,512 0.027 "0.4 0.09 4.99 3 10"6 0.97
BMDCS MS 863 0.019 "0.11 0.06 0.058 0.98
CHS MS 1,581 0.022 "0.55 0.11 5.15 3 10"7 0.88
FHS CLIA 5,402 0.021 "0.45 0.07 2.32 3 10"10 0.97
GenerationR MS 1,442 0.033 "0.66 0.1 1.78 3 10"6 1
GOOD CLIA 921 0.028 "0.14 0.14 0.31 0.96
MrOS MS 3,265 0.018 "0.76 0.09 5.63 3 10"16 0.96
MrOS Malmo CLIA 893 0.033 "0.33 0.14 0.016 0.94
MrOS GBG CLIA 945 0.026 "0.61 0.14 7.87 3 10"6 1
NEO MS 5,727 0.025 "0.54 0.06 2.73 3 10"19 1
PIVUS CLIA 943 0.028 "0.66 0.14 2.56 3 10"6 0.99
RSI ECLIA 3,320 0.025 "0.19 0.08 0.019 0.98
RSII ECLIA 2,022 0.033 "0.37 0.09 2.38 3 10"5 0.99
RSIII ECLIA 2,913 0.027 "0.51 0.08 4.61 3 10"10 0.98
TUK imputed CLIA 1,919 0.021 "0.1 0.11 0.35 0.98
TUK WGS CLIA 1,013 0.025 "0.39 0.14 0.006 NA
ULSAM MS 1,095 0.025 "0.33 0.14 0.02 1
Abbreviations are as follows: CLIA, chemiluminescence immunoassay; EAF, effect allele frequency; ECLIA, electrochemiluminescence immunoassay; MS, mass
spectrometry; NA, not applicable; 25OHD, 25-hydroxyvitamin D.
aEffect allele is the 25OHD decreasing allele.
bBeta values represent changes in standard deviations of the standardized log-transformed 25OHD levels.
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a p value of 6.0 3 10"9. Both variants were present in all
19 studies, and the direction of the effect was the same
among the 19 studies (Figure 6). Neither the HAL nor the
GEMIN2 locus is previously known to be associated with
25OHD levels. Of note, neither variant was present in
the HapMap imputation reference used in the SUNLIGHT
study.
Interaction Analysis
CYP2R1 encodes the enzyme responsible for 25-hydroxyl-
ation of vitamin D in the liver,32 a necessary step in the
conversion of dietary vitamin D and vitamin D oral supple-
ments to the active metabolite, 1,25 dihydroxy-vitamin D.
Therefore, we hypothesized that, in contrast with non-
carriers, individuals heterozygous or homozygous for
rs117913124 in CYP2R1 would not show a response in
their 25OHD levels to vitamin D intake. In other words,
we expected carriers of the effect allele of rs117913124
to have steadily lower 25OHD levels, independently of
their vitamin D intake. To investigate this hypothesis, we
tested the presence of interaction between rs117913124
and vitamin D dietary intake (continuous values and
tertiles) on 25OHD levels in 9,224 individuals from
five studies (Figure S2). We found no interaction
between rs117913124 and dietary vitamin D intake (beta
value¼"0.0002 and interaction p value¼ 0.41 for contin-
uous vitamin D intake; beta value ¼ 0.012 and p value ¼
0.60 for tertiles of vitamin D intake). Given that the two
common 25OHD-associated SNVs are located in genes
(HAL and GEMIN2) with no known role in the processing
of dietary vitamin D, we found no biological rationale for
undertaking a gene-diet interaction analysis for these
variants.
25OHD-Assosiated Variants and Risk of Multiple
Sclerosis
We tested whether the CYP2R1 low-frequency variant
rs117913124 and the common variants rsrs3819817 and
Figure 4. Association Signals from 11p.15.2
(A) UCSC Genome Browser snapshot including the top low-frequency SNVs (see Table 2) and the lead common variant rs10741657 in
CYP2R1. The position of rs117913124 is highlighted in light blue.
(B) Regional disequilibrium plot showing rs117913124 (purple dot), its perfect proxy rs11670203 (red dot), and the other genome-wide-
significant SNVs in the same locus (blue and green dots). The plot depicts SNVs within 1 Mb of a locus’s lead SNV (x axis) and their asso-
ciated meta-analysis p value ("log10) (see Table S10 for more details). SNVs are color coded according to r2 with the lead SNV (labeled; r2
was calculated from the UK10K WGS dataset). The recombination rate (blue line), position of genes and their exons, and direction of
transcription are also displayed (below plot).
(C) Linkage-disequilibriumplot indicating the r2 values between the SNVs of Table 2 (top low-frequency variants) and between these low-
frequency SNVs and the lead common variant (rs107416570) at the same CYP2R1 locus (r2 calculated from the 1000 Genomes dataset).
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rs2277458 in HAL and GEMIN2, respectively, influence
the risk of multiple sclerosis. In 5,927 multiple sclerosis
samples and 5,599 control samples, we found that the
25OHD decreasing allele at rs117913124[A] was associated
with increased odds of multiple sclerosis (OR ¼ 1.40; 95%
CI ¼ 1.19–1.64; p value ¼ 2.6 3 10"5). By way of compar-
ison, the OR of multiple sclerosis for the common CYP2R1
variant was 1.03 (95% CI ¼ 0.97–1.08; p value ¼ 0.03) in
the same study and has previously been reported to be
1.05 (95% CI ¼ 1.02–1.09; p value 0.004) in a separate
study.33 Thus, the effect per allele of rs117913124 on mul-
tiple sclerosis was 12.4-fold larger than that attributed to
the already known common variant at CYP2R1. With re-
gard to the two common SNVs, the 25OHD decreasing
allele (T) at theHAL variant rs3819817 was not clearly asso-
ciated with risk of multiple sclerosis; however, there was a
trend in the expected direction: OR¼ 1.05 (95%CI¼ 1.00–
1.11; p value ¼ 0.07). We found no association between
the 25OHD decreasing allele (G) at the GEMIN2 variant
rs2277458 and risk of multiple sclerosis: OR ¼ 1.03 (95%
CI ¼ 0.96–1.11; p value ¼ 0.34).
Discussion
In the largest GWAS meta-analysis of 25OHD levels in Eu-
ropean populations to date, we have identified a low-fre-
quency, synonymous coding genetic variant that has a
large effect and strongly associates with 25OHD levels.
This variant has an effect size 4-fold larger than that
described for the common variant in the same gene
(CYP2R1) and is associated with a 2-fold increase in risk
of vitamin D insufficiency and a 40% increase in the
odds of developing multiple sclerosis. The biological plau-
sibility of these findings is supported by the fact that the
low-frequency variant is located in CYP2R1, encoding the
major hepatic 25-hydroxylase for vitamin D.32 These find-
ings are of clinical relevance given that 5% of the general
European population carries this variant in either the ho-
mozygous or heterozygous state, and it is associated with
a clinically relevant increase in the risk of multiple
sclerosis.
Our study was enabled by large imputation reference
panels (UK10K-1000 Genomes and HRC) that offer at least
10-fold more European samples than the 1000 Genomes
reference panel alone. We did not identify genome-wide-
significant variants with a large effect on 25OHD in
novel genes in Europeans, although we did find variants
with smaller effects in two loci not previously known to
be associated with 25OHD. We also identified in a known
vitamin-D-related gene low-frequency variants with much
larger effects than those of the previously described com-
mon variants.
CYP2R1 encodes the enzyme that is responsible for
25-hydroxylation of vitamin D and is one of the
two main enzymes responsible for vitamin D hepatic
metabolism32 (Figure 7). Rare mutations in CYP2R1
have already been described to cause rickets (MIM:
27744).32,34 Given the important role of CYP2R1 in the
conversion of dietary vitamin D and vitamin D oral sup-
plements to the active form of vitamin D, we hypothe-
sized that carriers of the low-frequency CYP2R1 variant
might respond poorly to vitamin D replacement therapy.
We tested this hypothesis by undertaking an interaction
analysis between the CYP2R1 low-frequency variant and
dietary vitamin D intake, which showed no clear interac-
tion. However, we note that studies of gene-environment
interactions are generally underpowered, measurement
error in dietary data is common, and this interaction
was further limited by time differences between assess-
ment of dietary intake and measurement of 25OHD
levels. Therefore, whether this genetic variant influences
25OHD response to vitamin D administration requires
further study.
Although the aim of the present study was to
describe variants of low MAF and large effect on
25OHD, we report two common chromosome 12 (HAL)
and 14 (GEMIN2) variants that have a small effect
size and reached genome-wide significance in our
Figure 5. Effect of rs117913124 on Vitamin D Insufficiency
Forest plot of the effect of the low-frequency CYP2R1 variant
rs117913124 on vitamin D insufficiency in four studies. Squares
represent odds ratios for vitamin D insufficiency in the four
studies, and bars represent 95% CIs.
Table 4. Effect of Different Haplotype Combinations of the Low-
Frequency (rs117913124) and Common (rs10741657) CYP2R1
Variants on 25OHD Levels
Haplotypea Betab p Value n
GA GA "0.02 0.79 156
AG GA "0.49 0.02 23
AG GG "0.3 0.13 27
GA GG 0.01 0.87 477
GG GG 0.05 0.58 330
Results are based on individuals from the TUK WGS cohort.
aThe first allele in each chromatid corresponds to the low-frequency variant
rs117913124; the second allele corresponds to the common variant
rs10741657. The two AG blocks contain the 25OHD decreasing allele (A) of
the low-frequency variant, which is always inherited with the 25OHD
decreasing allele (G) of the common variant.
bBeta values represent changes in standard deviations of the standardized log-
transformed 25OHD levels.
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meta-analysis. Although no existing evidence implicates
GEMIN2 in vitamin-D-related physiological pathways,
HAL is expressed in the skin and is involved in the for-
mation of urocanic acid, a ‘‘natural sunscreen.’’35,36
Thus, this could constitute a plausible pathophysiologic
mechanism implicating HAL in vitamin D synthesis
in the skin. Additional functional follow-up of the
signals in chromosomes 12 and 14 is needed to charac-
terize the genes and/or mechanisms underlying these
associations.
Our findings could have clinical relevance for several
reasons. First, individuals carrying at least one copy of
the low-frequency CYP2R1 variant have lower levels of
25OHD by a clinically relevant degree. Specifically, the
risk of vitamin D insufficiency is doubled in these individ-
uals. Second, their risk ofmultiple sclerosis is also increased
in accordance with previous evidence supporting a causal
role for vitamin D in the risk of multiple sclerosis.10 Third,
these findings affect #5% of individuals of European
descent. Fourth and finally, rs117913124 could be used
along with the previously identified common vitamin-D-
related variants as an additional genetic predictor of low
25OHD levels inMendelian randomization studies investi-
gating the causal role of low vitamin D levels in human
disease.
Our study also has its limitations. First, although the
scope of our study was detection of low-frequency and
rare variants, we opted to include in our meta-analysis
two WGS studies with a relatively low read depth of
6.73, as well as three studies imputed to older imputa-
tion panels (1000 Genomes and UK10K). These studies
have a limited capacity to capture very rare variants,
which might explain why we failed to identify such asso-
ciations. In addition to the limitations arising from
the time difference between assessment of dietary
vitamin D intake and 25OHD measurements, the analysis
of the gene-diet interaction, as mentioned above, might
have lacked statistical power. Because our analysis
was restricted to populations of European ancestry, we


















































Figure 6. Association Signals from Chromosomes 12 and 14
Forest plots with (A) estimates for the chromosome 12 common variant rs3819817 and (B) estimates for the chromosome 14 common
variant rs2277458 from all 19 studies of the meta-analysis where both variants were present. Squares represent beta values in the 19
studies, and bars around the squares represent 95% CIs.
Table 5. Main Findings of the GWAS Meta-analysis
SNP Chr Candidate Gene EA EAF Betaa p Value n
rs117913124 11 CYP2R1 A 0.025 "0.43 1.5 3 10"88 41,336
rs3819817 12 HAL C 0.45 0.04 3.2 3 10"10 41,071
rs2277458 14 GEMIN2 G 0.21 "0.05 6.0 3 10"9 39,746
Abbreviations are as follows: Chr, chromosome; EA, effect allele; EAF, effect allele frequency; SNP, single-nucleotide polymorphism.
aBeta values represent changes in standard deviations of the standardized log-transformed 25OHD levels while controlling for age, sex, BMI, and season of
measurement.
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rs117913124 in non-European populations. Nonetheless,
according to the 1000 Genomes reference, this variant
is rare in Africans (MAF ¼ 0.3%) and has not been
described in East Asians (MAF ¼ 0%). Therefore,
describing with any certainty the effect of this variant
on 25OHD levels in these populations will require
large sample sizes of these populations. Finally, in the
absence of functional experiments showing the exact
function of rs117913124 in CYP2R1 and given that this
synonymous polymorphism does not affect protein
sequence, we cannot unequivocally confirm that this
low-frequency variant is causal; however, given that this
is a coding variant in a well-documented 25OHD-associ-
ated gene, it seems likely that it exerts its effect on
CYP2R1.
In conclusion, our findings demonstrate the utility of
WGS-based discovery and deep imputation for enabling
the characterization of genetic associations, offering
an improved understanding of the pathophysiology of
vitamin D, providing an enriched set of genetic predictors
of 25OHD levels for future study, and enabling the identi-
fication of groups at increased risk for vitamin D insuffi-
ciency and multiple sclerosis.
Accession Numbers
The GWAS summary statistics reported in this paper have
been deposited in the Genome-wide Repository of Associations
between SNPs and Phenotypes (GRASP).
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Assessing the causal association between 25-hydroxyvitamin D
and the risk of oral and oropharyngeal cancer using Mendelian
randomization
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Circulating 25-hydroxyvitamin D (25OHD) is an appealing potential intervention for cancer risk and has been associated with
oral and oropharyngeal cancer risk but evidence is inconsistent. The availability of genetic variants, uncorrelated with known
confounders, but predictive of 25OHD and genetic data in a large oral and oropharyngeal cancer collaboration aids causal
inference when assessing this association. A total of 5,133 oral and oropharyngeal cancer cases and 5,984 controls with
genetic data were included in the study. Participants were based in Europe, North America and South America and were part
of the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network. Five genetic variants reliably associated with
circulating 25OHD were used to create a relative genetic measure of 25OHD. In the absence of measured 25OHD, two-sample
Mendelian randomization using individual level outcome data were used to estimate causal odds ratios (OR) for cancer case
status per standard deviation increase in log25OHD. Analyses were replicated in an independent population-based cohort
(UK Biobank). In the GAME-ON study, there was little evidence of a causal association between circulating 25OHD and oral
cancer (OR 5 0.86 [0.68;1.09], p 5 0.22), oropharyngeal cancer (OR 5 1.28 [0.72;2.26], p 5 0.40) or when sites were combined
(OR 5 1.01 [0.74;1.40], p 5 0.93). Replication in UK Biobank and pooled estimates produced similar results. Our study sug-
gests that a clinically relevant protective effect of 25OHD on oral and oropharyngeal cancer risk is unlikely and supplementa-
tion of the general population with 25OHD is unlikely to be beneficial in preventing these cancers.
Introduction
Each year, there are approximately 300,000 new oral cavity
and 230,000 new oropharyngeal cancers worldwide.1 Squa-
mous cell cancers of the head and neck (HNC) are heteroge-
neous and oral and oropharyngeal cancers have differing
aetiology. Alcohol and tobacco use are the major risk factors
for oral and oropharyngeal cancers,2,3 explaining approxi-
mately 65–70% of the population attributable risk.4 Infection
with human papillomavirus (HPV) has emerged as an impor-
tant risk factor, particularly in oropharyngeal cancers.5 The
disease burden of these cancers remains high despite reduc-
tions in the prevalence of tobacco and alcohol use. Oropha-
ryngeal cancer incidence continues to increase in the UK
despite no increase in HPV infection in the past 10 years;6
therefore, identification of other modifiable risk factors
remains important.
Key words: oral cancer, oropharyngeal cancer, 25-hydroxyvitamin D, Mendelian randomization
Abbreviations: 1,25OH2D: 1,25 di-hydroxyvitamin D; 25OHD: 25-hydroxyvitamin D; CI: confidence interval; CEU ancestry: northern
Europeans from Utah; GAME-ON: Genetic Associations and Mechanisms in Oncology; GWAS: Genome Wide Association Study;
HNC: head and neck cancer; MAF: minor allele frequency; MR: Mendelian randomization; OR: odds ratio; QC: quality control; RCT:
randomized controlled trial; SNP: single nucleotide polymorphism
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Vitamin D is predominantly synthesised by exposure to
ultra-violet light. The inactive metabolite (25-hydroxyvitamin
D [25OHD]) is the most commonly clinically measured and
supplemented form and is correlated with the active form,
1,25-dihydroxyvitamin D (1,25OH2D). An endocrine feed-
back mechanism controls activation of 25OHD to 1,25OH2D
in the kidneys which is important for calcium and phosphate
balance.7 Evidence from mechanistic studies suggests a pro-
tective role of 1,25OH2D on cancer incidence and progres-
sion,8,9 and this may act by the same endocrine mechanism
or via paracrine effects at the cancer site. It is not clear
whether higher circulating 25OHD is itself protective against
cancer or whether other factors such as the ratio of 25OHD
to 1,25OH2D at the cancer site add further complexity (Tan V
et al., Submitted for publication).
Evidence for a role of vitamin D in HNCs is contradic-
tory. In an observational study of tobacco-related tumours,
participants with 50% lower circulating 25OHD were more
likely to develop HNC after accounting for available potential
confounders (Hazard ratio5 1.44 [95% confidence interval
(CI): 1.19, 1.73]).10 A recent prospective European cohort
study also found strong evidence for an inverse association
between circulating 25OHD on HNC risk (odds ratio [OR]
per doubling of circulating 25OHD concentration5 0.69
[95% CI: 0.56, 0.87], p5 931024).11 However, Arem et al.12
and Skaaby et al.13 found no convincing evidence of a protec-
tive effect of higher 25OHD levels on HNC.
Well-designed randomized studies of 25OHD supplementa-
tion are required to identify whether there is a true causal link
with cancer incidence. However, randomized controlled trials
(RCTs) are not well suited to investigate the effect of 25OHD
supplementation on rare diseases. Long follow-up duration,
non-adherence to intervention or control regime and an
unknown optimal supplementation dose limit such trials14
meaning they are prohibitively expensive and lack power to
detect relatively small but potentially clinically important effects.
In the context of this lack of evidence in the literature,
Mendelian randomization (MR) can help assess whether
there is a causal association between 25OHD and oral and
oropharyngeal cancer risk by utilising genetic data, even in
studies where 25OHD itself has not been measured. MR uses
genetic variants known to be reliably associated with a risk
factor of interest (e.g., 25OHD) to derive estimates of the
causal effect of that risk factor on health outcomes (e.g., oral
cavity and oropharyngeal cancer risk).15–17 Other studies
have used these methods to provide evidence for causal asso-
ciations of 25OHD with health outcomes including other
cancers18 and multiple sclerosis.19
Our study aims to assess the causal association between
vitamin D and oral and oropharyngeal cancer risk and esti-
mate the size of any effect using MR.
Methods
Participants and genotyping
GAME-ON. The study comprised 6,034 HNC cases and
6,585 controls from studies which were part of the Genetic
Associations and Mechanisms in Oncology (GAME-ON)
Network. Cases and controls from 10 different case–control
studies were included, as well as from the European cohort
study (EPIC) and cases from a UK case series (Head and
Neck 5000 [HN5000]). Details of the studies included have
been described previously.20 Informed consent was obtained
for all participants and studies were approved by respective
institutional review boards. For our study, cancer cases of
interest comprised the following ICD codes: oral cavity
(C02.0–C02.9, C03.0–C03.9, C04.0–C04.9 and C05.0–C06.9)
and oropharynx (C01.9, C02.4 and C09.0–C10.9). DNA
extraction, genotyping, quality control and imputation has
been described previously.20 The study population included
participants from Europe, North America and South Amer-
ica. To reduce the effect of heterogeneity across these regions,
only participants with >70% CEU ancestry were included in
analyses (n5 11,117). These consisted of 5,133 cases (oral
n5 2,700 and oropharyngeal n5 2,433) and 5,984 controls
(Table 1).
SNP selection and validation
Common genetic variants have been identified in Genome
Wide Association Studies (GWAS)21,22 of 25OHD, only
variants that passed a genome wide association threshold
(p< 5 3 1028) and had been replicated were selected. These
genetic proxies or instruments are located in or near four
25OHD related genes: Group-specific component (GC), cyto-
chrome P450 family 2, subfamily R, polypeptide 1 (CYP2R1 ),
7-dehydrocholesterol reductase (DHCR7 ) and cytochrome
P450, family 24, polypeptide 1 (CYP24A1 ). A recent GWAS
of 25OHD, a meta-analysis of 19 studies totalling 42,274
individuals with European ancestry, identified a low fre-
quency variant in CYP2R1 (rs117913124), independent of the
common variant in the same gene.23 Effect estimates for all
What’s new?
Evidence for a role of vitamin D in head and neck cancers is contradictory, and randomized controlled trials are not well suited
to investigate the potential effect of 25-hydroxyvitamin D (25OHD) supplementation. For the first time, this study used Mende-
lian randomization with genetic variants associated with 25OHD and uncorrelated with known confounders to derive the
causal effect of 25OHD on oral cavity and oropharyngeal cancer risk. The findings suggest that a clinically-relevant protective
effect of 25OHD on oral and oropharyngeal cancer risk is unlikely, making supplementation of the general population with
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single nucleotide polymorphism (SNP) associations with
serum 25OHD concentrations were taken from this GWAS.
To assess SNP independence, SNPs on the same chromosome
were assessed for linkage disequilibrium (LD) using SNAP
(http://archive.broadinstitute.org/mpg/snap/ldsearchpw.php)
in Europeans from the 1,000 Genomes (Pilot 1) project. Five
SNPs were identified for 25OHD from GWAS (Table 2).
rs4588 in GC, rs10741657 in CYP2R1 and rs6013897 in
CYP24A1 have been used in genetic instruments for 25OHD
in MR studies before. rs4423214 near DHCR7 is in perfect
LD with rs12785878, identified in the original SUNLIGHT
consortium 25OHD GWAS.22 Finally, rs116970203 near
CYP2R1 is a low frequency variant identified in the most
recent GWAS of 25OHD and has been shown to act inde-
pendently of rs10741657.23
In both studies, to correct for within region population
structure, region specific principal components were added to
the logistic regression models. Effect allele frequencies of the
five 25OHD genetic variants were calculated within the three
GAME-ON regions and plotted in pie charts superimposed
over a world map.
For each individual, the five 25OHD variants were com-
bined into a genetic risk score. To ease clinical interpretation,
this score was converted from a per allele scale to the stan-
dardized log 25OHD scale by weighting by the beta coeffi-
cients derived from GWAS. Therefore, each unit increase in
this variable (hereafter referred to as relative 25OHD) repre-
sented a standard deviation (SD) increase in log 25OHD.
Assessment of potential confounders
One of the principals of MR is that as alleles are assigned
randomly during gamete formation and segregation, the
genetic instrument is not associated with factors that typically
confound the observational association. To test this assump-
tion, associations between the 25OHD instrument and all
available potential confounders in GAME-ON were investi-
gated. Sex, smoking status (never, ever and current) and alco-
hol use (never and ever) were recorded by questionnaire in
both cohorts. GAME-ON sub-study and study country were
also considered potential confounders.
Associations of the 25OHD instrument with strata of
potential confounders was examined in boxplots of range and
means6 1 SD. Tests of associations were made using linear
regression with categorical variables as factor variables, the
overall p values for the model is shown on the boxplots.
Replication dataset
UK Biobank is a population-based health research resource
consisting of approximately 500,000 people, aged between 38
years and 73 years, who were recruited between the years
2006 and 2010 from across the UK.24 Age on 31 December
2010 (coinciding with the approximate end of baseline data
Table 1. GAME-ON participant summaries
All, n (%) Case, n (%) Control, n (%)





!50 2,217 (19.9) 1,071 (20.9) 1,146 (19.2)
50–<60 3,443 (31.0) 1,696 (33.0) 1,747 (29.2)
60–<70 3,348 (30.1) 1,504 (29.3) 1,844 (30.8)
"70 2,108 (19.0) 861 (16.8) 1,247 (20.8)
Missing 1 (0.01) 1 (0.02) 0 (0.00)
Sex
Male 7,680 (69.1) 3,798 (74.0) 3,882 (64.9)
Female 3,437 (30.9) 1,335 (26.0) 2,102 (35.1)
Smoking status
Never 3,302 (29.7) 1,002 (19.5) 2,300 (38.4)
Previous 3,655 (32.9) 1,590 (31.0) 2,065 (34.5)
Current 3,300 (29.7) 2,019 (39.3) 1,281 (21.4)
Missing 860 (7.74) 522 (10.2) 338 (5.65)
Alcohol use
Never 1,825 (16.4) 767 (14.9) 1,058 (17.7)
Ever 8,422 (75.8) 4,030 (78.5) 4,392 (73.4)
Missing 870 (7.83) 336 (6.55) 534 (8.92)
Geographic region
Europe 5,251 (47.2) 2,323 (45.3) 2,928 (48.9)
North America 4,583 (41.2) 2,254 (43.9) 2,329 (38.9)
South America 1,283 (11.5) 556 (10.8) 727 (12.1)
Table 2. 25OHD genetic variant details





Vitamin D GWAS GAME ON
EAF Beta SE p value Rsq (minimac3) EAF
rs4588 4 72618323 GC G T 0.717 0.2469 0.0070 1.68E-263 Genotyped 0.722
rs116970203 11 14876718 PDE3B G A 0.975 0.4323 0.0209 2.29E-90 0.98 0.978
rs4423214 11 71173254 DHCR7 T C 0.697 0.0998 0.0073 1.39E-40 0.99 0.718
rs10741657 11 14914878 CYP2R1 A G 0.415 0.0938 0.0065 8.76E-45 Genotyped 0.383
rs6013897 20 52742479 CYP24A1 T A 0.791 0.0658 0.0080 9.06E-16 0.77 0.781
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collection) was used as the age variable and not age at cancer
diagnosis. Prevalent and incident oral and oropharyngeal
cancers (ICD10 codes matched to GAME-ON) were identi-
fied from linked cancer registry data. To reduce selection bias
in allocating controls, all remaining participants, after remov-
ing those participants with other HNC, were used as controls.
A full description of the study design, participants and qual-
ity control (QC) methods have been described in detail previ-
ously.25 UK Biobank received ethical approval from the
Research Ethics Committee (REC reference for UK Biobank
is 11/NW/0382).26 In UK Biobank, analyses were restricted
to individuals of white British ancestry who self-report as
“White British” and who have very similar ancestral back-
grounds according to the principal component analysis, as
described by Bycroft.27 The full data release contains the
cohort of successfully genotyped samples (n5 488,377). Any
impact of genotyping array was investigated and did not
meaningfully affect results (Supporting Information text).
Pre-imputation QC, phasing and imputation are described
elsewhere.27 Individuals with sex-mismatch or sex-
chromosome aneuploidy (n5 814) and related individuals
(n5 79,448) were excluded from the analysis (Supporting
Information text). After removing related and non-White
British participants, there were 337,108 eligible participants,
consisting of 585 cases (oral n5 294, oropharyngeal n5 291)
and 336,523 controls (Supporting Information Table 1).
Statistical analyses
MR analyses. In a method analogous to using a genetic risk
score,28 relative 25OHD was used in logistic regression mod-
els to estimate a causal OR for a SD increase in log 25OHD.
The standard error of this estimate was corrected to account
for the imprecision of the beta coefficients used to generate
the relative 25OHD estimates using a bootstrap technique
(Supporting Information text).
GAME-ON. MR analyses were performed within each
geographic region of the GAME-ON consortium accounting
for age, sex and the first 15 population specific principal
components. As there were likely to be differences between
the causal estimates across regions, a random-effects meta-
analysis was used to combine GAME-ON causal estimates
using the R package ‘meta’.29 Heterogeneity between study
populations was assessed using I2.30 Meta analyses were
repeated excluding geographical regions that were outliers to
assess for their influence on the overall estimate.
Replication in UK biobank and Meta-analysis. MR analy-
ses were repeated in UK Biobank. GAME-ON and UK Bio-
bank estimates were compared and then combined using
meta-analysis. This used a random-effects model and was
conducted using the ‘meta’ package in R.29 Heterogeneity
between studies was assessed using I2.30
Sensitivity analyses. To assess whether any single SNP was
driving a causal estimate, which could be driven by events
such as horizontal pleiotropy which invalidate the MR
assumptions, a leave-one out method was applied. This
repeats the analysis sequentially removing one SNP from the
genetic instrument used to derive relative 25OHD. To further
demonstrate this, where a SNP overtly influences an associa-
tion, each possible genetic instrument from combinations of
the five 25OHD SNPs was used to estimate relative 25OHD
and thereafter a causal OR. These OR were plotted as histo-
grams highlighting those that include the highly influential
SNP to see whether there was an obvious grouping of these
estimates.
Power. The 25OHD genetic variants have been reported to
explain 3–5% of the variance in 25OHD.21,22,31 Given this, in
the GAME-ON study for oral (n5 2,700 cases, 5984 con-
trols) or oropharyngeal sites (n5 2,433 cases, 5984 controls)
alone, there was adequate power to detect an OR of 0.67 to
0.74 per SD increase in log 25OHD with power of 0.8 and an
alpha of 0.05. For all sites combined (n5 5,133 cases, 5984
controls), the study was powered to detect an OR of between
0.74 and 0.79 (http://cnsgenomics.com/shiny/mRnd/).32
Results
Of the five SNPs included in the analyses, rs4588 and
rs10741657 were directly genotyped in both the GAME-ON
and UK Biobank studies. All other SNPs were imputed and
the imputation quality metric (Minimac3 r2 for GAME-ON;
SNPTEST info score for UK Biobank) was >0.98, except
rs6013897 in the GAME-ON study which had an r2 of 0.77
(Table 2; Supporting Information Table 2). No two SNPs on
the same chromosome had an LD r2 >0.01. Allele frequen-
cies were similar across all three regions (Supporting Infor-
mation Fig. 1).
In the GAME-ON study, there was no strong evidence of
association of the 25OHD genetic instrument with sex, smok-
ing status or drinking status after taking multiple testing into
account. There was evidence for a difference in the 25OHD
genetic instrument across regions and sub-studies (Fig. 1).
The region showing deviation from the others was South
America and any differences across confounders were no lon-
ger seen when the South American region was excluded from
analyses (Supporting Information Fig. 2a). Within the South
American region alone, there was no strong evidence for
associations between the 25OHD genetic instrument and
confounders (Supporting Information Fig. 2a). In UK Bio-
bank, there was no evidence for a difference in relative
25OHD across strata of sex, smoking status or drinking sta-
tus (Supporting Information Fig. 3).
In GAME-ON, for oral and oropharyngeal cancer, there
was little evidence for a causal link with relative 25OHD
when the three geographic regions were meta-analysed
OR5 0.86 [0.68, 1.09], p5 0.22 and OR5 1.28 [0.72; 2.26],
p5 0.40, respectively. For oral sites, estimates were homoge-
nous (I250% [0, 87], phet50.44) but due to only having three
estimates to meta-analyse (one for each geographic region),
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Despite this, there was evidence of heterogeneity between
regions for the oropharyngeal sites (I2574% [16, 92],
phet50.02). This was also reflected in all sites (I
2555% [0,
87], phet50.10) and was most likely driven by the strong risk
increasing association with oropharyngeal cancer identified in
the South American region (OR5 3.91 [1.64; 9.29], p< 0.01)
compared to null associations in both European (OR5 0.98
[0.67; 1.44], p5 0.94) and North American regions
(OR5 0.92 [0.64; 1.34], p0.68) (Fig. 2).
When replicated in UK Biobank, estimates for oral cancer
(OR5 0.86 [0.50; 1.51], p5 0.61) were very similar with
those from the GAME-ON study. For oropharyngeal sites
(OR5 0.85 [0.49; 1.47], p5 0.56), point estimates differed
between GAME-ON and UK Biobank although CIs over-
lapped. When the two studies were meta-analysed using
random-effects, there was no convincing evidence of a causal
association with either cancer or when all sites were analysed
(Supporting Information Fig. 4).
Sensitivity analyses
In leave one out analyses, sequentially omitting each of the
five SNPs provided similar causal estimates for any site
within the European and North American regions of GAME-
ON. In the South American region of the GAME-ON study,
the risk increasing association between 25OHD and oropha-
ryngeal cancer was most strongly influenced by the rs4588
variant (Supporting Information Fig. 5). In analyses using an
instrument with all possible combinations of the 25OHD
SNPs, even with the rs4588 variant removed there was still a
risk increasing association for oropharyngeal cancer in the
South American region (Supporting Information Fig. 6).
Removing the South American region from the oropharyn-
geal analyses reduced heterogeneity between the GAME-ON
studies (OR5 0.95 [0.73, 1.25], p5 0.73; I2 5 0, phet50.82)
(Supporting Information Fig. 7).
Discussion
Our study set out to investigate the causal association
between 25OHD and oral and oropharyngeal cancer risk.
Given the lack of 25OHD measures in large scale oral and
oropharyngeal cancer studies, a two-sample MR approach,33
that allowed genetic variants to be used as largely uncon-
founded measures of 25OHD, was used. No strong evidence
of a causal association was identified with oral or oropharyn-
geal cancer. Given power calculations predict an OR smaller
than 0.74 could be detected, if present any potential true
Figure 1. Mean (6 SD) and range of 25OHD weighted genetic instrument across strata of potential confounders for GAME-ON. Overall mean
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effect is likely to be smaller than this and thus threaten the
clinical relevance of the association.
These findings mirror a recently published MR study of
colorectal, breast, prostate, ovarian, lung and pancreatic can-
cer, and neuroblastoma that did not support a causal role of
25OHD in the risk of these cancers.34 Similar to the inference
from this work on oral and pharyngeal cancer, the authors of
the previous study state that although they are unable to rule
out clinically relevant effects of small magnitude, their study
combined with previous literature, ‘provide evidence that
population-wide screening for vitamin D deficiency and sub-
sequent widespread vitamin D supplementation should not
currently be recommended as a strategy for primary cancer
prevention’. Recent RCTs examining the effect of vitamin D
on cancer incidence do not show strong evidence of a protec-
tive effect, although these studies are limited to older
females.35,36 Contrary to this, Ong et al.18 did demonstrate a
protective role for 25OHD in ovarian cancer in a well pow-
ered MR study. Despite the body of evidence that does not
support a protective effect of 25OHD on cancer incidence,
there is evidence to support the hypothesis that vitamin D
has an effect on cancer progression.8,11
The genetic instrument used in our study specifically
proxies average total (free and bound) circulating 25OHD
and does not necessarily predict the concentrations of free
25OHD available at the tissues or concentrations of free or
bound 1,25OH2D in circulation or at the tissue level. Poten-
tial anti-cancer effects of vitamin D are via free 1,25OH2D
interacting with the vitamin D receptor within tissues result-
ing in reduced angiogenesis, metastasis, cell invasion,
inflammation, and proliferation as well as upregulation of
apoptosis.8 Levels of 1,25OH2D are assumed to be correlated
with circulating 25OHD, but this is not necessarily the case.
Although less likely than a null association between 25OHD
and oral and oropharyngeal cancer risk, the instrument
being invalid for 25OHD could explain the disparity
between the results of our study and previous findings
showing a protective effect of 25OHD. However, as the
genetic variants used here as instruments for 25OHD have
robust associations with 25OHD and are in genes known to
Figure 2. OR (95% CI) for developing cancer for a SD increase in 25OHD for all sites (a), oral sites (b) and oropharyngeal sites (c) in Mende-
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effect this metabolite they are likely to be valid for the pur-
poses of MR.
To be valid, the genetic instrument must proxy circulating
25OHD without affecting cancer risk through other casual
pathways (violation of this assumption is referred to as hori-
zontal pleiotropy). The SNPs used in this instrument are in
genes with known effects on vitamin D pathways and have
been consistently associated with circulating levels of 25OHD
in GWA21,22 and MR studies,37 reducing the chance of hori-
zontal pleiotropy. Sensitivity analyses such as MR Egger38
and the weighted median method39 can detect or correct for
the presence of directional pleiotropy but have low power
with few SNPs comprising the genetic instrument, as in this
case. Here, causal estimates in the European and North
American populations are largely consistent across all five
SNPs, providing some evidence against the presence of strong
pleiotropy that could bias findings.
In the South American population, a risk increasing asso-
ciation was identified between 25OHD and oropharyngeal
cancer. Use of individual level data in our study allowed
scrutiny of the genetic instrument-confounder independence
assumption and showed that the 25OHD instrument gener-
ally held up to this assumption; however, there was some evi-
dence the genetic instrument was associated with region and
sub-study, driven by the South American region. Given the
above points, it is unlikely then that pleiotropy or confound-
ing can explain the large risk increasing association seen for
oropharyngeal cancer in the South American region. How-
ever, as this risk increasing association is inconsistent with
observational effect directions and MR estimates from other
geographic regions, it is unlikely to be truly causal: it most
likely represents structure within this population that is by
chance associated with oropharyngeal cancer risk. To assess
the impact of this potentially biased estimate on the overall
causal OR, the analyses were repeated with the South Ameri-
can individuals removed, resulting in more consistent
estimates.
Conclusions
Our study does not support the observational association
between 25OHD and oral cancer risk and is consistent with
evidence that a causal, clinically relevant protective effect of
25OHD on oropharyngeal cancer risk is unlikely. The effect
of 25OHD on oral and oropharyngeal cancer progression was
not assessed here and requires further investigation.
The genetic instrument for 25OHD is a good proxy for
circulating total 25OHD, the same metabolite that is used in
supplementation and is measured in the observational stud-
ies. Despite being robustly associated with 25OHD, the
genetic variants used here only explain a relatively small
amount of variance in 25OHD. This means that causal effects
of small magnitude cannot be ruled out. Furthermore, it can-
not be determined whether 25OHD has an effect on cancer
risk in individuals below a certain 25OHD concentration
threshold. Where inference is likely to be useful clinically is
in relation to supplementation. Supplementation increases
total circulating 25OHD and is presumed to subsequently
increase free 1,25OH2D availability at the tissues. The SD
25OHD increase in our study will have a relative effect on
total 25OHD across the whole life course. If this long-term
difference in relative 25OHD does not produce a detectable
effect in our study, any 25OHD causal effect is unlikely to be
of a magnitude that would warrant long-term supplementa-
tion in the general population from a particular age.
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